0001410578-23-001531.txt : 20230803 0001410578-23-001531.hdr.sgml : 20230803 20230803141448 ACCESSION NUMBER: 0001410578-23-001531 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230803 DATE AS OF CHANGE: 20230803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Quoin Pharmaceuticals, Ltd. CENTRAL INDEX KEY: 0001671502 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37846 FILM NUMBER: 231139311 BUSINESS ADDRESS: STREET 1: 23 HATA'AS STREET CITY: KFAR SABA STATE: L3 ZIP: 44425 BUSINESS PHONE: 97299741444 MAIL ADDRESS: STREET 1: 23 HATA'AS STREET CITY: KFAR SABA STATE: L3 ZIP: 44425 FORMER COMPANY: FORMER CONFORMED NAME: Cellect Biotechnology Ltd. DATE OF NAME CHANGE: 20160721 FORMER COMPANY: FORMER CONFORMED NAME: Cellect Biomed Ltd. DATE OF NAME CHANGE: 20160406 10-Q 1 qnrx-20230630x10q.htm 10-Q
http://fasb.org/srt/2023#OfficerMemberhttp://fasb.org/srt/2023#OfficerMemberhttp://fasb.org/srt/2023#OfficerMemberhttp://fasb.org/srt/2023#OfficerMemberhttp://fasb.org/srt/2023#OfficerMemberhttp://fasb.org/srt/2023#OfficerMemberhttp://fasb.org/srt/2023#OfficerMember0001671502--12-312023Q2falsehttp://fasb.org/us-gaap/2023#RelatedPartyMemberhttp://fasb.org/us-gaap/2023#RelatedPartyMemberhttp://fasb.org/srt/2023#OfficerMemberhttp://fasb.org/srt/2023#OfficerMember987217242330247995923302479940388425000http://fasb.org/us-gaap/2023#RelatedPartyMemberhttp://fasb.org/us-gaap/2023#RelatedPartyMemberhttp://fasb.org/srt/2023#OfficerMemberhttp://fasb.org/srt/2023#OfficerMemberhttp://fasb.org/srt/2023#OfficerMemberhttp://fasb.org/srt/2023#OfficerMemberhttp://fasb.org/srt/2023#OfficerMemberP10D0001671502qnrx:WarrantAmendmentsMember2023-02-240001671502us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2023-06-300001671502us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2023-06-300001671502us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001671502us-gaap:FairValueMeasurementsRecurringMember2023-06-300001671502us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2022-12-310001671502us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2022-12-310001671502us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001671502us-gaap:FairValueMeasurementsRecurringMember2022-12-310001671502dei:AdrMemberqnrx:PublicOfferingMember2023-02-242023-02-240001671502qnrx:PublicOfferingMember2023-02-242023-02-240001671502us-gaap:CommonStockMember2023-01-012023-03-310001671502dei:AdrMember2023-01-012023-03-310001671502qnrx:ConvertibleNotesWarrantsCommonStockMemberqnrx:Convertiblenotes2020Member2021-01-012021-12-310001671502dei:AdrMemberus-gaap:SubsequentEventMember2023-07-182023-07-180001671502us-gaap:TreasuryStockCommonMember2023-06-300001671502us-gaap:RetainedEarningsMember2023-06-300001671502us-gaap:AdditionalPaidInCapitalMember2023-06-300001671502us-gaap:TreasuryStockCommonMember2023-03-310001671502us-gaap:RetainedEarningsMember2023-03-310001671502us-gaap:AdditionalPaidInCapitalMember2023-03-3100016715022023-03-310001671502us-gaap:TreasuryStockCommonMember2022-12-310001671502us-gaap:RetainedEarningsMember2022-12-310001671502us-gaap:AdditionalPaidInCapitalMember2022-12-310001671502us-gaap:TreasuryStockCommonMember2022-06-300001671502us-gaap:RetainedEarningsMember2022-06-300001671502us-gaap:AdditionalPaidInCapitalMember2022-06-300001671502us-gaap:TreasuryStockCommonMember2022-03-310001671502us-gaap:RetainedEarningsMember2022-03-310001671502us-gaap:AdditionalPaidInCapitalMember2022-03-3100016715022022-03-310001671502us-gaap:TreasuryStockCommonMember2021-12-310001671502us-gaap:RetainedEarningsMember2021-12-310001671502us-gaap:AdditionalPaidInCapitalMember2021-12-310001671502dei:AdrMemberqnrx:PublicOfferingMember2023-02-240001671502qnrx:CommonWarrantsMember2023-01-012023-06-300001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2023-01-012023-06-300001671502qnrx:AmendedAndRestatedEquityIncentivePlanMemberdei:AdrMember2022-01-012022-12-310001671502qnrx:AmendedAndRestatedEquityIncentivePlanMemberdei:AdrMember2022-12-310001671502qnrx:PreFundedWarrantsMemberdei:AdrMember2023-01-012023-06-300001671502qnrx:CommonWarrantsMemberdei:AdrMember2023-01-012023-06-300001671502qnrx:AmendedAndRestatedEquityIncentivePlanMemberdei:AdrMember2023-01-012023-06-300001671502qnrx:TherapeuticsInc.Memberus-gaap:ResearchAndDevelopmentArrangementMember2023-04-012023-06-300001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2023-04-012023-06-300001671502qnrx:NethertonSyndromeMemberus-gaap:ResearchAndDevelopmentArrangementMember2023-04-012023-06-300001671502qnrx:TherapeuticsInc.Memberus-gaap:ResearchAndDevelopmentArrangementMember2023-01-012023-06-300001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2023-01-012023-06-300001671502qnrx:NethertonSyndromeMemberus-gaap:ResearchAndDevelopmentArrangementMember2023-01-012023-06-300001671502qnrx:TherapeuticsInc.Memberus-gaap:ResearchAndDevelopmentArrangementMember2022-04-012022-06-300001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-04-012022-06-300001671502qnrx:NethertonSyndromeMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-04-012022-06-300001671502qnrx:TherapeuticsInc.Memberus-gaap:ResearchAndDevelopmentArrangementMember2022-01-012022-06-300001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-01-012022-06-300001671502qnrx:NethertonSyndromeMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-01-012022-06-300001671502qnrx:Ms.CarterMember2023-04-012023-06-300001671502qnrx:Dr.MyersMember2023-04-012023-06-300001671502qnrx:Ms.CarterMember2022-04-012022-06-300001671502qnrx:Dr.MyersMember2022-04-012022-06-300001671502qnrx:Ms.CarterMember2022-01-012022-06-300001671502qnrx:Dr.MyersMember2022-01-012022-06-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2023-04-012023-06-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2023-01-012023-06-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2022-04-012022-06-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2022-01-012022-06-300001671502qnrx:InvoicePaidOnBehalfOfCompanyMember2023-06-300001671502qnrx:Ms.CarterMember2023-06-300001671502qnrx:Dr.MyersMember2023-06-300001671502qnrx:SalaryAndOtherCompensationMember2023-06-300001671502qnrx:SalaryAndOtherCompensationMember2022-12-310001671502qnrx:InvoicePaidOnBehalfOfCompanyMember2022-12-310001671502qnrx:ConsultingExpenseMember2023-04-012023-06-300001671502qnrx:ConsultingExpenseMember2023-01-012023-06-300001671502qnrx:ConsultingExpenseMember2022-04-012022-06-300001671502qnrx:ConsultingExpenseMember2022-01-012022-06-300001671502us-gaap:RetainedEarningsMember2023-04-012023-06-300001671502us-gaap:RetainedEarningsMember2023-01-012023-03-310001671502us-gaap:RetainedEarningsMember2022-04-012022-06-300001671502us-gaap:RetainedEarningsMember2022-01-012022-03-310001671502qnrx:Convertiblenotes2020Member2023-06-300001671502qnrx:Convertiblenotes2020Member2022-12-310001671502qnrx:ConvertibleNotesWarrantsCommonStockMember2021-12-310001671502qnrx:Convertiblenotes2020Member2023-04-012023-06-300001671502qnrx:Convertiblenotes2020Member2023-01-012023-06-300001671502qnrx:Convertiblenotes2020Member2022-04-012022-06-300001671502qnrx:Convertiblenotes2020Member2022-01-012022-06-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2022-03-012022-03-310001671502us-gaap:TechnologyBasedIntangibleAssetsMember2023-06-300001671502us-gaap:LicensingAgreementsMember2023-06-300001671502us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310001671502us-gaap:LicensingAgreementsMember2022-12-310001671502dei:AdrMember2023-04-012023-06-300001671502dei:AdrMember2023-01-012023-06-300001671502dei:AdrMember2022-01-012022-06-300001671502us-gaap:CommonStockMember2023-06-300001671502us-gaap:CommonStockMember2023-03-310001671502dei:AdrMember2023-03-310001671502us-gaap:CommonStockMember2022-12-310001671502us-gaap:CommonStockMember2022-06-300001671502dei:AdrMember2022-06-300001671502us-gaap:CommonStockMember2022-03-310001671502dei:AdrMember2022-03-310001671502us-gaap:CommonStockMember2021-12-310001671502dei:AdrMember2021-12-310001671502dei:AdrMember2023-06-300001671502dei:AdrMember2022-12-3100016715022022-11-0200016715022022-11-0300016715022022-04-120001671502qnrx:AmendedAndRestatedEquityIncentivePlanMemberdei:AdrMember2023-06-300001671502qnrx:AmendedAndRestatedEquityIncentivePlanMember2023-06-300001671502qnrx:PreFundedWarrantsMemberdei:AdrMemberqnrx:PublicOfferingMember2023-02-240001671502qnrx:PreFundedWarrantsMemberqnrx:PublicOfferingMember2023-02-240001671502qnrx:CommonWarrantsMemberdei:AdrMemberqnrx:PublicOfferingMember2023-02-240001671502qnrx:WarrantAmendmentsMemberdei:AdrMember2023-02-240001671502dei:AdrMember2023-02-2400016715022022-06-3000016715022021-12-310001671502qnrx:SkinvisibleLicenseAgreementMember2019-10-310001671502us-gaap:EmployeeStockOptionMemberdei:AdrMember2023-01-012023-06-300001671502qnrx:OutstandingWarrantsMemberdei:AdrMember2023-01-012023-06-300001671502us-gaap:EmployeeStockOptionMemberdei:AdrMember2023-01-012023-03-310001671502qnrx:OutstandingWarrantsMemberdei:AdrMember2023-01-012023-03-310001671502us-gaap:EmployeeStockOptionMemberdei:AdrMember2022-01-012022-06-300001671502qnrx:OutstandingWarrantsMemberdei:AdrMember2022-01-012022-06-300001671502us-gaap:EmployeeStockOptionMemberdei:AdrMember2022-01-012022-03-310001671502qnrx:OutstandingWarrantsMemberdei:AdrMember2022-01-012022-03-310001671502us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001671502us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001671502us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001671502us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001671502us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001671502us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001671502us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100016715022022-01-012022-03-310001671502us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000016715022023-04-012023-06-300001671502us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100016715022023-01-012023-03-310001671502us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-3000016715022022-04-012022-06-300001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2021-12-3100016715022023-02-242023-02-240001671502dei:AdrMemberus-gaap:SubsequentEventMember2023-08-012023-08-010001671502dei:AdrMember2023-04-052023-04-050001671502us-gaap:CommonStockMember2022-04-012022-06-300001671502dei:AdrMember2022-04-012022-06-300001671502us-gaap:CommonStockMember2022-01-012022-03-3100016715022023-07-182023-07-180001671502qnrx:SecuritiesPurchaseAgreementInPolytherapeuticsincMember2018-03-242018-03-240001671502srt:MinimumMember2023-07-180001671502srt:MaximumMember2023-07-180001671502dei:AdrMemberus-gaap:SubsequentEventMember2023-07-180001671502qnrx:PreFundedWarrantsMemberdei:AdrMemberqnrx:PublicOfferingMember2023-02-242023-02-240001671502qnrx:Ms.CarterMember2023-01-012023-06-300001671502qnrx:Dr.MyersMember2023-01-012023-06-300001671502dei:AdrMemberus-gaap:SubsequentEventMember2023-08-010001671502dei:AdrMember2023-04-0500016715022022-01-012022-06-3000016715022022-01-012022-12-310001671502qnrx:InvestorRelationsFirmMemberqnrx:ConsultingAgreementMember2023-06-300001671502qnrx:TherapeuticsInc.Memberqnrx:ConsultingAgreementMember2022-12-310001671502qnrx:TherapeuticsInc.Memberqnrx:ConsultingAgreementMember2022-06-300001671502qnrx:SclerodermaMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-05-310001671502qnrx:NethertonSyndromeMemberqnrx:ConsultingAgreementMember2021-11-300001671502qnrx:SkinvisibleLicenseAgreementMember2019-10-012019-10-310001671502qnrx:TherapeuticsInc.Memberqnrx:ConsultingAgreementMember2020-11-012020-11-3000016715022023-06-3000016715022022-12-310001671502us-gaap:CommonStockMember2023-08-020001671502dei:AdrMember2023-08-0200016715022023-01-012023-06-30xbrli:sharesiso4217:USDxbrli:pureqnrx:itemiso4217:USDxbrli:sharesqnrx:agreementqnrx:Yqnrx:Voteqnrx:segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to __________

Commission file number: 001-37846

QUOIN PHARMACEUTICALS LTD.

(Exact name of registrant as specified in its charter)

State of Israel

    

92-2593104

(State or other jurisdiction of

(I.R.S. Employer

incorporation or organization)

Identification No.)

42127 Pleasant Forest Court

    

Ashburn, VA

20148-7349

(Address of principal executive offices)

(Zip Code)

(703) 980-4182

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading Symbol(s)

    

Name of each exchange on which registered

American Depositary Shares, each representing sixty thousand (60,000) Ordinary Shares, no par value per share

QNRX

The Nasdaq Stock Market LLC

Ordinary Shares, no par value per share*

N/A

*

Not for trading, but only in connection with the registration of the American Depositary Shares (“ADSs”) pursuant to requirements of the Securities and Exchange Commission.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of August 2, 2023, there were 59,233,024,799 ordinary shares, no par value per share, of the registrant outstanding, and 987,217 ADSs of the registrant outstanding (assuming all ordinary shares are represented by ADSs), with each ADS representing 60,000 ordinary shares.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (“Form 10-Q”) contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Form 10-Q, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

Although we believe that we have a reasonable basis for each forward-looking statement contained in this Form 10-Q, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. Forward-looking statements are subject to risks and uncertainties that could cause actual results to be materially different from those indicated (both favorably and unfavorably). These risks and uncertainties include, but are not limited to, those described in Part I – Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2022 (“Form 10-K”), as well as our subsequent reports filed with the Securities and Exchange Commission (“SEC”). Caution should be taken not to place undue reliance on any such forward-looking statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

You should read this Form 10-Q and the documents that we reference in this Form 10-Q and have filed as exhibits completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this Form 10-Q by these cautionary statements.

Unless otherwise indicated or the context otherwise requires, all references in this Form 10-Q to the terms “Quoin,” “Quoin Ltd.,” the “Company,” “us,” “we”, and “our” refer to Quoin Pharmaceuticals Ltd. and its consolidated subsidiaries.

1

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

QUOIN PHARMACEUTICALS LTD.

Condensed Consolidated Balance Sheets

June 30, 

December 31, 

    

2023

    

2022

 

(Unaudited)

 

ASSETS

Current assets:

 

  

 

  

Cash and cash equivalents

$

4,759,129

$

2,860,628

Investments

10,680,160

9,992,900

Prepaid expenses

 

234,226

 

516,584

Total current assets

 

15,673,515

 

13,370,112

Prepaid expenses - long term

383,390

383,390

Intangible assets, net

 

652,539

 

704,561

Total assets

$

16,709,444

$

14,458,063

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

  

 

  

Current liabilities:

 

  

 

  

Accounts payable

$

707,935

$

605,600

Accrued expenses

 

1,834,653

 

1,175,705

Accrued interest and financing expense

 

1,146,251

 

1,146,251

Due to officers – short term

 

725,000

 

600,000

Total current liabilities

 

4,413,839

 

3,527,556

Due to officers – long term

3,223,733

3,523,733

Total liabilities

$

7,637,572

$

7,051,289

Commitments and contingencies

 

  

 

  

Shareholders’ equity:

 

  

 

  

Ordinary shares, no par value per share, 500,000,000,000 ordinary shares authorized – 59,233,024,799 (987,217 ADS’s) ordinary shares issued and outstanding at June 30, 2023 and 24,233,024,799 (403,884 ADS’s) at December 31, 2022

$

$

Treasury stock, 2,641,693, ordinary shares

 

(2,932,000)

 

(2,932,000)

Additional paid in capital

 

54,230,635

 

47,855,521

Accumulated deficit

 

(42,226,763)

 

(37,516,747)

Total shareholders’ equity

 

9,071,872

 

7,406,774

Total liabilities and shareholders’ equity

$

16,709,444

$

14,458,063

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements

2

QUOIN PHARMACEUTICALS LTD.

Condensed Consolidated Statements of Operations (Unaudited)

Three months ended June 30, 

    

Six months ended June 30, 

    

2023

    

2022

    

2023

    

2022

Operating expenses

General and administrative

$

1,634,960

$

1,941,473

$

3,318,777

$

3,529,943

Research and development

 

625,104

 

726,694

 

1,716,837

1,314,263

Total operating expenses

 

2,260,064

 

2,668,167

 

5,035,614

4,844,206

Other (income) and expenses

Forgiveness of accounts payable

 

 

 

 

(416,000)

Warrant liability (income) expense

(77,237)

Unrealized loss

34,472

14,045

Interest income

 

(187,589)

 

 

(339,643)

 

Total other income

 

(153,117)

 

 

(325,598)

 

(493,237)

Net loss

$

(2,106,947)

$

(2,668,167)

$

(4,710,016)

$

(4,350,969)

Loss per ADS

 

 

  

 

  

 

  

Loss per ADS

 

  

 

  

 

  

 

  

Basic

$

(2.13)

$

(38.91)

$

(5.79)

$

(69.90)

Fully-diluted

$

(2.13)

$

(38.91)

$

(5.79)

$

(69.90)

Weighted average number of ADS’s outstanding

 

  

 

  

 

  

 

  

Basic

 

987,217

 

68,573

 

813,184

 

62,242

Fully-diluted

 

987,217

 

68,573

 

813,184

 

62,242

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements

3

QUOIN PHARMACEUTICALS LTD.

Condensed Consolidated Statements of Shareholders’ Equity (Unaudited)

Three and Six months ended June 30, 2022

    

    

    

No

    

    

Additional

    

    

Ordinary

Par

Treasury

Paid in

Accumulated

    

Shares

    

ADS’s

    

Value

    

Stock

    

Capital

    

Deficit

    

Total

Balance at January 1, 2022

 

3,354,650,799

 

55,911

 

$

(2,932,000)

$

31,659,017

$

(28,069,985)

$

657,032

Net loss

 

 

 

 

 

 

(1,682,802)

 

(1,682,802)

Cashless exercise of warrants

3,200

Reclassification of warrant liability upon issuance of Exchange warrant

296,362

296,362

Balance at March 31, 2022

3,354,653,999

55,911

$

(2,932,000)

$

31,955,379

$

(29,752,787)

$

(729,408)

Net loss

(2,668,167)

(2,668,167)

Stock based compensation

229,441

229,441

Cashless exercise of warrants

1,710,500,800

28,508

Balance at June 30, 2022

5,065,154,799

84,419

$

(2,932,000)

$

32,184,820

$

(32,420,954)

$

(3,168,134)

Three and Six months ended June 30, 2023

    

    

No

    

    

Additional

    

    

    

Ordinary

Par

Treasury

Paid in

Accumulated

    

Shares

    

ADS’s

    

Value

    

Stock

    

Capital

    

Deficit

    

Total

Balance at January 1, 2023

24,233,024,799

403,884

$

(2,932,000)

$

47,855,521

$

(37,516,747)

$

7,406,774

Net loss

(2,603,069)

(2,603,069)

Issuance of ADS and Pre-Funded Warrants, net

 

35,000,000,000

 

583,333

 

 

 

5,849,266

 

 

5,849,266

Stock based compensation

 

 

 

 

 

261,472

 

 

261,472

Balance at March 31, 2023

 

59,233,024,799

 

987,217

 

$

(2,932,000)

$

53,966,259

$

(40,119,816)

$

10,914,443

Net loss

 

 

 

 

 

 

(2,106,947)

 

(2,106,947)

Stock based compensation

 

 

 

264,376

 

 

264,376

Balance at June 30, 2023

 

59,233,024,799

 

987,217

 

$

(2,932,000)

$

54,230,635

$

(42,226,763)

$

9,071,872

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements

4

QUOIN PHARMACEUTICALS LTD.

Condensed Consolidated Statements of Cash Flows (unaudited)

    

Six Months Ended June 30,

    

2023

    

2022

Cash flows used in operating activities:

Net loss

$

(4,710,016)

$

(4,350,969)

Change in fair value of warrant liability

 

 

(77,237)

Stock based compensation

 

525,848

 

229,441

Forgiveness of trade payable

 

 

(416,000)

Amortization of intangibles

 

52,022

 

52,021

Increase in accrued interest and financing expense

(311,670)

Unrealized loss and accrued interest on investments

(230,755)

Changes in assets and liabilities:

 

 

Increase in accounts payable and accrued expenses

 

761,283

 

440,817

Decrease in prepaid expenses & other assets

 

282,358

 

188,671

Net cash used in operating activities

$

(3,319,260)

$

(4,244,926)

Cash flows used in investing activities:

 

  

 

  

Purchase of investments

$

(13,491,505)

$

Proceeds from maturity of investments

13,035,000

Payment for license acquisition

 

 

(250,000)

Net cash used in investing activities

$

(456,505)

$

(250,000)

Cash flows provided by (used in) financing activities:

 

  

 

  

Payment of amounts due to officers

 

(175,000)

 

(300,000)

Proceeds from sale of equity securities, net

5,849,266

Net cash provided by (used in) financing activities

$

5,674,266

$

(300,000)

Net change in cash and cash equivalents:

 

1,898,501

 

(4,794,926)

Cash and cash equivalents - beginning of period

 

2,860,628

 

7,482,773

Cash and cash equivalents - end of period

$

4,759,129

$

2,687,847

Supplemental information - Non cash items:

 

  

 

  

Reclassification of warrant liability to equity upon issuance of “Exchange warrants”

$

$

296,362

Offering expenses associated with warrant modification

$

238,231

$

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements

5

Table of Contents

QUOIN PHARMACEUTICALS LTD.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

NOTE 1 – ORGANIZATION AND BUSINESS

Quoin Pharmaceuticals Ltd. (“Quoin Ltd.,” or the “Company”), formerly known as Cellect Biotechnology Ltd. (“Cellect”), is the holding company for Quoin Pharmaceuticals, Inc., a Delaware corporation (“Quoin Inc.”). On October 28, 2021, Cellect completed the business combination with Quoin Inc., with Quoin Inc. surviving as a wholly-owned subsidiary of Cellect (the “Merger”). Immediately after completion of the Merger, Cellect changed its name to “Quoin Pharmaceuticals Ltd.”

Effective July 18, 2023, the ratio of American Depositary Shares (“ADSs”) evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs (the “Ratio Change”). All ADSs and related option and warrant information presented in these financial statements and accompanying footnotes has been retroactively adjusted to reflect the number of ADSs resulting from the Ratio Change.

Quoin Inc. was incorporated in Delaware on March 5, 2018. Quoin Inc. is clinical stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently no approved treatments or cures. The Company’s initial focus is on the development of products, using proprietary owned and in-licensed drug delivery technologies, that could help address rare skin diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary in-licensed Invisicare® technology, is under development as a potential treatment for Netherton Syndrome (“NS”), a rare hereditary genetic disease. QRX003 is currently being tested in two clinical studies in the United States (“U.S.”) under an open Investigational New Drug (“IND”) application with the Food and Drug Administration (“FDA”). Dosing of patients commenced in December 2022 for the first study and in March 2023 for the second study. The Company is also developing QRX004 as a potential treatment for Recessive Dystrophic Epidermolysis Bullosa (“RDEB”). In addition, the Company has entered into Research Agreements with the Queensland University of Technology (“QUT”), which include an option for global licenses to QRX007 for the potential treatment of NS and QRX008 for the potential treatment of scleroderma. To date, no products have been commercialized and revenue has not been generated.

NOTE 2 - LIQUIDITY RISKS AND OTHER UNCERTAINTIES

The unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”), which contemplates continuation of the Company as a going concern. The Company has incurred net losses every year since inception and has an accumulated deficit of approximately $42.2 million at June 30, 2023. The Company has limited operating history and has historically funded its operations through debt and equity financings. The Company incurred net losses of approximately $4.7 million, and negative cash flows from operations of $3.3 million for the six months ended June 30, 2023. At June 30, 2023, the Company had cash balances totaling $4.8 million and investments of $10.7 million. The Company has determined that it has sufficient cash and liquidity to effect its business plan for at least one year from the issuance of these unaudited condensed consolidated financial statements.

Additional financing will still be required to complete the research and development of the Company’s therapeutic targets and its other operating requirements until it achieves commercial profitability, if ever. Such financing may not be available at acceptable terms, if at all. If the Company is unable to obtain additional funding when it becomes necessary, the development of its product candidates will be impacted and the Company would likely be forced to delay, reduce, or terminate some or all of its development programs, all of which could have a material adverse effect on the Company’s business and financial condition.

Other risks and uncertainties:

The Company is subject to risks common to development stage biopharmaceutical companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, pre-clinical and clinical trial outcome risks, regulatory approval risks, uncertainty of market acceptance and additional financing requirements.

6

Table of Contents

QUOIN PHARMACEUTICALS LTD.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

The Company’s products require approval or clearance from the FDA prior to commencing commercial sales in the United States. There can be no assurance that the Company’s products will receive all of the required approvals or clearances. Approvals or clearances are also required in foreign jurisdictions in which the Company may license or sell its products.

There can be no assurance that the Company’s products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed.

The Company is also dependent on several third party suppliers, in some cases a single source supplier including the contract research organization managing both of the Company’s current clinical studies, the supplier of the active pharmaceutical ingredient (API), as well as the contract manufacturer of the drug substance for the expected clinical development.

Nasdaq Listing

On April 5, 2023, the Company received a letter from the Listing Qualifications staff of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that the closing bid price per ADS was below the required minimum of $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2). Pursuant to Nasdaq Rule 5810(c)(3)(A), the Company had a period of one hundred eighty (180) calendar days, or until October 2, 2023 (the “Compliance Period”), to regain compliance with Nasdaq’s minimum bid price requirement. On August 1, 2023, the Company received a letter from Nasdaq stating that the Company’s closing bid price per ADS was at $1.00 or greater for the last 10 consecutive business days. Accordingly, the Company regained compliance with Listing Rule 5550(a)(2) and the matter was closed.

There can be no assurance that the Company will be able to maintain compliance with Nasdaq’s minimum bid-price requirement for continued listing. If the Company’s ADSs are delisted from Nasdaq, it will have a material negative impact on the actual and potential liquidity of the Company’s securities, as well as a material negative impact on the Company’s ability to raise future capital.

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation:

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of June 30, 2023 and for the three and six months then ended. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of December 31, 2022 and for the year then ended which are included in the Company’s Annual Report on Form 10- K, filed with the SEC on March 15, 2023. The Company operates in one segment.

Use of estimates:

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation

7

Table of Contents

QUOIN PHARMACEUTICALS LTD.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

research and development expense recognition, intangible asset estimated useful lives and impairment assessments, allowances of deferred tax assets, and cash flow assumptions regarding going concern considerations.

Cash and cash equivalents:

The Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents. The Company, from time to time during the periods presented, has had bank account balances in excess of federally insured limits where substantially all cash is held in the United States. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

Warrants:

The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) provided that such contracts are indexed to the Company’s own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).

The Company assesses classification of its warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets, liabilities and equity is required. The Company evaluated the warrants to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that such warrants meet the criteria for equity classification in the accompanying unaudited condensed consolidated balance sheets as of June 30, 2023 and December 31, 2022, respectively.

Investments:

Investments as of June 30, 2023 and December 31, 2022 consist of U.S. Treasury Bills, which are classified as trading securities, totaling $10.7 million and $10.0 million, respectively. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date.

Long-lived assets:

Long-lived assets are comprised of acquired technology and licensed rights to use technology, which are considered platform technology with alternative future uses beyond the current products in development. Such intangible assets are being amortized on a straight-line basis over their expected useful life of 10 years.

The Company assesses the impairment for long-lived assets whenever events or circumstances indicate the carrying value may not be recoverable. Factors we consider that could trigger an impairment review include the following:

Significant changes in the manner of the Company’s use of the acquired assets or the strategy for its overall business,
Significant underperformance relative to expected historical or projected development milestones,
Significant negative regulatory or economic trends, and
Significant technological changes which could render the platform technology obsolete.

8

Table of Contents

QUOIN PHARMACEUTICALS LTD.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the three and six months ended June 30, 2023 and 2022, there were no impairment indicators which required an impairment loss measurement.

Research and development:

Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials when applicable, administrative costs incurred by third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expenses in future periods as the related services are rendered.

Income taxes:

The Company accounts for its income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company maintains a full valuation allowance on its existing deferred tax assets.

The Company also accounts for uncertain tax positions using the more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company’s income tax returns. As of June 30, 2023 and December 31, 2022, the Company had no uncertain tax positions which affected its financial position and its results of operations or its cash flows and will continue to evaluate for uncertain tax positions in the future. If at any time the Company should record interest and penalties in connection with income taxes, the interest and the penalties will be expensed within the interest and general and administrative expenses, respectively.

Stock based compensation:

The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period.

The Company’s expected stock volatility is based on the historical data regarding the volatility of a publicly traded set of peer companies, since it has a limited history of trading as a public company. The Company utilizes the simplified method to estimate the expected term. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield was assumed to be zero as the Company has not paid and dividends since its inception and does not anticipate paying dividends in the foreseeable future.

Fair value of financial instruments:

The Company considers its cash and cash equivalents, investments, accounts payable, accrued expenses to meet the definition of financial instruments. The carrying amounts of these financial instruments approximated their fair values due to the short maturities.

9

Table of Contents

QUOIN PHARMACEUTICALS LTD.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

The Company measures fair value as required by ASC Topic 820, Fair Value Measurements and Disclosures (“ASC Topic 820”). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.

Earnings (loss) per share:

The Company reports loss per share in accordance with ASC 260-10, Earnings Per Share, which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives effect to ordinary shares equivalents; however, potential common shares are excluded if their effect is anti-dilutive.

For the three and six months ended June 30, 2023, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 864,068 ADS and outstanding stock options to purchase 25,595 ADS. For the three and six months ended June 30, 2022, the number of shares excluded from the diluted net earnings (loss) per share included warrants to purchase 87,742 ADSs and outstanding options to purchase 25,760 ADSs, respectively. The inclusion of these stock options and warrants from both periods in 2023 and 2022 in the denominator would be anti-dilutive.

NOTE 4 – ACCRUED INTEREST AND FINANCING EXPENSE

On October 2, 2020, Quoin Inc. commenced an offering of promissory notes (the “2020 Notes”) and warrants to certain investors (“2020 Noteholders”). 2020 Notes were mandatorily convertible into 432 ADSs in 2021.

The ADSs issued to the 2020 Noteholders did not include the accrued interest which was estimated to be approximately $744,000 at December 31, 2021 of which $312,000 was paid to two of the five 2020 Noteholders during the year ended December 31, 2022. Based on the terms of the cash settlement with these two 2020 Noteholders, the Company’s estimate of the liability to the remaining three 2020 Noteholders was $1,146,000 as of June 30, 2023 and December 31, 2022.

There was no interest expense recognized in both the three and six month periods ended June 30, 2023 and 2022.

NOTE 5 - FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company applies fair value accounting for all assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. For certain instruments, including cash and cash equivalents, accounts payable, and accrued expenses, it was estimated that the carrying amount approximated fair value because of the short maturities of these instruments.

Fair value is estimated using various valuation models, which utilize certain inputs and assumptions that market participants would use in pricing the asset or liability. The inputs and assumptions used in valuation models are classified in the fair value hierarchy as follows:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Quoted market prices for similar instruments in an active market; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations inputs of which are observable and can be corroborated by market data.

10

Table of Contents

QUOIN PHARMACEUTICALS LTD.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

Level 3: Unobservable inputs and assumptions that are supported by little or no market activity and that are significant to the fair value of the asset and liability. The fair value hierarchy gives the lowest priority to Level 3 inputs.

In determining the appropriate hierarchy levels, the Company analyzes the assets and liabilities that are subject to fair value disclosure. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to their fair value measurement.

The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis by fair value hierarchy at June 30, 2023 and December 31, 2022:

June 30, 2023

    

Level 1

    

Level 2

    

Level 3

    

Total

US Treasury Bills

 

$

10,680,160

 

$

$

$

10,680,160

Total US Treasury Bills Asset

 

$

10,680,160

 

$

$

$

10,680,160

December 31, 2022

    

Level 1

    

Level 2

    

Level 3

    

Total

US Treasury Bills

$

9,992,900

$

$

$

9,992,900

Total US Treasury Bills Asset

$

9,992,900

$

$

$

9,992,900

NOTE 6 – STOCK BASED COMPENSATION

In March 2022, the Board of Directors of the Company approved the Amended and Restated Equity Incentive Plan (the “Amended Plan”), which was approved by the shareholders at the Company’s Annual General Meeting of Shareholders held on April 12, 2022. The Amended Plan increased the number of ordinary shares reserved for issuance under such equity incentive plan to 15% of the Company’s outstanding ordinary shares on a fully-diluted basis, or 16,891,925,220 ordinary shares represented by 281,532 ADSs as of June 30, 2023. Under the Amended Plan, the Company may grant options to its directors, officers, employees, consultants, advisers and service providers. As of June 30, 2023, 255,937 ADSs remained available for grant under the Amended Plan.

The following table summarizes stock-based activities under the Amended Plan:

    

    

Weighted

    

Weighted

Average

Average

ADS Underlying

Exercise

Contractual

Options

Price

Terms

Outstanding at December 31, 2022

 

25,595

$

210.00

 

9.28

Granted

 

$

 

Forfeited/Cancelled

 

$

 

Outstanding at June 30, 2023

 

25,595

$

210.00

 

8.78

Exercisable options at June 30, 2023

 

6,845

$

210.00

 

8.78

The intrinsic value of outstanding options at June 30, 2023 was $0.

Stock based compensation expense was approximately $264,000 ($34,000 included in research and development expense and $230,000 included in general and administrative expenses) in the three months ended June 30, 2023 and approximately $526,000 ($69,000 included in research and development expense and $457,000 included in general and administrative expenses) in the six months ended June 30, 2023.

Stock based compensation expense was approximately $229,000 ($30,000 included in research and development expense and $199,000 included in general and administrative expenses) in both the three and six months ended June 30, 2022.

11

Table of Contents

QUOIN PHARMACEUTICALS LTD.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

At June 30, 2023, the total unrecognized compensation expense related to non-vested options was approximately $2,679,000 and is expected to be recognized over the remaining weighted average service period of approximately 2.60 years.

NOTE 7 – PREPAID EXPENSES

Prepaid expenses are as follows:

    

June 30, 

    

December 31, 

2023

2022

Prepaid R&D costs

$

383,390

$

383,390

Prepaid insurance

 

202,226

 

508,084

Prepaid expense

 

32,000

 

8,500

Total

$

617,616

$

899,974

Less: Short-term portion

(234,226)

(516,584)

Long-term portion

$

383,390

$

383,390

NOTE 8 - ACCRUED EXPENSES

Accrued expenses are as follows:

    

June 30, 

    

December 31, 

2023

2022

Research contract expenses (note 12)

$

343,152

$

105,071

Payroll (note 11)

 

1,168,486

 

788,169

Payroll taxes (note 11)

 

199,408

 

159,593

Professional fees

 

85,299

 

44,278

Other Expenses

 

38,308

 

78,594

Total

$

1,834,653

$

1,175,705

NOTE 9 – IN-LICENSED TECHNOLOGY

Polytherapeutics:

On March 24, 2018, Quoin Inc. entered into a securities purchase agreement (the “Acquisition Agreement”), in which it agreed to acquire all of the equity interests in Polytherapeutics, Inc. (the “Seller” or “Polytherapeutics”) for $40,833 and future royalties provided Quoin Inc. commercializes products using the technology developed by the Seller. The terms of any royalty payments to the Seller are 4.0% of the net revenue of royalty products, as defined in the Acquisition Agreement during the ten (10) year period commencing from the date of first sale of a royalty product. If a generic product is introduced by a third party to the market, during the royalty period, the royalty fees shall be reduced from 4% to 2%. If, during the royalty period, two or more generic products are introduced, the royalty fees shall be reduced from 2% to 0%.

Skinvisible:

In October 2019, Quoin Inc. entered into the Exclusive Licensing Agreement (as amended from time to time, the “License Agreement”) with Skinvisible Pharmaceuticals, Inc. (“Skinvisible”), under which Skinvisible granted the Company an exclusive royalty-bearing license relating to the production and manufacture of prescription drug products related to certain patents held by Skinvisible, including those related to QRX003 and QRX004. The Company made Skinvisible a one-time non-refundable, non-creditable license fee of $1 million (the “License Fee”). In addition, the Company agreed to pay Skinvisible a single digit royalty percentage of the Company’s net sales revenues for any licensed product covered by the patent rights licensed under the License Agreement. The Company also agreed

12

Table of Contents

QUOIN PHARMACEUTICALS LTD.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

to pay Skinvisible 25% of any revenues the Company receives as royalties in the event that the Company sublicense any licensed products to a third party. The License Agreement also requires that the Company make a $5 million payment to Skinvisible upon receiving approval in the U.S. or European Union, whichever occurs first, for the first drug product developed using intellectual property licensed thereunder.

NOTE 10 - INTANGIBLE ASSETS

Intangible assets are as follows:

    

June 30, 

    

December 31, 

2023

2022

Acquired technology – Polytherapeutics

$

40,433

$

40,433

Technology license – Skinvisible

 

1,000,000

 

1,000,000

Total cost

 

1,040,433

 

1,040,433

Accumulated amortization

 

(387,894)

 

(335,872)

Net book value

$

652,539

$

704,561

The Company recorded amortization expense of approximately $52,000 for the six months ended June 30, 2023 and 2022. The Company recorded amortization expense of approximately $26,000 for the three months ended June 30, 2023 and 2022. The annual amortization expense expected to be recorded for existing intangible assets for the years 2023 through 2026, and thereafter, is approximately $52,000, $104,000, $104,000, $104,000 and $288,000, respectively.

NOTE 11 - RELATED PARTY TRANSACTIONS

Employment Agreements and Due to Officers/Founders:

Due to the limited funding of Quoin Inc. prior to the consummation of the Merger, the compensation, including salary, office and car allowances and other benefits, due to Dr. Myers and Ms. Carter under their respective employment agreements, as well as reimbursement of expenses and other amounts paid to third parties on behalf of Quoin Inc., were accrued as indebtedness to Dr. Myers and Ms. Carter. Following the closing of the Merger, Quoin Inc. began making payments of $25,000 per month to each of Dr. Myers and Ms. Carter to repay the above-described non-interest-bearing indebtedness. The Company repaid $75,000 and $75,000 of such indebtedness to Dr. Myers and $0 and $75,000 to Ms. Carter in the three months ended June 30, 2023 and 2022, respectively. The Company repaid $150,000 and $150,000 of such indebtedness to Dr. Myers and $25,000 and $150,000 to Ms. Carter in the six months ended June 30, 2023 and 2022, respectively.

As of June 30, 2023, approximately $2,109,000 and $1,840,000 of such indebtedness was outstanding to Dr. Myers and Ms. Carter, respectively.

Amounts due to officers at June 30, 2023 and December 31, 2022 consisted of the following:

    

June 30, 

    

December 31, 

2023

2022

Salaries and other compensation

$

3,948,733

 

$

4,108,500

Invoices paid on behalf of the Company

 

 

15,232

Total

$

3,948,733

 

$

4,123,732

Less: Short-term portion

 

(725,000)

 

(600,000)

Long-term portion

$

3,223,733

$

3,523,733

13

Table of Contents

QUOIN PHARMACEUTICALS LTD.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

Expenses:

Research and development expense, incurred in the three months ended June 30, 2023 and 2022, was $0 and $12,000 and it was $12,000 and $24,000 in the six months ended June 30, 2023 and 2022, respectively, for payments to the CEO Dr. Myers’ son, who had been consulting for the Company on research and development matters from time to time. As of March 31, 2023, Dr. Myers’ son no longer provided consulting services to the Company.

Interest Payable:

See Note 4 for interest payable on the 2020 Notes.

NOTE 12 – RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS

Research agreements

In November 2020, Quoin Inc. entered into a Master Service Agreement for an initial term of three years with Therapeutics Inc. for managing preclinical and clinical development for new products in the field of dermatology. The agreement required the execution of individual work orders. Quoin Inc. may terminate any work order for any reason with 90 days written notice subject to costs incurred through termination and a defined termination fee, unless there is a material breach by Therapeutics Inc. A work order was entered into in June 2022 for the first QRX003 clinical study at an expected estimated cost of approximately $4.4 million through 2024. A further work order was entered into in December 2022 for the second QRX003 clinical study at an expected estimated cost of approximately $830,000 through 2024. For the three and six months ended June 30, 2023 and 2022, the Company incurred a research and development expense under these agreements of approximately $360,000 and $959,000, and $309,000 and $480,000 respectively.

In November 2021, the Company entered into a commitment with Queensland University of Technology for research related services associated with Netherton Syndrome of approximately $250,000 for an expected period of eighteen months. For the three and six months ended June 30, 2023 and 2022, the Company incurred research and development costs related to this agreement of approximately $0 and $50,000, and $77,000 and $77,000 respectively.

In May 2022, the Company entered into a commitment with Queensland University of Technology for research related services associated with Scleroderma of approximately $610,000 for an expected period of eighteen months. For the three and six months ended June 30, 2023 and 2022, the Company incurred research and development costs related to this agreement of approximately $138,000 and $226,000, and $-0- and $-0- respectively.

Consulting agreement:

Quoin Inc. entered into a consulting agreement with an Investor Relations (IR) firm, which provided for a monthly fee of $14,000. The agreement had an automatic annual renewal clause and was in effect in November 2017. The Company owed the IR firm $584,000 as of December 31, 2021. Effective March 31, 2022, the Company entered into a settlement agreement with the IR firm reducing the liability to $168,000 and recognized $416,000 as other income in the accompanying consolidated statement of operations. The liability was fully repaid as of April 1, 2023. No expenses were incurred in both the three and six months ended June 30, 2023 and 2022, respectively.

Performance milestones and Royalties

See Note 9 for asset and in-licensed technology commitments.

14

Table of Contents

QUOIN PHARMACEUTICALS LTD.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

NOTE 13 – SHAREHOLDERS’ EQUITY

The Company held its Annual General Meeting on April 12, 2022, at which the Company’s shareholders approved an increase to the authorized share capital to 50,000,000,000, no par value. The Company held a further Annual General Meeting on November 3, 2022, at which the Company’s shareholders approved an increase to the authorized share capital to 500,000,000,000 ordinary shares from 50,000,000,000, no par value. These ordinary shares are not redeemable and do not have any preemptive rights.

Holders of the Company’s ordinary shares have one vote for each ordinary share held on all matters submitted to a vote of shareholders at a shareholders meeting. The board of directors shall determine and provide a record date for each shareholders meeting and all shareholders at such record date may vote. Unless stipulated differently in the Companies Law or in the articles of association, all shareholders’ resolutions shall be approved by a simple majority vote.

Under Israeli law, the Company may declare and pay dividends only if, upon the determination of its board of directors, there is no reasonable concern that the distribution will prevent the Company from being able to meet the terms of its existing and foreseeable obligations as they become due. Under the Companies Law, the distribution amount is further limited to the greater of retained earnings or earnings generated over the two most recent years legally available for distribution according to the Company’s then last reviewed or audited financial statements, provided that the date of the financial statements is not more than six months prior to the date of distribution. In the event that the Company does not have retained earnings or earnings generated over the two most recent years legally available for distribution, the Company may seek the approval of the court in order to distribute a dividend. The court may approve the Company’s request if it determines that there is no reasonable concern that the payment of a dividend will prevent the Company from satisfying existing and foreseeable obligations as they become due.

Each ADS will also represent any other securities, cash or other property which may be held by the depositary. ADSs may be held either (a) directly (1) by having an American Depositary Receipt, also referred to as an ADR, which is a certificate evidencing a specific number of ADSs or (2) by having uncertificated ADSs, or (b) indirectly by holding a security entitlement in ADSs through a broker or other financial institution that is a direct or indirect participant in The Depository Trust Company, also called DTC.

February 2023 Offering

On February 24, 2023 (the “February Closing Date”), the Company completed an offering (the “February Offering”) of 24,750,000,000 ordinary shares represented by 412,500 ADSs at a purchase price of $12.00 per ADS and a pre-funded warrant (the “February Pre-Funded Warrant”) to purchase 10,250,000,000 ordinary shares represented by 170,833 ADSs at a per pre-funded warrant price of $11.9988, with each ADS and February Pre-Funded Warrant accompanied by an ordinary warrant (the “February Common Warrant”) for aggregate gross proceeds of $7.0 million, resulting in net proceeds of approximately $5.8 million, after deducting the placement agent’s fees and offering expenses. Each February Common Warrant has an exercise price of $12.00 per ADS and expires on the fifth anniversary of the February Closing Date. On the February Closing Date, the holder of the February Pre-Funded Warrant exercised its Pre-Funded Warrant in full.

In connection with the February Offering, the Company entered into a Securities Purchase Agreement (the “February Purchase Agreement”) with certain institutional investors. Under the February Purchase Agreement, subject to certain exemptions, the Company agreed not to: (i) for a period of ninety (90) days after the closing date of the February Offering, issue, enter into any agreement to issue or announce the issuance or proposed issuance of any ADSs, ordinary shares or ordinary share equivalents or (ii) file any registration statement or amendment or supplement thereto, other than a registration statement on Form S-8 in connection with any employee benefit plan or any post-effective amendment to a registration statement declared effective by the Securities and Exchange Commission (the “SEC”) and (ii) for a period of 180 days after the closing date of the February Offering, enter into an agreement to effect a “variable rate transaction” as defined in the Purchase Agreement.

15

Table of Contents

QUOIN PHARMACEUTICALS LTD.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

In connection with the February Offering, the Company entered into an Amendment No. 1 to Warrant to Purchase Ordinary Shares Represented by American Depositary Shares, dated February 24, 2023 (collectively, the “Warrant Amendments”), with each of the purchasers (the “2022 Purchasers”) who participated in both the Company’s offering completed in August 2022 (the “August Offering”) and February Offering. The Warrant Amendments amended certain terms of the Common Warrants issued in the August Offering to such 2022 Purchasers. Specifically, the Warrant Amendments reduced the exercise price of Common Warrants to purchase 235,833 ADSs out of the total 280,000 issued in the August Offering from $60.00 to $13.20 and extended the term during which those warrants could remain exercisable until February 24, 2028. The incremental fair value of the modified warrants was approximately $238,000, which was accounted for as an offering expense in connection with the February Offering.

Warrants

The following table summarizes warrant activities during the six months ended June 30, 2023:

    

    

Weighted

 

ADSs

Average

 

Underlying

Exercise Price

 

Warrants

Per ADS

Outstanding at December 31, 2022

 

280,735

 

$

24.85

*

Granted Common Warrants

 

583,333

12.00

Granted Pre-Funded Warrants

170,833

Exercised Pre-Funded Warrants

 

(170,833)

 

Outstanding and exercisable at June 30, 2023

 

864,068

$

16.17

*Includes the reduction of the exercise price from $60.00 per ADS to $13.20 per ADS for Common Warrants issued in the August Offering to investors who participated in both the Company’s August Offering and February Offering, see above.

NOTE 14 – CONTINGENCIES

From time to time, the Company may become involved in various legal matters arising in the ordinary course of business. Management is unaware of any matters requiring accrual for related losses in the financial statements.

NOTE 15 – LICENSE AGREEMENTS

As of June 30, 2023, the Company has entered into eight license and supply agreements, whereby the Company will receive a royalty or other proceeds from the specified product revenues in select non-US markets from the licensor, if and when the underlying products are approved and commercialized. No royalty revenues have been received through June 30, 2023 under any of these agreements.

NOTE 16 - SUBSEQUENT EVENTS

Effective July 18, 2023, the ratio of ADSs evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs. See Note 1.

On August 1, 2023, the Company received a letter from Nasdaq stating that the Company’s closing bid price per ADS was at $1.00 or greater for the last 10 consecutive business days. Accordingly, the Company regained compliance with Listing Rule 5550(a)(2) and the matter was closed. See Note 2.

16

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes thereto included in Part I-Item 1 of this Form 10-Q. This discussion and other parts of this report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Our actual results could differ materially from those discussed in these forward-looking statements. See “Cautionary Note Regarding Forward-Looking Statements” in this Form 10-Q.

Overview

We are a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently no approved treatments or cures. Our initial focus is on the development of products, using our proprietary owned and in-licensed drug delivery technologies, that could help address rare skin diseases. Our first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary in-licensed Invisicare® technology, is under development as a potential treatment fort Netherton Syndrome (“NS”), a rare hereditary genetic disease. QRX003 is currently being tested in two clinical studies in the United States (“U.S.”) under an open Investigational New Drug (“IND”) application with the Food and Drug Administration (“FDA”). We are also developing QRX004 as a potential treatment for Recessive Dystrophic Epidermolysis Bullosa (“RDEB”). In addition, we entered into Research Agreements with the Queensland University of Technology (“QUT”), under which we have obtained an option for global licenses to QRX007 for the potential treatment of NS and QRX008 for the potential treatment of scleroderma.

Our objective is to develop and commercialize proprietary therapeutic drug products. To this effect, we intend to develop and seek marketing approvals from the FDA and other worldwide regulatory bodies for rare and orphan diseases. To achieve these objectives, we plan to:

complete the late-stage clinical testing of QRX003 and, if successful, file for marketing approval in the United States and other territories;
prepare to commercialize QRX003 by establishing our own sales infrastructure in the U.S. and Europe and entering into distribution partnerships in other territories such as those currently established for Canada, Australia/New Zealand, the Middle East, China, Hong Kong, Taiwan, Latin America, Central and Eastern Europe, Turkey; and
pursue business development activities by seeking partnering, licensing, merger and acquisition opportunities or other transactions to further expand our pipeline and drug-development capabilities.

We do not expect to generate revenue from product sales unless and until we successfully complete development and obtain marketing approval for one or more of our product candidates, which we expect will take a number of years and is subject to significant uncertainty. Accordingly, we will need to raise additional capital prior to the commercialization of QRX003 or any other product candidate. Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our operating activities through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to continue our operations. See “Liquidity and Capital Resources”.

ADS Ratio Change

Effective July 18, 2023, the ratio of American Depositary Shares (“ADSs”) evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs (the “Ratio Change”). All ADSs and related option and warrant information presented in this section, as well as our financial statements and accompanying footnotes, has been retroactively adjusted to reflect the number of ADSs resulting from the Ratio Change.

17

Key Events

Clinical Development

Quoin’s lead asset, QRX003, is currently in late-stage clinical development in the U.S. under an open IND application with the FDA. Five clinical sites in the U.S. have been opened for this study, patients are actively being screened and recruited into the study and dosing commenced in December 2022. This study is a randomized, double blinded assessment of two different doses of QRX003 versus a placebo vehicle in NS patients. The test materials are applied once daily, over a twelve-week period, to pre-selected areas of the patient’s body. Based on discussions with the FDA, a number of different clinical endpoints are being assessed in the study, including but not limited to, an Investigators Global Assessment (IGA), Patient’s Global Assessment (PaGA) and Pruritis.

In November 2022, we submitted a protocol for our second clinical study in NS patients to the FDA under our currently open IND. This study was cleared by the FDA to initiate in December 2022. Patients are actively being screened and recruited into the study, dosing commenced in March 2023. This study is being conducted in ten NS patients who are currently receiving off-label systemic therapy, primarily systemic biologic therapy. This is an open-label study with no placebo control. Both of our NS clinical studies are running concurrently and utilize the same clinical trial sites and investigators.

Public Offering

On February 24, 2023 (the “February Closing Date”), we completed an offering (the “February Offering”) of 24,750,000,000 ordinary shares represented by 412,500 ADSs at a purchase price of $12.00 per ADS and a pre-funded warrant (the “February Pre-Funded Warrant”) to purchase 10,250,000,000 ordinary shares represented by 170,833 ADSs at a per pre-funded warrant price of $11.9988, with each ADS and February Pre-Funded Warrant accompanied by an ordinary warrant (the “February Common Warrant”) for aggregate gross proceeds of $7.0 million, resulting in net proceeds of approximately $5.8 million, after deducting the placement agent’s fees and offering expenses paid by us, and excluding the proceeds, if any, from the subsequent exercise of the February Common Warrants. Each February Common Warrant has an exercise price of $12.00 per ADS and expires on the fifth anniversary of the February Closing Date. On the February Closing Date, the holder of the February Pre-Funded Warrant exercised its Pre-Funded Warrant in full.

In connection with the February Offering, we entered into a Securities Purchase Agreement (the “February Purchase Agreement”) with certain institutional investors. Under the February Purchase Agreement, subject to certain exemptions, we agreed not to: (i) for a period of ninety (90) days after the closing date of the February Offering, issue, enter into any agreement to issue or announce the issuance or proposed issuance of any ADSs, ordinary shares or ordinary share equivalents or (ii) file any registration statement or amendment or supplement thereto, other than a registration statement on Form S-8 in connection with any employee benefit plan or any post-effective amendment to a registration statement declared effective by the Securities and Exchange Commission (the “SEC”) and (ii) for a period of 180 days after the closing date of the February Offering, enter into an agreement to effect a “variable rate transaction” as defined in the February Purchase Agreement.

In connection with the February Offering, we entered into an Amendment No. 1 to Warrant to Purchase Ordinary Shares Represented by American Depositary Shares, dated February 24, 2023 (collectively, the “Warrant Amendments”), with each of the purchasers (the “2022 Purchasers”) who participated in both our offering completed in August 2022 (the “August Offering”) and the February Offering. The Warrant Amendments amended certain terms of the Common Warrants issued to such 2022 Purchasers in the August Offering. Specifically, the Warrant Amendments reduced the exercise price of such warrants to $13.20 and extended the term during which those warrants could remain exercisable until February 24, 2028.

18

Nasdaq Listing

On April 5, 2023, we received a letter from Listing Qualifications staff of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying us that the closing bid price per ADS was below the required minimum of $1.00 for a period of 30 consecutive business days and that the we did not meet the minimum bid price requirements set forth in Nasdaq Rule 5550(a)(2). Pursuant to Nasdaq Rule 5810(c)(3)(A), we had a period of one hundred eighty (180) calendar days, or until October 2, 2023 (the “Compliance Period”), to regain compliance with Nasdaq’s minimum bid price requirement. On August 1, 2023, we received a letter from Nasdaq stating that the closing bid price per ADS was at $1.00 or greater for the last 10 consecutive business days. Accordingly, we regained compliance with Listing Rule 5550(a)(2) and the matter was closed.

There can be no assurance that we will be able to maintain compliance with Nasdaq’s minimum bid-price requirement for continued listing. If our ADSs are delisted from Nasdaq, it will have a material negative impact on the actual and potential liquidity our securities, as well as a material negative impact on our ability to raise future capital.

Components of Our Results of Operations

Operating Expenses

Our current operating expenses consist of two components - research and development expenses, and general and administrative expenses.

Research and Development Expenses

Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. We utilize outside consultants and third parties to conduct the majority of our research and development, under the supervision of our management team.

Future research and development expenses may include:

employee-related expenses, such as salaries, bonuses and benefits, consultant-related expenses, share-based compensation, overhead related expenses and travel related expenses for our research and development personnel;
expenses incurred under agreements with CROs, as well as consultants that support the implementation of the clinical studies described above;
manufacturing and packaging costs in connection with conducting clinical trials and for stability and other studies required to support the NDA filing as well as manufacturing drug product for commercial launch;
formulation, research and development expenses related to QRX003; and other products we may choose to develop; and
costs for sponsored research.

Research and development activities will continue to be central to our business plan. Products in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to be significant over the next several years as personnel and compensation costs increase and we conduct late-stage clinical studies and prepare to seek regulatory approval for QRX003 and any other future product.

The duration, costs and timing of clinical trials of QRX003 and any other future product will depend on a variety of factors that include, but are not limited to:

the number of trials required for approval;

19

the per patient trial costs;
the number of patients that participate in the trials;
the number of sites included in the trials;
the countries in which the trial is conducted;
the length of time required to enroll eligible patients;
the number of doses that patients receive;
the drop-out or discontinuation rates of patients;
the potential additional safety monitoring or other studies requested by regulatory agencies;
the duration of patient follow-up;
the timing and receipt of regulatory approvals; and
the efficacy and safety profile of our product candidates.

General and Administrative Expenses

General and administrative expenses consist primarily of compensation and employee related expenses including non-cash stock-based compensation, professional fees and other corporate expenses.

We anticipate that our general and administrative expenses may increase during the remainder of 2023 to support our continued research and development activities. These increases will include compensation and employee-related expenses including stock-based compensation, increased costs related to the potential hiring of personnel, travel costs and fees to outside consultants, lawyers and accountants.

Other Expenses (income)

Other expenses (income) consist primarily of non cash fair value adjustments of warrants, forgiveness of trade payable, interest income and unrealized loss on investments.

20

Results of Operations – Three months ended June 30, 2023 compared to the three months ended June 30, 2022

The following table sets forth our results of operations for the three months ended June 30, 2023, compared to the three months ended June 30, 2022:

Three months ended June 30,

2023

2022

Change

Operating expenses

    

  

    

  

    

  

General and administrative

$

1,634,960

$

1,941,473

$

(306,513)

Research and development

 

625,104

 

726,694

 

(101,590)

Total operating expenses

 

2,260,064

 

2,668,167

 

(408,103)

Other (income) and expenses

 

 

 

Unrealized loss

 

34,472

 

 

34,472

Interest income

 

(187,589)

 

 

(187,589)

Total other income

 

(153,117)

 

 

(153,117)

Net loss

$

(2,106,947)

$

(2,668,167)

$

561,220

General and Administrative Expenses

General and administrative expenses were approximately $1,635,000 and $1,941,000, in the three months ended June 30, 2023 and 2022, respectively, representing a decrease of approximately $307,000, or approximately 16%. The decrease was primarily due to a decrease in legal fees and other public company costs of $448,000, offset by an increase in salary and benefit costs of $98,000 and an increase in non-cash stock-based compensation expense of $30,000.

Research and Development Expenses

Our research and development expenses during the three months ended June 30, 2023 and 2022 were approximately $625,000 and $727,000, respectively, representing a decrease of approximately $102,000, or approximately 14%. The decrease was primarily due to $142,000 in decreased expenditures on our development programs, including work related to the clinical studies for the development of QRX003 and our research collaborations with Queensland University of Technology. We expect to increase our research and development efforts during the remainder of 2023 by conducting the remaining studies necessary for the development and approval of QRX003, see “Components of Our Results of Operations - Research and Development Expenses” above.

We amortize licensed or acquired intellectual property over its expected useful life, included in research and development expenses set forth above. The license from Skinvisible was obtained in October 2019. Amortization of intangible assets was approximately $26,000 in each of the three month periods ended June 30, 2023 and 2022.

Other (Income) and Expenses:

Interest income and unrealized loss

We earned approximately $188,000 in interest income and incurred approximately $34,000 in unrealized loss in the three months ended June 30, 2023 from our cash and cash equivalents and investments in marketable debt securities.

21

Results of Operations – Six months ended June 30, 2023 compared to the six months ended June 30, 2022

The following table sets forth our results of operations for the six months ended June 30, 2023, compared to the six months ended June 30, 2022:

Six months ended June 30,

2023

2022

Change

Operating expenses

    

  

    

  

    

  

General and administrative

$

3,318,777

$

3,529,943

$

(211,166)

Research and development

 

1,716,837

 

1,314,263

 

402,574

Total operating expenses

 

5,035,614

 

4,844,206

 

191,408

Other (income) and expenses

 

 

 

Forgiveness of trade payable

(416,000)

416,000

Warrant liability (income) expense

 

 

(77,237)

 

77,237

Unrealized loss

 

14,045

14,045

Interest income

 

(339,643)

 

 

(339,643)

Total other income

 

(325,598)

 

(493,237)

 

167,639

Net loss

$

(4,710,016)

$

(4,350,969)

$

(359,047)

General and Administrative Expenses

General and administrative expenses were approximately $3,319,000 and $3,530,000, in the six months ended June 30, 2023 and 2022, respectively, representing a decrease of approximately $211,000, or approximately 6%. The decrease was primarily due to a decrease in legal fees and other public company expenses of $627,000 offset by increases of $70,000 in salary and benefit expenses, $43,000 in travel related expenses and non-cash stock-based compensation expense of $258,000.

Research and Development Expenses

Our research and development expenses during the six months ended June 30, 2023 and 2022 were approximately $1,717,000 and $1,314,000, respectively, representing an increase of approximately $403,000, or approximately 31%. The increase was primarily due to $323,000 in increased expenditures on our development programs, including work related to the clinical studies for the development of QRX003 and our research collaborations with Queensland University of Technology. Also, included in the 2023 expenses were approximately $39,000 of non-cash stock-based compensation expense allocated to research and development expense following the issuance of options under the Amended Plan in April 2022. We expect to increase our research and development efforts during the remainder of 2023 by conducting the remaining studies necessary for the development and approval of QRX003, see “Components of Our Results of Operations - Research and Development Expenses” above.

We amortize licensed or acquired intellectual property over its expected useful life, included in research and development expenses set out above. The license from Skinvisible was obtained in October 2019. Amortization of intangible assets was approximately $52,000 in each of the six month periods ended June 30, 2023 and 2022.

Other (Income) and Expenses:

Interest and unrealized loss

We earned approximately $339,000 in interest income and incurred approximately $14,000 in unrealized loss in the six months ended June 30, 2023 from our cash and cash equivalents and investments in marketable debt securities.

22

Warrant liability income

We determined our warrants issued to investors in our 2020 notes (the “2020 Noteholder Warrants”) required liability treatment at fair value, which was remeasured at each reporting period up to March 2022. The 2020 Noteholder Warrants were exchanged for new warrants and reclassified as an equity instrument in March 2022. In the six months ended June 30, 2022, we incurred a fair value gain of $77,000 related to the 2020 Noteholder Warrants.

Forgiveness of trade payable

In our balance sheet as of December 31, 2021 we had a liability of $584,000 representing amounts due to an investor relations firm for services commencing in 2017. Effective March 31, 2022, we entered into a settlement with such firm to decrease the liability to $168,000 which resulted in approximately $416,000 of income recognized in the six months ended June 30, 2022.

Liquidity and Capital Resources

We have incurred net losses every year since inception and had an accumulated deficit of approximately $42.2 million at June 30, 2023. We have a limited operating history and have historically funded our operations through debt and equity financings. We incurred net losses of approximately $4.7 million and negative cash flows from operations of $3.3 million for the six months ended June 30, 2023. At June 30, 2023, we had cash and cash equivalent balances totaling $4.8 million and investments of $10.7 million. We have determined that we have sufficient resources to effect our business plan for at least one year from the issuance of the unaudited consolidated financial statements included in this report. However, we do not expect to generate revenue from product sales unless and until we successfully complete development and obtain marketing approval for one or more of our product candidates, which we expect will take a number of years and is subject to significant uncertainty. Additional financing will be required to complete the research and development of our therapeutic targets and our other operating requirements, which may not be available at acceptable terms, if at all. If we are unable to obtain additional funding when it becomes necessary, the development of our product candidates will be impacted and we would likely be forced to delay, reduce, or terminate some or all of our development programs, all of which could have a material adverse effect on our business, results of operations and financial condition.

Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of planned clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will continue to increase in 2023 as we advance the clinical development of QRX003.

Future Funding Requirements

We will need to obtain further funding through public or private offerings of our capital stock, debt financing, collaboration and licensing arrangements or other sources, the requirements for which will depend on many factors, including:

the scope, timing, rate of progress and costs of our drug development efforts, preclinical development activities, the timing of laboratory testing and clinical trials for our product candidates;
the number and scope of clinical programs we decide to pursue;
the cost, timing and outcome of preparing for and undergoing regulatory review of our product candidates;
the scope and costs of development and commercial manufacturing activities;
the cost and timing associated with commercializing our product candidates, if they receive marketing approval;
the extent to which we acquire or in-license other product candidates and technologies;
the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;

23

our ability to establish and maintain collaborations on favorable terms, if at all;
our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates and, ultimately, the sale of our products, following FDA approval;
our implementation of operational, financial and management systems; and
the costs associated with being a public company.

Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of QRX003, any future product, or potentially discontinue operations.

To the extent that we raise additional capital through the sale of our equity or convertible debt securities, and pursuant to the exercise of warrants issued to our investors in the August Offering and February Offering, the ownership interest of our equity holders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our equity holders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or proposed products, or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market any future product that we would otherwise prefer to develop and market ourselves.

Summary Statement of Cash Flows

As of June 30, 2023, we had approximately $4,759,000 in cash and cash equivalents and $10,680,000 in investments in marketable securities. The table below presents our cash flows for the six month periods ended June 30, 2023 and 2022:

Six months ended June 30,

    

2023

    

2022

Net cash used in operating activities

$

(3,319,260)

$

(4,244,926)

Net cash used in investing activities

 

(456,505)

 

(250,000)

Net cash provided by (used in) financing activities

 

5,674,266

 

(300,000)

Net increase (decrease) in cash and cash equivalents

$

1,898,501

$

(4,794,926)

Operating Activities

Net cash used in operating activities was approximately $3,319,000 and $4,245,000 in the six months ended June 30, 2023 and 2022, respectively. The decrease in 2023 was primarily due to an increase in accounts payable and accrued expenses, offset by a decrease in prepaid expenses.

24

Investing Activities

Net cash used in investing activities was approximately $457,000 and $250,000 in the six months ended June 30, 2023 and 2022, respectively. The cash used in investing activities for the six months ended June 30, 2023 consisted of net purchases of short maturity US Treasury Bills from the proceeds of the February Offering, and the cash used in investing activities in the six months ended June 30, 2022 consisted of payments of remaining amounts due under our license agreement with Skinvisible, see “Research and Development Commitments” below.

Financing Activities

Net cash provided by financing activities was approximately $5,674,000 for the six months ended June 30, 2023. The net cash provided increased due to the receipt of approximately $5,849,000 in net proceeds from the February Offering partially offset by repayments of amounts due to officers of $175,000. Net cash (used in) financing activities in the six months ended June 30, 2022 was $300,000, representing repayments of amounts due to officers.

Research and Development Commitments

In October 2019, Quoin Inc. entered into the Exclusive Licensing Agreement (as amended from time to time, the “License Agreement”) with Skinvisible Pharmaceuticals, Inc. (“Skinvisible”), under which Skinvisible granted us an exclusive royalty-bearing license relating to the production and manufacture of prescription drug products related to certain patents held by Skinvisible, including those related to QRX003 and QRX004. We made Skinvisible a one-time non-refundable, non-creditable license fee of $1 million (the “License Fee”). In addition, we agreed to pay Skinvisible a single digit royalty percentage of our net sales revenues for any licensed product covered by the patent rights licensed under the License Agreement. We also agreed to pay Skinvisible 25% of any revenues we receive as royalties in the event that we sublicense any licensed products to a third party. The License Agreement also requires that we make a $5 million payment to Skinvisible upon receiving approval in the U.S. or European Union, whichever occurs first, for the first drug product developed using intellectual property licensed thereunder.

In November 2020, Quoin Inc. entered into a Master Service Agreement for an initial term of three years with Therapeutics Inc. for managing preclinical and clinical development for new products in the field of dermatology. The agreement required the execution of individual work orders. Quoin Inc. may terminate any work order for any reason with 90 days written notice subject to costs incurred through termination and a defined termination fee, unless there is a material breach by Therapeutics Inc. A work order was entered into in June 2022 for the first QRX003 clinical study at an expected estimated cost of approximately $4.4 million through 2024. A further work order was entered into in December 2022 for the second QRX003 clinical study at an expected estimated cost of approximately $830,000 through 2024. For the three and six months ended June 30, 2023 and 2022, we incurred a research and development expense under these agreements of approximately $360,000 and $959,000, and $309,000 and $480,000, respectively.

In November 2021, we entered into a commitment with Queensland University of Technology for research related services associated with Netherton Syndrome of approximately $250,000 for an initial expected period of eighteen months. For the three and six months ended June 30, 2023 and 2022, we incurred research and development costs related to this agreement of approximately $0 and $50,000, and $77,000 and $77,000, respectively.

In May 2022, we entered into a commitment with Queensland University of Technology for research related services associated with Scleroderma of approximately $610,000 for an initial expected period of eighteen months. We incurred research and development expenses of approximately $138,000 and $226,000 for the three and six months ended June 30, 2023.

Critical Accounting Policies and Use of Estimates

There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in our Annual Report on Form 10-K for the year ended December 31, 2022.

25

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and are not required to provide the information otherwise required under this Item 3.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. As of June 30, 2023, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2023. In designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and implemented, can provide only reasonable assurance of achieving the desired control objectives.

Changes in Internal Control over Financial Reporting

During the quarter ended June 30, 2023, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

26

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in legal or administrative proceedings or be subject to claims arising in the ordinary course of our business. We are currently not a party to any material legal or administrative proceedings, and we are not aware of any pending or threatened material legal or administrative proceedings against us.

Item 1A. Risk Factors.

There have been no material changes in our risk factors from the risks previously reported in Part 1, Item 1A, “Risk Factors” of our Form 10-K. You should carefully consider the factors discussed in Form 10-K, which could materially affect our business, financial condition or future results. The risks described in our Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

27

Item 6. Exhibits.

The following exhibits are included in this Form 10-Q or incorporated herein by reference:

Exhibit No.

    

Exhibit Description

3.1

Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on February 28, 2022 (incorporated by reference to Annex A included in Exhibit 99.1 to Form 6-K filed with the SEC on February 8, 2022).

3.2

Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on April 12, 2022 (incorporated by reference to Annex A included in Exhibit 99.1 to Form 6-K filed with the SEC on March 8, 2022).

3.3

Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on November 3, 2022 (incorporated by reference to Annex A included in Exhibit 99.1 to Form 6-K filed with the SEC on September 21, 2022).

31.1*

Certification of Chief Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

31.2*

Certification of Chief Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

32.1*

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350

32.2*

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350

101*

Information formatted in Extensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Shareholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.

104*

Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101)

*Filed herewith

28

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Quoin Pharmaceuticals Ltd.

August 3, 2023

By:

/s/ Gordon Dunn

Name: Gordon Dunn

Title: Chief Financial Officer

29

EX-31.1 2 qnrx-20230630xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Dr. Michael Myers, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q of Quoin Pharmaceuticals Ltd. (the “registrant”);

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Dr. Michael Myers

Name:

Dr. Michael Myers

Title:

Chief Executive Officer

Date:

August 3, 2023


EX-31.2 3 qnrx-20230630xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Gordon Dunn, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q of Quoin Pharmaceuticals Ltd. (the “registrant”);

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Gordon Dunn

Name:

Gordon Dunn

Title:

Chief Financial Officer

Date:

August 3, 2023


EX-32.1 4 qnrx-20230630xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Quoin Pharmaceuticals Ltd. (the “Company”) for the quarter ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Dr. Michael Myers

Name:

Dr. Michael Myers

Title:

Chief Executive Officer

Date:

August 3, 2023

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


EX-32.2 5 qnrx-20230630xex32d2.htm EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Quoin Pharmaceuticals Ltd. (the “Company”) for the quarter ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Gordon Dunn

Name:

Gordon Dunn

Title:

Chief Financial Officer

Date:

August 3, 2023

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


EX-101.SCH 6 qnrx-20230630.xsd EX-101.SCH 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - PREPAID EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - PREPAID EXPENSES (Details) (Calc 2) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - ORGANIZATION AND BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - LIQUIDITY RISKS AND OTHER UNCERTAINTIES (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (loss) per share (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - ACCRUED INTEREST AND FINANCING EXPENSE (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair value on a recurring basis (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - STOCK BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - STOCK BASED COMPENSATION - Option activity (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - STOCK BASED COMPENSATION - Stock based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - IN-LICENSED TECHNOLOGY - Polytherapeutics (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - IN-LICENSED TECHNOLOGY - Skinvisible (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - RELATED PARTY TRANSACTIONS - Amounts due to officers (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - SHAREHOLDERS' EQUITY - Share Capital (Details) link:presentationLink link:calculationLink link:definitionLink 41302 - Disclosure - SHAREHOLDERS' EQUITY - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 41601 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - ORGANIZATION AND BUSINESS link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - LIQUIDITY RISKS AND OTHER UNCERTAINTIES link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - ACCRUED INTEREST AND FINANCING EXPENSE link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - STOCK BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - PREPAID EXPENSES link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - IN-LICENSED TECHNOLOGY link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - LICENSE AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - STOCK BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - PREPAID EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - SHAREHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-lived assets & Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - LICENSE AGREEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 qnrx-20230630_cal.xml EX-101.CAL EX-101.DEF 8 qnrx-20230630_def.xml EX-101.DEF EX-101.LAB 9 qnrx-20230630_lab.xml EX-101.LAB EX-101.PRE 10 qnrx-20230630_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2023
Aug. 02, 2023
Document and Entity Information    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2023  
Entity File Number 001-37846  
Entity Registrant Name QUOIN PHARMACEUTICALS LTD.  
Entity Incorporation, State or Country Code L3  
Entity Tax Identification Number 92-2593104  
Entity Address, Address Line One 42127 Pleasant Forest Court  
Entity Address State Or Province VA  
Entity Address, City or Town Ashburn  
Entity Address, Postal Zip Code 20148  
City Area Code 703  
Local Phone Number 980-4182  
Title of 12(g) Security American Depositary Shares  
Trading Symbol QNRX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Current Fiscal Year End Date --12-31  
Amendment Flag false  
Entity Central Index Key 0001671502  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Ordinary shares    
Document and Entity Information    
Entity Common Stock, Shares Outstanding   59,233,024,799
ADS    
Document and Entity Information    
Entity Common Stock, Shares Outstanding   987,217
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 4,759,129 $ 2,860,628
Investments 10,680,160 9,992,900
Prepaid expenses 234,226 516,584
Total current assets 15,673,515 13,370,112
Prepaid expenses - long term 383,390 383,390
Intangible assets, net 652,539 704,561
Total assets 16,709,444 14,458,063
Current liabilities:    
Accounts payable 707,935 605,600
Accrued expenses 1,834,653 1,175,705
Accrued interest and financing expense 1,146,251 1,146,251
Due to officers - short term 725,000 600,000
Total current liabilities 4,413,839 3,527,556
Due to officers - long term 3,223,733 3,523,733
Total liabilities 7,637,572 7,051,289
Commitments and contingencies
Other Liability, Current, Related Party, Type [Extensible Enumeration] srt:OfficerMember srt:OfficerMember
Other Liability, Noncurrent, Related Party, Type [Extensible Enumeration] srt:OfficerMember srt:OfficerMember
Shareholders' equity:    
Ordinary shares, no par value per share, 500,000,000,000 ordinary shares authorized - 59,233,024,799 (987,217 ADS's) ordinary shares issued and outstanding at June 30, 2023 and 24,233,024,799 (403,884 ADS's) at December 31, 2022 $ 0 $ 0
Treasury stock, 2,641,693, ordinary shares (2,932,000) (2,932,000)
Additional paid in capital 54,230,635 47,855,521
Accumulated deficit (42,226,763) (37,516,747)
Total shareholders' equity 9,071,872 7,406,774
Total liabilities and shareholders' equity $ 16,709,444 $ 14,458,063
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Ordinary shares, par value $ 0 $ 0
Ordinary shares, shares authorized 500,000,000,000 500,000,000,000
Ordinary shares, shares issued 59,233,024,799 24,233,024,799
Ordinary shares, shares outstanding 59,233,024,799 24,233,024,799
Treasury Stock, ordinary shares 2,641,693 2,641,693
ADS    
Ordinary shares, shares issued 987,217 403,884
Ordinary shares, shares outstanding 987,217 403,884
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Operating expenses        
General and administrative $ 1,634,960 $ 1,941,473 $ 3,318,777 $ 3,529,943
Research and development 625,104 726,694 1,716,837 1,314,263
Total operating expenses 2,260,064 2,668,167 5,035,614 4,844,206
Other (income) and expenses        
Forgiveness of accounts payable       (416,000)
Warrant liability (income) expense       (77,237)
Unrealized loss 34,472   14,045  
Interest income (187,589)   (339,643)  
Total other income (153,117)   (325,598) (493,237)
Net loss $ (2,106,947) $ (2,668,167) $ (4,710,016) $ (4,350,969)
ADS        
Loss per ADS        
Basic $ (2.13) $ (38.91) $ (5.79) $ (69.90)
Fully-diluted $ (2.13) $ (38.91) $ (5.79) $ (69.90)
Weighted average number of ADS's outstanding        
Basic 987,217 68,573 813,184 62,242
Fully-diluted 987,217 68,573 813,184 62,242
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Shareholders' Equity - USD ($)
Common Stock
Treasury Stock
Additional Paid In Capital
Accumulated Deficit
ADS
Total
Balance at beginning of year at Dec. 31, 2021   $ (2,932,000) $ 31,659,017 $ (28,069,985)   $ 657,032
Balance at beginning of year (in shares) at Dec. 31, 2021 3,354,650,799       55,911  
Net loss       (1,682,802)   (1,682,802)
Cashless exercise of warrants (in shares) 3,200          
Reclassification of warrant liability upon issuance of Exchange warrant     296,362     296,362
Balance at end of year at Mar. 31, 2022   (2,932,000) 31,955,379 (29,752,787)   (729,408)
Balance at ending of year (in shares) at Mar. 31, 2022 3,354,653,999       55,911  
Balance at beginning of year at Dec. 31, 2021   (2,932,000) 31,659,017 (28,069,985)   657,032
Balance at beginning of year (in shares) at Dec. 31, 2021 3,354,650,799       55,911  
Net loss           (4,350,969)
Balance at end of year at Jun. 30, 2022   (2,932,000) 32,184,820 (32,420,954)   (3,168,134)
Balance at ending of year (in shares) at Jun. 30, 2022 5,065,154,799       84,419  
Balance at beginning of year at Mar. 31, 2022   (2,932,000) 31,955,379 (29,752,787)   (729,408)
Balance at beginning of year (in shares) at Mar. 31, 2022 3,354,653,999       55,911  
Net loss       (2,668,167)   (2,668,167)
Cashless exercise of warrants (in shares) 1,710,500,800       28,508  
Stock based compensation     229,441     229,441
Balance at end of year at Jun. 30, 2022   (2,932,000) 32,184,820 (32,420,954)   (3,168,134)
Balance at ending of year (in shares) at Jun. 30, 2022 5,065,154,799       84,419  
Balance at beginning of year at Dec. 31, 2022   (2,932,000) 47,855,521 (37,516,747)   $ 7,406,774
Balance at beginning of year (in shares) at Dec. 31, 2022 24,233,024,799       403,884 24,233,024,799
Net loss       (2,603,069)   $ (2,603,069)
Stock based compensation     261,472     261,472
Issuance of ADS and Pre-Funded Warrants, net     5,849,266     5,849,266
Issuance of ADS and Pre-Funded Warrants, net (in shares) 35,000,000,000       583,333  
Balance at end of year at Mar. 31, 2023   (2,932,000) 53,966,259 (40,119,816)   10,914,443
Balance at ending of year (in shares) at Mar. 31, 2023 59,233,024,799       987,217  
Balance at beginning of year at Dec. 31, 2022   (2,932,000) 47,855,521 (37,516,747)   $ 7,406,774
Balance at beginning of year (in shares) at Dec. 31, 2022 24,233,024,799       403,884 24,233,024,799
Net loss           $ (4,710,016)
Balance at end of year at Jun. 30, 2023   (2,932,000) 54,230,635 (42,226,763)   $ 9,071,872
Balance at ending of year (in shares) at Jun. 30, 2023 59,233,024,799       987,217 59,233,024,799
Balance at beginning of year at Mar. 31, 2023   (2,932,000) 53,966,259 (40,119,816)   $ 10,914,443
Balance at beginning of year (in shares) at Mar. 31, 2023 59,233,024,799       987,217  
Net loss       (2,106,947)   (2,106,947)
Stock based compensation     264,376     264,376
Balance at end of year at Jun. 30, 2023   $ (2,932,000) $ 54,230,635 $ (42,226,763)   $ 9,071,872
Balance at ending of year (in shares) at Jun. 30, 2023 59,233,024,799       987,217 59,233,024,799
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows used in operating activities:    
Net loss $ (4,710,016) $ (4,350,969)
Change in fair value of warrant liability   (77,237)
Stock based compensation 525,848 229,441
Forgiveness of trade payable   (416,000)
Amortization of intangibles 52,022 52,021
Increase in accrued interest and financing expense   (311,670)
Unrealized loss and accrued interest on investments (230,755)  
Changes in assets and liabilities:    
Increase in accounts payable and accrued expenses 761,283 440,817
Decrease in prepaid expenses & other assets 282,358 188,671
Net cash used in operating activities (3,319,260) (4,244,926)
Cash flows used in investing activities:    
Purchase of investments (13,491,505)  
Proceeds from maturity of investments 13,035,000  
Payment for license acquisition   (250,000)
Net cash used in investing activities (456,505) (250,000)
Cash flows provided by (used in) financing activities:    
Payment of amounts due to officers (175,000) (300,000)
Proceeds from sale of equity securities, net 5,849,266  
Net cash provided by (used in) financing activities 5,674,266 (300,000)
Net change in cash and cash equivalents: 1,898,501 (4,794,926)
Cash and cash equivalents - beginning of period 2,860,628 7,482,773
Cash and cash equivalents - end of period 4,759,129 2,687,847
Supplemental information - Non cash items:    
Reclassification of warrant liability to equity upon issuance of "Exchange warrants"   $ 296,362
Offering expenses associated with warrant modification $ 238,231  
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.2
ORGANIZATION AND BUSINESS
6 Months Ended
Jun. 30, 2023
ORGANIZATION AND BUSINESS  
ORGANIZATION AND BUSINESS

NOTE 1 – ORGANIZATION AND BUSINESS

Quoin Pharmaceuticals Ltd. (“Quoin Ltd.,” or the “Company”), formerly known as Cellect Biotechnology Ltd. (“Cellect”), is the holding company for Quoin Pharmaceuticals, Inc., a Delaware corporation (“Quoin Inc.”). On October 28, 2021, Cellect completed the business combination with Quoin Inc., with Quoin Inc. surviving as a wholly-owned subsidiary of Cellect (the “Merger”). Immediately after completion of the Merger, Cellect changed its name to “Quoin Pharmaceuticals Ltd.”

Effective July 18, 2023, the ratio of American Depositary Shares (“ADSs”) evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs (the “Ratio Change”). All ADSs and related option and warrant information presented in these financial statements and accompanying footnotes has been retroactively adjusted to reflect the number of ADSs resulting from the Ratio Change.

Quoin Inc. was incorporated in Delaware on March 5, 2018. Quoin Inc. is clinical stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently no approved treatments or cures. The Company’s initial focus is on the development of products, using proprietary owned and in-licensed drug delivery technologies, that could help address rare skin diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary in-licensed Invisicare® technology, is under development as a potential treatment for Netherton Syndrome (“NS”), a rare hereditary genetic disease. QRX003 is currently being tested in two clinical studies in the United States (“U.S.”) under an open Investigational New Drug (“IND”) application with the Food and Drug Administration (“FDA”). Dosing of patients commenced in December 2022 for the first study and in March 2023 for the second study. The Company is also developing QRX004 as a potential treatment for Recessive Dystrophic Epidermolysis Bullosa (“RDEB”). In addition, the Company has entered into Research Agreements with the Queensland University of Technology (“QUT”), which include an option for global licenses to QRX007 for the potential treatment of NS and QRX008 for the potential treatment of scleroderma. To date, no products have been commercialized and revenue has not been generated.

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.2
LIQUIDITY RISKS AND OTHER UNCERTAINTIES
6 Months Ended
Jun. 30, 2023
LIQUIDITY RISKS AND OTHER UNCERTAINTIES  
LIQUIDITY RISKS AND OTHER UNCERTAINTIES

NOTE 2 - LIQUIDITY RISKS AND OTHER UNCERTAINTIES

The unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”), which contemplates continuation of the Company as a going concern. The Company has incurred net losses every year since inception and has an accumulated deficit of approximately $42.2 million at June 30, 2023. The Company has limited operating history and has historically funded its operations through debt and equity financings. The Company incurred net losses of approximately $4.7 million, and negative cash flows from operations of $3.3 million for the six months ended June 30, 2023. At June 30, 2023, the Company had cash balances totaling $4.8 million and investments of $10.7 million. The Company has determined that it has sufficient cash and liquidity to effect its business plan for at least one year from the issuance of these unaudited condensed consolidated financial statements.

Additional financing will still be required to complete the research and development of the Company’s therapeutic targets and its other operating requirements until it achieves commercial profitability, if ever. Such financing may not be available at acceptable terms, if at all. If the Company is unable to obtain additional funding when it becomes necessary, the development of its product candidates will be impacted and the Company would likely be forced to delay, reduce, or terminate some or all of its development programs, all of which could have a material adverse effect on the Company’s business and financial condition.

Other risks and uncertainties:

The Company is subject to risks common to development stage biopharmaceutical companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, pre-clinical and clinical trial outcome risks, regulatory approval risks, uncertainty of market acceptance and additional financing requirements.

The Company’s products require approval or clearance from the FDA prior to commencing commercial sales in the United States. There can be no assurance that the Company’s products will receive all of the required approvals or clearances. Approvals or clearances are also required in foreign jurisdictions in which the Company may license or sell its products.

There can be no assurance that the Company’s products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed.

The Company is also dependent on several third party suppliers, in some cases a single source supplier including the contract research organization managing both of the Company’s current clinical studies, the supplier of the active pharmaceutical ingredient (API), as well as the contract manufacturer of the drug substance for the expected clinical development.

Nasdaq Listing

On April 5, 2023, the Company received a letter from the Listing Qualifications staff of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that the closing bid price per ADS was below the required minimum of $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2). Pursuant to Nasdaq Rule 5810(c)(3)(A), the Company had a period of one hundred eighty (180) calendar days, or until October 2, 2023 (the “Compliance Period”), to regain compliance with Nasdaq’s minimum bid price requirement. On August 1, 2023, the Company received a letter from Nasdaq stating that the Company’s closing bid price per ADS was at $1.00 or greater for the last 10 consecutive business days. Accordingly, the Company regained compliance with Listing Rule 5550(a)(2) and the matter was closed.

There can be no assurance that the Company will be able to maintain compliance with Nasdaq’s minimum bid-price requirement for continued listing. If the Company’s ADSs are delisted from Nasdaq, it will have a material negative impact on the actual and potential liquidity of the Company’s securities, as well as a material negative impact on the Company’s ability to raise future capital.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Jun. 30, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation:

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of June 30, 2023 and for the three and six months then ended. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of December 31, 2022 and for the year then ended which are included in the Company’s Annual Report on Form 10- K, filed with the SEC on March 15, 2023. The Company operates in one segment.

Use of estimates:

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation

research and development expense recognition, intangible asset estimated useful lives and impairment assessments, allowances of deferred tax assets, and cash flow assumptions regarding going concern considerations.

Cash and cash equivalents:

The Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents. The Company, from time to time during the periods presented, has had bank account balances in excess of federally insured limits where substantially all cash is held in the United States. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

Warrants:

The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) provided that such contracts are indexed to the Company’s own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).

The Company assesses classification of its warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets, liabilities and equity is required. The Company evaluated the warrants to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that such warrants meet the criteria for equity classification in the accompanying unaudited condensed consolidated balance sheets as of June 30, 2023 and December 31, 2022, respectively.

Investments:

Investments as of June 30, 2023 and December 31, 2022 consist of U.S. Treasury Bills, which are classified as trading securities, totaling $10.7 million and $10.0 million, respectively. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date.

Long-lived assets:

Long-lived assets are comprised of acquired technology and licensed rights to use technology, which are considered platform technology with alternative future uses beyond the current products in development. Such intangible assets are being amortized on a straight-line basis over their expected useful life of 10 years.

The Company assesses the impairment for long-lived assets whenever events or circumstances indicate the carrying value may not be recoverable. Factors we consider that could trigger an impairment review include the following:

Significant changes in the manner of the Company’s use of the acquired assets or the strategy for its overall business,
Significant underperformance relative to expected historical or projected development milestones,
Significant negative regulatory or economic trends, and
Significant technological changes which could render the platform technology obsolete.

The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the three and six months ended June 30, 2023 and 2022, there were no impairment indicators which required an impairment loss measurement.

Research and development:

Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials when applicable, administrative costs incurred by third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expenses in future periods as the related services are rendered.

Income taxes:

The Company accounts for its income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company maintains a full valuation allowance on its existing deferred tax assets.

The Company also accounts for uncertain tax positions using the more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company’s income tax returns. As of June 30, 2023 and December 31, 2022, the Company had no uncertain tax positions which affected its financial position and its results of operations or its cash flows and will continue to evaluate for uncertain tax positions in the future. If at any time the Company should record interest and penalties in connection with income taxes, the interest and the penalties will be expensed within the interest and general and administrative expenses, respectively.

Stock based compensation:

The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period.

The Company’s expected stock volatility is based on the historical data regarding the volatility of a publicly traded set of peer companies, since it has a limited history of trading as a public company. The Company utilizes the simplified method to estimate the expected term. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield was assumed to be zero as the Company has not paid and dividends since its inception and does not anticipate paying dividends in the foreseeable future.

Fair value of financial instruments:

The Company considers its cash and cash equivalents, investments, accounts payable, accrued expenses to meet the definition of financial instruments. The carrying amounts of these financial instruments approximated their fair values due to the short maturities.

The Company measures fair value as required by ASC Topic 820, Fair Value Measurements and Disclosures (“ASC Topic 820”). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.

Earnings (loss) per share:

The Company reports loss per share in accordance with ASC 260-10, Earnings Per Share, which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives effect to ordinary shares equivalents; however, potential common shares are excluded if their effect is anti-dilutive.

For the three and six months ended June 30, 2023, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 864,068 ADS and outstanding stock options to purchase 25,595 ADS. For the three and six months ended June 30, 2022, the number of shares excluded from the diluted net earnings (loss) per share included warrants to purchase 87,742 ADSs and outstanding options to purchase 25,760 ADSs, respectively. The inclusion of these stock options and warrants from both periods in 2023 and 2022 in the denominator would be anti-dilutive.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.2
ACCRUED INTEREST AND FINANCING EXPENSE
6 Months Ended
Jun. 30, 2023
ACCRUED INTEREST AND FINANCING EXPENSE  
ACCRUED INTEREST AND FINANCING EXPENSE

NOTE 4 – ACCRUED INTEREST AND FINANCING EXPENSE

On October 2, 2020, Quoin Inc. commenced an offering of promissory notes (the “2020 Notes”) and warrants to certain investors (“2020 Noteholders”). 2020 Notes were mandatorily convertible into 432 ADSs in 2021.

The ADSs issued to the 2020 Noteholders did not include the accrued interest which was estimated to be approximately $744,000 at December 31, 2021 of which $312,000 was paid to two of the five 2020 Noteholders during the year ended December 31, 2022. Based on the terms of the cash settlement with these two 2020 Noteholders, the Company’s estimate of the liability to the remaining three 2020 Noteholders was $1,146,000 as of June 30, 2023 and December 31, 2022.

There was no interest expense recognized in both the three and six month periods ended June 30, 2023 and 2022.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE OF FINANCIAL INSTRUMENTS
6 Months Ended
Jun. 30, 2023
FAIR VALUE OF FINANCIAL INSTRUMENTS  
FAIR VALUE OF FINANCIAL INSTRUMENTS

NOTE 5 - FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company applies fair value accounting for all assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. For certain instruments, including cash and cash equivalents, accounts payable, and accrued expenses, it was estimated that the carrying amount approximated fair value because of the short maturities of these instruments.

Fair value is estimated using various valuation models, which utilize certain inputs and assumptions that market participants would use in pricing the asset or liability. The inputs and assumptions used in valuation models are classified in the fair value hierarchy as follows:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Quoted market prices for similar instruments in an active market; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations inputs of which are observable and can be corroborated by market data.

Level 3: Unobservable inputs and assumptions that are supported by little or no market activity and that are significant to the fair value of the asset and liability. The fair value hierarchy gives the lowest priority to Level 3 inputs.

In determining the appropriate hierarchy levels, the Company analyzes the assets and liabilities that are subject to fair value disclosure. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to their fair value measurement.

The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis by fair value hierarchy at June 30, 2023 and December 31, 2022:

June 30, 2023

    

Level 1

    

Level 2

    

Level 3

    

Total

US Treasury Bills

 

$

10,680,160

 

$

$

$

10,680,160

Total US Treasury Bills Asset

 

$

10,680,160

 

$

$

$

10,680,160

December 31, 2022

    

Level 1

    

Level 2

    

Level 3

    

Total

US Treasury Bills

$

9,992,900

$

$

$

9,992,900

Total US Treasury Bills Asset

$

9,992,900

$

$

$

9,992,900

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK BASED COMPENSATION
6 Months Ended
Jun. 30, 2023
STOCK BASED COMPENSATION  
STOCK BASED COMPENSATION

NOTE 6 – STOCK BASED COMPENSATION

In March 2022, the Board of Directors of the Company approved the Amended and Restated Equity Incentive Plan (the “Amended Plan”), which was approved by the shareholders at the Company’s Annual General Meeting of Shareholders held on April 12, 2022. The Amended Plan increased the number of ordinary shares reserved for issuance under such equity incentive plan to 15% of the Company’s outstanding ordinary shares on a fully-diluted basis, or 16,891,925,220 ordinary shares represented by 281,532 ADSs as of June 30, 2023. Under the Amended Plan, the Company may grant options to its directors, officers, employees, consultants, advisers and service providers. As of June 30, 2023, 255,937 ADSs remained available for grant under the Amended Plan.

The following table summarizes stock-based activities under the Amended Plan:

    

    

Weighted

    

Weighted

Average

Average

ADS Underlying

Exercise

Contractual

Options

Price

Terms

Outstanding at December 31, 2022

 

25,595

$

210.00

 

9.28

Granted

 

$

 

Forfeited/Cancelled

 

$

 

Outstanding at June 30, 2023

 

25,595

$

210.00

 

8.78

Exercisable options at June 30, 2023

 

6,845

$

210.00

 

8.78

The intrinsic value of outstanding options at June 30, 2023 was $0.

Stock based compensation expense was approximately $264,000 ($34,000 included in research and development expense and $230,000 included in general and administrative expenses) in the three months ended June 30, 2023 and approximately $526,000 ($69,000 included in research and development expense and $457,000 included in general and administrative expenses) in the six months ended June 30, 2023.

Stock based compensation expense was approximately $229,000 ($30,000 included in research and development expense and $199,000 included in general and administrative expenses) in both the three and six months ended June 30, 2022.

At June 30, 2023, the total unrecognized compensation expense related to non-vested options was approximately $2,679,000 and is expected to be recognized over the remaining weighted average service period of approximately 2.60 years.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.2
PREPAID EXPENSES
6 Months Ended
Jun. 30, 2023
PREPAID EXPENSES  
PREPAID EXPENSES

NOTE 7 – PREPAID EXPENSES

Prepaid expenses are as follows:

    

June 30, 

    

December 31, 

2023

2022

Prepaid R&D costs

$

383,390

$

383,390

Prepaid insurance

 

202,226

 

508,084

Prepaid expense

 

32,000

 

8,500

Total

$

617,616

$

899,974

Less: Short-term portion

(234,226)

(516,584)

Long-term portion

$

383,390

$

383,390

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.2
ACCRUED EXPENSES
6 Months Ended
Jun. 30, 2023
ACCRUED EXPENSES  
ACCRUED EXPENSES

NOTE 8 - ACCRUED EXPENSES

Accrued expenses are as follows:

    

June 30, 

    

December 31, 

2023

2022

Research contract expenses (note 12)

$

343,152

$

105,071

Payroll (note 11)

 

1,168,486

 

788,169

Payroll taxes (note 11)

 

199,408

 

159,593

Professional fees

 

85,299

 

44,278

Other Expenses

 

38,308

 

78,594

Total

$

1,834,653

$

1,175,705

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.2
IN-LICENSED TECHNOLOGY
6 Months Ended
Jun. 30, 2023
IN-LICENSED TECHNOLOGY  
IN-LICENSED TECHNOLOGY

NOTE 9 – IN-LICENSED TECHNOLOGY

Polytherapeutics:

On March 24, 2018, Quoin Inc. entered into a securities purchase agreement (the “Acquisition Agreement”), in which it agreed to acquire all of the equity interests in Polytherapeutics, Inc. (the “Seller” or “Polytherapeutics”) for $40,833 and future royalties provided Quoin Inc. commercializes products using the technology developed by the Seller. The terms of any royalty payments to the Seller are 4.0% of the net revenue of royalty products, as defined in the Acquisition Agreement during the ten (10) year period commencing from the date of first sale of a royalty product. If a generic product is introduced by a third party to the market, during the royalty period, the royalty fees shall be reduced from 4% to 2%. If, during the royalty period, two or more generic products are introduced, the royalty fees shall be reduced from 2% to 0%.

Skinvisible:

In October 2019, Quoin Inc. entered into the Exclusive Licensing Agreement (as amended from time to time, the “License Agreement”) with Skinvisible Pharmaceuticals, Inc. (“Skinvisible”), under which Skinvisible granted the Company an exclusive royalty-bearing license relating to the production and manufacture of prescription drug products related to certain patents held by Skinvisible, including those related to QRX003 and QRX004. The Company made Skinvisible a one-time non-refundable, non-creditable license fee of $1 million (the “License Fee”). In addition, the Company agreed to pay Skinvisible a single digit royalty percentage of the Company’s net sales revenues for any licensed product covered by the patent rights licensed under the License Agreement. The Company also agreed

to pay Skinvisible 25% of any revenues the Company receives as royalties in the event that the Company sublicense any licensed products to a third party. The License Agreement also requires that the Company make a $5 million payment to Skinvisible upon receiving approval in the U.S. or European Union, whichever occurs first, for the first drug product developed using intellectual property licensed thereunder.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.2
INTANGIBLE ASSETS
6 Months Ended
Jun. 30, 2023
INTANGIBLE ASSETS  
INTANGIBLE ASSETS

NOTE 10 - INTANGIBLE ASSETS

Intangible assets are as follows:

    

June 30, 

    

December 31, 

2023

2022

Acquired technology – Polytherapeutics

$

40,433

$

40,433

Technology license – Skinvisible

 

1,000,000

 

1,000,000

Total cost

 

1,040,433

 

1,040,433

Accumulated amortization

 

(387,894)

 

(335,872)

Net book value

$

652,539

$

704,561

The Company recorded amortization expense of approximately $52,000 for the six months ended June 30, 2023 and 2022. The Company recorded amortization expense of approximately $26,000 for the three months ended June 30, 2023 and 2022. The annual amortization expense expected to be recorded for existing intangible assets for the years 2023 through 2026, and thereafter, is approximately $52,000, $104,000, $104,000, $104,000 and $288,000, respectively.

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.2
RELATED PARTY TRANSACTIONS
6 Months Ended
Jun. 30, 2023
RELATED PARTY TRANSACTIONS  
RELATED PARTY TRANSACTIONS

NOTE 11 - RELATED PARTY TRANSACTIONS

Employment Agreements and Due to Officers/Founders:

Due to the limited funding of Quoin Inc. prior to the consummation of the Merger, the compensation, including salary, office and car allowances and other benefits, due to Dr. Myers and Ms. Carter under their respective employment agreements, as well as reimbursement of expenses and other amounts paid to third parties on behalf of Quoin Inc., were accrued as indebtedness to Dr. Myers and Ms. Carter. Following the closing of the Merger, Quoin Inc. began making payments of $25,000 per month to each of Dr. Myers and Ms. Carter to repay the above-described non-interest-bearing indebtedness. The Company repaid $75,000 and $75,000 of such indebtedness to Dr. Myers and $0 and $75,000 to Ms. Carter in the three months ended June 30, 2023 and 2022, respectively. The Company repaid $150,000 and $150,000 of such indebtedness to Dr. Myers and $25,000 and $150,000 to Ms. Carter in the six months ended June 30, 2023 and 2022, respectively.

As of June 30, 2023, approximately $2,109,000 and $1,840,000 of such indebtedness was outstanding to Dr. Myers and Ms. Carter, respectively.

Amounts due to officers at June 30, 2023 and December 31, 2022 consisted of the following:

    

June 30, 

    

December 31, 

2023

2022

Salaries and other compensation

$

3,948,733

 

$

4,108,500

Invoices paid on behalf of the Company

 

 

15,232

Total

$

3,948,733

 

$

4,123,732

Less: Short-term portion

 

(725,000)

 

(600,000)

Long-term portion

$

3,223,733

$

3,523,733

Expenses:

Research and development expense, incurred in the three months ended June 30, 2023 and 2022, was $0 and $12,000 and it was $12,000 and $24,000 in the six months ended June 30, 2023 and 2022, respectively, for payments to the CEO Dr. Myers’ son, who had been consulting for the Company on research and development matters from time to time. As of March 31, 2023, Dr. Myers’ son no longer provided consulting services to the Company.

Interest Payable:

See Note 4 for interest payable on the 2020 Notes.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.2
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS
6 Months Ended
Jun. 30, 2023
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS  
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS

NOTE 12 – RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS

Research agreements

In November 2020, Quoin Inc. entered into a Master Service Agreement for an initial term of three years with Therapeutics Inc. for managing preclinical and clinical development for new products in the field of dermatology. The agreement required the execution of individual work orders. Quoin Inc. may terminate any work order for any reason with 90 days written notice subject to costs incurred through termination and a defined termination fee, unless there is a material breach by Therapeutics Inc. A work order was entered into in June 2022 for the first QRX003 clinical study at an expected estimated cost of approximately $4.4 million through 2024. A further work order was entered into in December 2022 for the second QRX003 clinical study at an expected estimated cost of approximately $830,000 through 2024. For the three and six months ended June 30, 2023 and 2022, the Company incurred a research and development expense under these agreements of approximately $360,000 and $959,000, and $309,000 and $480,000 respectively.

In November 2021, the Company entered into a commitment with Queensland University of Technology for research related services associated with Netherton Syndrome of approximately $250,000 for an expected period of eighteen months. For the three and six months ended June 30, 2023 and 2022, the Company incurred research and development costs related to this agreement of approximately $0 and $50,000, and $77,000 and $77,000 respectively.

In May 2022, the Company entered into a commitment with Queensland University of Technology for research related services associated with Scleroderma of approximately $610,000 for an expected period of eighteen months. For the three and six months ended June 30, 2023 and 2022, the Company incurred research and development costs related to this agreement of approximately $138,000 and $226,000, and $-0- and $-0- respectively.

Consulting agreement:

Quoin Inc. entered into a consulting agreement with an Investor Relations (IR) firm, which provided for a monthly fee of $14,000. The agreement had an automatic annual renewal clause and was in effect in November 2017. The Company owed the IR firm $584,000 as of December 31, 2021. Effective March 31, 2022, the Company entered into a settlement agreement with the IR firm reducing the liability to $168,000 and recognized $416,000 as other income in the accompanying consolidated statement of operations. The liability was fully repaid as of April 1, 2023. No expenses were incurred in both the three and six months ended June 30, 2023 and 2022, respectively.

Performance milestones and Royalties

See Note 9 for asset and in-licensed technology commitments.

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.2
SHAREHOLDERS' EQUITY
6 Months Ended
Jun. 30, 2023
SHAREHOLDERS' EQUITY  
SHAREHOLDERS' EQUITY

NOTE 13 – SHAREHOLDERS’ EQUITY

The Company held its Annual General Meeting on April 12, 2022, at which the Company’s shareholders approved an increase to the authorized share capital to 50,000,000,000, no par value. The Company held a further Annual General Meeting on November 3, 2022, at which the Company’s shareholders approved an increase to the authorized share capital to 500,000,000,000 ordinary shares from 50,000,000,000, no par value. These ordinary shares are not redeemable and do not have any preemptive rights.

Holders of the Company’s ordinary shares have one vote for each ordinary share held on all matters submitted to a vote of shareholders at a shareholders meeting. The board of directors shall determine and provide a record date for each shareholders meeting and all shareholders at such record date may vote. Unless stipulated differently in the Companies Law or in the articles of association, all shareholders’ resolutions shall be approved by a simple majority vote.

Under Israeli law, the Company may declare and pay dividends only if, upon the determination of its board of directors, there is no reasonable concern that the distribution will prevent the Company from being able to meet the terms of its existing and foreseeable obligations as they become due. Under the Companies Law, the distribution amount is further limited to the greater of retained earnings or earnings generated over the two most recent years legally available for distribution according to the Company’s then last reviewed or audited financial statements, provided that the date of the financial statements is not more than six months prior to the date of distribution. In the event that the Company does not have retained earnings or earnings generated over the two most recent years legally available for distribution, the Company may seek the approval of the court in order to distribute a dividend. The court may approve the Company’s request if it determines that there is no reasonable concern that the payment of a dividend will prevent the Company from satisfying existing and foreseeable obligations as they become due.

Each ADS will also represent any other securities, cash or other property which may be held by the depositary. ADSs may be held either (a) directly (1) by having an American Depositary Receipt, also referred to as an ADR, which is a certificate evidencing a specific number of ADSs or (2) by having uncertificated ADSs, or (b) indirectly by holding a security entitlement in ADSs through a broker or other financial institution that is a direct or indirect participant in The Depository Trust Company, also called DTC.

February 2023 Offering

On February 24, 2023 (the “February Closing Date”), the Company completed an offering (the “February Offering”) of 24,750,000,000 ordinary shares represented by 412,500 ADSs at a purchase price of $12.00 per ADS and a pre-funded warrant (the “February Pre-Funded Warrant”) to purchase 10,250,000,000 ordinary shares represented by 170,833 ADSs at a per pre-funded warrant price of $11.9988, with each ADS and February Pre-Funded Warrant accompanied by an ordinary warrant (the “February Common Warrant”) for aggregate gross proceeds of $7.0 million, resulting in net proceeds of approximately $5.8 million, after deducting the placement agent’s fees and offering expenses. Each February Common Warrant has an exercise price of $12.00 per ADS and expires on the fifth anniversary of the February Closing Date. On the February Closing Date, the holder of the February Pre-Funded Warrant exercised its Pre-Funded Warrant in full.

In connection with the February Offering, the Company entered into a Securities Purchase Agreement (the “February Purchase Agreement”) with certain institutional investors. Under the February Purchase Agreement, subject to certain exemptions, the Company agreed not to: (i) for a period of ninety (90) days after the closing date of the February Offering, issue, enter into any agreement to issue or announce the issuance or proposed issuance of any ADSs, ordinary shares or ordinary share equivalents or (ii) file any registration statement or amendment or supplement thereto, other than a registration statement on Form S-8 in connection with any employee benefit plan or any post-effective amendment to a registration statement declared effective by the Securities and Exchange Commission (the “SEC”) and (ii) for a period of 180 days after the closing date of the February Offering, enter into an agreement to effect a “variable rate transaction” as defined in the Purchase Agreement.

In connection with the February Offering, the Company entered into an Amendment No. 1 to Warrant to Purchase Ordinary Shares Represented by American Depositary Shares, dated February 24, 2023 (collectively, the “Warrant Amendments”), with each of the purchasers (the “2022 Purchasers”) who participated in both the Company’s offering completed in August 2022 (the “August Offering”) and February Offering. The Warrant Amendments amended certain terms of the Common Warrants issued in the August Offering to such 2022 Purchasers. Specifically, the Warrant Amendments reduced the exercise price of Common Warrants to purchase 235,833 ADSs out of the total 280,000 issued in the August Offering from $60.00 to $13.20 and extended the term during which those warrants could remain exercisable until February 24, 2028. The incremental fair value of the modified warrants was approximately $238,000, which was accounted for as an offering expense in connection with the February Offering.

Warrants

The following table summarizes warrant activities during the six months ended June 30, 2023:

    

    

Weighted

 

ADSs

Average

 

Underlying

Exercise Price

 

Warrants

Per ADS

Outstanding at December 31, 2022

 

280,735

 

$

24.85

*

Granted Common Warrants

 

583,333

12.00

Granted Pre-Funded Warrants

170,833

Exercised Pre-Funded Warrants

 

(170,833)

 

Outstanding and exercisable at June 30, 2023

 

864,068

$

16.17

*Includes the reduction of the exercise price from $60.00 per ADS to $13.20 per ADS for Common Warrants issued in the August Offering to investors who participated in both the Company’s August Offering and February Offering, see above.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.2
CONTINGENCIES
6 Months Ended
Jun. 30, 2023
CONTINGENCIES  
CONTINGENCIES

NOTE 14 – CONTINGENCIES

From time to time, the Company may become involved in various legal matters arising in the ordinary course of business. Management is unaware of any matters requiring accrual for related losses in the financial statements.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.2
LICENSE AGREEMENTS
6 Months Ended
Jun. 30, 2023
LICENSE AGREEMENTS  
LICENSE AGREEMENTS

NOTE 15 – LICENSE AGREEMENTS

As of June 30, 2023, the Company has entered into eight license and supply agreements, whereby the Company will receive a royalty or other proceeds from the specified product revenues in select non-US markets from the licensor, if and when the underlying products are approved and commercialized. No royalty revenues have been received through June 30, 2023 under any of these agreements.

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.2
SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2023
SUBSEQUENT EVENTS  
SUBSEQUENT EVENTS

NOTE 16 - SUBSEQUENT EVENTS

Effective July 18, 2023, the ratio of ADSs evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs. See Note 1.

On August 1, 2023, the Company received a letter from Nasdaq stating that the Company’s closing bid price per ADS was at $1.00 or greater for the last 10 consecutive business days. Accordingly, the Company regained compliance with Listing Rule 5550(a)(2) and the matter was closed. See Note 2.

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Jun. 30, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Basis of Presentation:

Basis of Presentation:

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of June 30, 2023 and for the three and six months then ended. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of December 31, 2022 and for the year then ended which are included in the Company’s Annual Report on Form 10- K, filed with the SEC on March 15, 2023. The Company operates in one segment.

Use of estimates:

Use of estimates:

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation

research and development expense recognition, intangible asset estimated useful lives and impairment assessments, allowances of deferred tax assets, and cash flow assumptions regarding going concern considerations.

Cash and cash equivalents:

Cash and cash equivalents:

The Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents. The Company, from time to time during the periods presented, has had bank account balances in excess of federally insured limits where substantially all cash is held in the United States. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

Warrants:

Warrants:

The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) provided that such contracts are indexed to the Company’s own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).

The Company assesses classification of its warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets, liabilities and equity is required. The Company evaluated the warrants to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that such warrants meet the criteria for equity classification in the accompanying unaudited condensed consolidated balance sheets as of June 30, 2023 and December 31, 2022, respectively.

Investments:

Investments:

Investments as of June 30, 2023 and December 31, 2022 consist of U.S. Treasury Bills, which are classified as trading securities, totaling $10.7 million and $10.0 million, respectively. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date.

Long-lived assets:

Long-lived assets:

Long-lived assets are comprised of acquired technology and licensed rights to use technology, which are considered platform technology with alternative future uses beyond the current products in development. Such intangible assets are being amortized on a straight-line basis over their expected useful life of 10 years.

The Company assesses the impairment for long-lived assets whenever events or circumstances indicate the carrying value may not be recoverable. Factors we consider that could trigger an impairment review include the following:

Significant changes in the manner of the Company’s use of the acquired assets or the strategy for its overall business,
Significant underperformance relative to expected historical or projected development milestones,
Significant negative regulatory or economic trends, and
Significant technological changes which could render the platform technology obsolete.

The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the three and six months ended June 30, 2023 and 2022, there were no impairment indicators which required an impairment loss measurement.

Research and development:

Research and development:

Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials when applicable, administrative costs incurred by third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expenses in future periods as the related services are rendered.

Income taxes:

Income taxes:

The Company accounts for its income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company maintains a full valuation allowance on its existing deferred tax assets.

The Company also accounts for uncertain tax positions using the more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company’s income tax returns. As of June 30, 2023 and December 31, 2022, the Company had no uncertain tax positions which affected its financial position and its results of operations or its cash flows and will continue to evaluate for uncertain tax positions in the future. If at any time the Company should record interest and penalties in connection with income taxes, the interest and the penalties will be expensed within the interest and general and administrative expenses, respectively.

Stock based compensation:

Stock based compensation:

The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period.

The Company’s expected stock volatility is based on the historical data regarding the volatility of a publicly traded set of peer companies, since it has a limited history of trading as a public company. The Company utilizes the simplified method to estimate the expected term. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield was assumed to be zero as the Company has not paid and dividends since its inception and does not anticipate paying dividends in the foreseeable future.

Fair value of financial instruments:

Fair value of financial instruments:

The Company considers its cash and cash equivalents, investments, accounts payable, accrued expenses to meet the definition of financial instruments. The carrying amounts of these financial instruments approximated their fair values due to the short maturities.

The Company measures fair value as required by ASC Topic 820, Fair Value Measurements and Disclosures (“ASC Topic 820”). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.

Earnings (loss) per share:

Earnings (loss) per share:

The Company reports loss per share in accordance with ASC 260-10, Earnings Per Share, which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives effect to ordinary shares equivalents; however, potential common shares are excluded if their effect is anti-dilutive.

For the three and six months ended June 30, 2023, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 864,068 ADS and outstanding stock options to purchase 25,595 ADS. For the three and six months ended June 30, 2022, the number of shares excluded from the diluted net earnings (loss) per share included warrants to purchase 87,742 ADSs and outstanding options to purchase 25,760 ADSs, respectively. The inclusion of these stock options and warrants from both periods in 2023 and 2022 in the denominator would be anti-dilutive.

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)
6 Months Ended
Jun. 30, 2023
FAIR VALUE OF FINANCIAL INSTRUMENTS  
Schedule of assets and liabilities measured at fair value on a recurring basis

June 30, 2023

    

Level 1

    

Level 2

    

Level 3

    

Total

US Treasury Bills

 

$

10,680,160

 

$

$

$

10,680,160

Total US Treasury Bills Asset

 

$

10,680,160

 

$

$

$

10,680,160

December 31, 2022

    

Level 1

    

Level 2

    

Level 3

    

Total

US Treasury Bills

$

9,992,900

$

$

$

9,992,900

Total US Treasury Bills Asset

$

9,992,900

$

$

$

9,992,900

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK BASED COMPENSATION (Tables)
6 Months Ended
Jun. 30, 2023
STOCK BASED COMPENSATION  
Summary of stock-based activities

    

    

Weighted

    

Weighted

Average

Average

ADS Underlying

Exercise

Contractual

Options

Price

Terms

Outstanding at December 31, 2022

 

25,595

$

210.00

 

9.28

Granted

 

$

 

Forfeited/Cancelled

 

$

 

Outstanding at June 30, 2023

 

25,595

$

210.00

 

8.78

Exercisable options at June 30, 2023

 

6,845

$

210.00

 

8.78

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.2
PREPAID EXPENSES (Tables)
6 Months Ended
Jun. 30, 2023
PREPAID EXPENSES  
Schedule of prepaid expenses

    

June 30, 

    

December 31, 

2023

2022

Prepaid R&D costs

$

383,390

$

383,390

Prepaid insurance

 

202,226

 

508,084

Prepaid expense

 

32,000

 

8,500

Total

$

617,616

$

899,974

Less: Short-term portion

(234,226)

(516,584)

Long-term portion

$

383,390

$

383,390

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.2
ACCRUED EXPENSES (Tables)
6 Months Ended
Jun. 30, 2023
ACCRUED EXPENSES  
Schedule of accrued expenses

    

June 30, 

    

December 31, 

2023

2022

Research contract expenses (note 12)

$

343,152

$

105,071

Payroll (note 11)

 

1,168,486

 

788,169

Payroll taxes (note 11)

 

199,408

 

159,593

Professional fees

 

85,299

 

44,278

Other Expenses

 

38,308

 

78,594

Total

$

1,834,653

$

1,175,705

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.2
INTANGIBLE ASSETS (Tables)
6 Months Ended
Jun. 30, 2023
INTANGIBLE ASSETS  
Schedule of intangible assets

    

June 30, 

    

December 31, 

2023

2022

Acquired technology – Polytherapeutics

$

40,433

$

40,433

Technology license – Skinvisible

 

1,000,000

 

1,000,000

Total cost

 

1,040,433

 

1,040,433

Accumulated amortization

 

(387,894)

 

(335,872)

Net book value

$

652,539

$

704,561

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.2
RELATED PARTY TRANSACTIONS (Tables)
6 Months Ended
Jun. 30, 2023
RELATED PARTY TRANSACTIONS  
Schedule of amounts due to officers

    

June 30, 

    

December 31, 

2023

2022

Salaries and other compensation

$

3,948,733

 

$

4,108,500

Invoices paid on behalf of the Company

 

 

15,232

Total

$

3,948,733

 

$

4,123,732

Less: Short-term portion

 

(725,000)

 

(600,000)

Long-term portion

$

3,223,733

$

3,523,733

XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.2
SHAREHOLDERS' EQUITY (Tables)
6 Months Ended
Jun. 30, 2023
SHAREHOLDERS' EQUITY  
Schedule of warrant activities

    

    

Weighted

 

ADSs

Average

 

Underlying

Exercise Price

 

Warrants

Per ADS

Outstanding at December 31, 2022

 

280,735

 

$

24.85

*

Granted Common Warrants

 

583,333

12.00

Granted Pre-Funded Warrants

170,833

Exercised Pre-Funded Warrants

 

(170,833)

 

Outstanding and exercisable at June 30, 2023

 

864,068

$

16.17

*Includes the reduction of the exercise price from $60.00 per ADS to $13.20 per ADS for Common Warrants issued in the August Offering to investors who participated in both the Company’s August Offering and February Offering, see above.
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.2
ORGANIZATION AND BUSINESS (Details)
Jul. 18, 2023
shares
ORGANIZATION AND BUSINESS  
Shares owned (as a percent) 12.00%
Minimum  
ORGANIZATION AND BUSINESS  
Number of shares represented for one ADS 5,000
Maximum  
ORGANIZATION AND BUSINESS  
Number of shares represented for one ADS 60,000
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.2
LIQUIDITY RISKS AND OTHER UNCERTAINTIES (Details) - USD ($)
3 Months Ended 6 Months Ended
Aug. 01, 2023
Apr. 05, 2023
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
LIQUIDITY RISKS AND OTHER UNCERTAINTIES                  
Accumulated deficit     $ 42,200,000       $ 42,200,000    
Net loss     (2,106,947) $ (2,603,069) $ (2,668,167) $ (1,682,802) (4,710,016) $ (4,350,969)  
Net cash used in operating activities             (3,319,260) $ (4,244,926)  
Cash balance     4,759,129       4,759,129   $ 2,860,628
Investments     $ 10,680,160       $ 10,680,160   $ 9,992,900
ADS                  
LIQUIDITY RISKS AND OTHER UNCERTAINTIES                  
Minimum closing bid price required per ADS   $ 1.00              
Threshold number of consecutive business days for calculating closing bid price per ads   30 days              
ADS | Subsequent Event                  
LIQUIDITY RISKS AND OTHER UNCERTAINTIES                  
Minimum closing bid price required per ADS $ 1.00                
Threshold number of consecutive business days for calculating closing bid price per ads 10 days                
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)
$ in Millions
6 Months Ended
Jun. 30, 2023
USD ($)
segment
Dec. 31, 2022
USD ($)
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES    
Number of operating segments | segment 1  
U.S. Treasury Bills | $ $ 10.7 $ 10.0
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-lived assets & Income taxes (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Intangible assets, useful life     10 years  
Impairment loss measurement $ 0.0 $ 0.0 $ 0.0 $ 0.0
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (loss) per share (Details) - ADS - shares
3 Months Ended 6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Employee stock option        
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Antidilutive securities 25,595 25,760 25,595 25,760
Outstanding warrants        
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Antidilutive securities 864,068 87,742 864,068 87,742
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.2
ACCRUED INTEREST AND FINANCING EXPENSE (Details)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
item
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
item
Dec. 31, 2021
USD ($)
shares
ACCRUED INTEREST AND FINANCING EXPENSE            
Expected accrued interest         $ 312,000  
Accrued interest and financing expense $ 1,146,251   $ 1,146,251   $ 1,146,251  
Total number of notes holders | item         5  
Number of notes holders who received consideration | item     2   2  
Number of remaining noteholders | item     3   3  
Convertible Notes Warrants, Common Stock            
ACCRUED INTEREST AND FINANCING EXPENSE            
Accrued interest and financing expense           $ 744,000
Convertible notes 2020            
ACCRUED INTEREST AND FINANCING EXPENSE            
Accrued interest and financing expense 1,146,000   $ 1,146,000   $ 1,146,000  
Interest expense $ 0 $ 0 $ 0 $ 0    
Convertible notes 2020 | Convertible Notes Warrants, Common Stock            
ACCRUED INTEREST AND FINANCING EXPENSE            
Shares issued upon conversion | shares           432
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair value on a recurring basis (Details) - Recurring - USD ($)
Jun. 30, 2023
Dec. 31, 2022
FAIR VALUE OF FINANCIAL INSTRUMENTS    
Warrant liability $ 10,680,160 $ 9,992,900
US Treasury Bills    
FAIR VALUE OF FINANCIAL INSTRUMENTS    
Warrant liability 10,680,160 9,992,900
Level 1    
FAIR VALUE OF FINANCIAL INSTRUMENTS    
Warrant liability 10,680,160 9,992,900
Level 1 | US Treasury Bills    
FAIR VALUE OF FINANCIAL INSTRUMENTS    
Warrant liability $ 10,680,160 $ 9,992,900
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK BASED COMPENSATION (Details) - Amended plan
6 Months Ended
Jun. 30, 2023
shares
STOCK BASED COMPENSATION  
Percentage of ordinary shares reserved for issuance 15.00%
Number of ordinary shares reserved for future issuance 16,891,925,220
ADS  
STOCK BASED COMPENSATION  
Number of ordinary shares reserved for future issuance 281,532
Granted 255,937
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK BASED COMPENSATION - Option activity (Details) - $ / shares
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Weighted Average Exercise Price    
Outstanding at December 31, 2022 $ 24.85  
Outstanding and exercisable at June 30, 2023 $ 16.17 $ 24.85
ADS    
ADS Underlying Options    
Outstanding at December 31, 2022 280,735  
Outstanding and exercisable at June 30, 2023 864,068 280,735
Amended plan | ADS    
ADS Underlying Options    
Outstanding at December 31, 2022 25,595  
Granted 255,937  
Outstanding and exercisable at June 30, 2023 25,595 25,595
Exercisable options (in shares) 6,845  
Weighted Average Exercise Price    
Outstanding at December 31, 2022 $ 210.00  
Outstanding and exercisable at June 30, 2023 210.00 $ 210.00
Exercisable options (in dollars per share) $ 210.00  
Weighted Average Contractual Terms    
Contractual term (in years) 8 years 9 months 10 days 9 years 3 months 10 days
Exercisable options (in years) 8 years 9 months 10 days  
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK BASED COMPENSATION - Stock based compensation expense (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2023
Jun. 30, 2022
STOCK BASED COMPENSATION      
Intrinsic value of outstanding options $ 0 $ 0  
Stock-based compensation expense 264,000 526,000 $ 229,000
Unrecognized stock compensation expense 2,679,000 $ 2,679,000  
Unrecognized stock compensation expense expected to be recognized over the remaining weighted average service period   2 years 7 months 6 days  
Research and Development Expense      
STOCK BASED COMPENSATION      
Stock-based compensation expense 34,000 $ 69,000 30,000
General and Administrative Expense      
STOCK BASED COMPENSATION      
Stock-based compensation expense $ 230,000 $ 457,000 $ 199,000
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.2
PREPAID EXPENSES (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
PREPAID EXPENSES    
Prepaid R&D costs $ 383,390 $ 383,390
Prepaid insurance 202,226 508,084
Prepaid expense 32,000 8,500
Total 617,616 899,974
Less: Short-term portion (234,226) (516,584)
Long-term portion $ 383,390 $ 383,390
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.2
ACCRUED EXPENSES (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
ACCRUED EXPENSES    
Research contract expenses $ 343,152 $ 105,071
Payroll 1,168,486 788,169
Payroll taxes 199,408 159,593
Professional fees 85,299 44,278
Other Expenses 38,308 78,594
Total $ 1,834,653 $ 1,175,705
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.2
IN-LICENSED TECHNOLOGY - Polytherapeutics (Details) - Polytherapeutics
Mar. 24, 2018
USD ($)
IN-LICENSED TECHNOLOGY  
Purchase price agreement $ 40,833
Royalty payment period 10 years
Percentage of royalty payments of net revenue 4.00%
Royalty payments with generic product introduced, as a percent of net revenue 2.00%
Royalty payments with two or more generic product introduced, as a percent of net revenue 0.00%
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.2
IN-LICENSED TECHNOLOGY - Skinvisible (Details) - Skinvisible Licensing agreement
$ in Millions
1 Months Ended
Oct. 31, 2019
USD ($)
IN-LICENSED TECHNOLOGY  
License Fee $ 1
Percentage of revenues to be paid 25.00%
Amount of payment to be made $ 5
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.2
INTANGIBLE ASSETS (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
INTANGIBLE ASSETS    
Total cost $ 1,040,433 $ 1,040,433
Accumulated amortization (387,894) (335,872)
Net book value 652,539 704,561
Acquired technology - Polytherapeutics    
INTANGIBLE ASSETS    
Total cost 40,433 40,433
Technology license - Skinvisible    
INTANGIBLE ASSETS    
Total cost $ 1,000,000 $ 1,000,000
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.2
INTANGIBLE ASSETS - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
INTANGIBLE ASSETS        
Amortization of intangibles $ 26,000 $ 26,000 $ 52,022 $ 52,021
Expected amortization expense        
2023 52,000   52,000  
2024 104,000   104,000  
2025 104,000   104,000  
2026 104,000   104,000  
Thereafter $ 288,000   $ 288,000  
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.2
RELATED PARTY TRANSACTIONS - Narrative (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
RELATED PARTY TRANSACTIONS          
Non-bearing interest indebtedness     $ 175,000 $ 300,000  
Outstanding indebtedness $ 725,000   $ 725,000   $ 600,000
Other Liability, Related Party, Type [Extensible Enumeration] srt:OfficerMember   srt:OfficerMember   srt:OfficerMember
Operating Costs and Expenses $ 2,260,064 $ 2,668,167 $ 5,035,614 $ 4,844,206  
Operating Cost and Expense, Related Party, Type [Extensible Enumeration]     us-gaap:RelatedPartyMember us-gaap:RelatedPartyMember  
Consulting expense          
RELATED PARTY TRANSACTIONS          
Operating Costs and Expenses 0 12,000 $ 12,000 $ 24,000  
Dr. Myers          
RELATED PARTY TRANSACTIONS          
Monthly payment amounts due to related party     25,000    
Non-bearing interest indebtedness 75,000 75,000 150,000 150,000  
Outstanding indebtedness $ 2,109,000   $ 2,109,000    
Other Liability, Related Party, Type [Extensible Enumeration] us-gaap:RelatedPartyMember   us-gaap:RelatedPartyMember    
Ms. Carter          
RELATED PARTY TRANSACTIONS          
Monthly payment amounts due to related party     $ 25,000    
Non-bearing interest indebtedness $ 0 $ 75,000 25,000 $ 150,000  
Outstanding indebtedness $ 1,840,000   $ 1,840,000    
Other Liability, Related Party, Type [Extensible Enumeration] us-gaap:RelatedPartyMember   us-gaap:RelatedPartyMember    
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.2
RELATED PARTY TRANSACTIONS - Amounts due to officers (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
RELATED PARTY TRANSACTIONS    
Total $ 3,948,733 $ 4,123,732
Other Liability, Related Party, Type [Extensible Enumeration] srt:OfficerMember srt:OfficerMember
Less: Short-term portion $ (725,000) $ (600,000)
Other Liability, Current, Related Party, Type [Extensible Enumeration] srt:OfficerMember srt:OfficerMember
Long-term portion $ 3,223,733 $ 3,523,733
Other Liability, Noncurrent, Related Party, Type [Extensible Enumeration] srt:OfficerMember srt:OfficerMember
Salaries and other compensation    
RELATED PARTY TRANSACTIONS    
Total $ 3,948,733 $ 4,108,500
Other Liability, Related Party, Type [Extensible Enumeration] srt:OfficerMember srt:OfficerMember
Invoices paid on behalf of the Company    
RELATED PARTY TRANSACTIONS    
Total   $ 15,232
Other Liability, Related Party, Type [Extensible Enumeration] srt:OfficerMember srt:OfficerMember
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.2
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 31, 2022
Nov. 30, 2020
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
May 31, 2022
Dec. 31, 2021
Nov. 30, 2021
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS                    
Research and development     $ 625,104 $ 726,694 $ 1,716,837 $ 1,314,263        
Accrued expenses     1,834,653   1,834,653   $ 1,175,705      
Other income     153,117   325,598 493,237        
Gain on reduction in liability           416,000        
Research and consulting agreement | Netherton Syndrome                    
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS                    
Research and development     0 77,000 50,000 77,000        
Research and consulting agreement | Therapeutics Inc.                    
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS                    
Research and development     360,000 309,000 959,000 480,000        
Research and consulting agreement | Scleroderma                    
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS                    
Total amount of agreement               $ 610,000    
Research and development     138,000 0 226,000 0        
Consulting agreements | Investor Relations firm                    
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS                    
Monthly payments     14,000   14,000          
Accrued expenses                 $ 584,000  
Other income $ 416,000                  
Gain on reduction in liability $ 168,000                  
Consulting fees     $ 0 0 $ 0 0        
Consulting agreements | Netherton Syndrome                    
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS                    
Total amount of agreement                   $ 250,000
Consulting agreements | Therapeutics Inc.                    
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS                    
Initial term   3 years                
Written termination notice period   90 days                
Total amount of agreement       $ 4,400,000   $ 4,400,000 $ 830,000      
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.2
SHAREHOLDERS' EQUITY - Share Capital (Details)
3 Months Ended 6 Months Ended
Feb. 24, 2023
USD ($)
$ / shares
shares
Mar. 31, 2023
shares
Jun. 30, 2023
Vote
Y
$ / shares
shares
Dec. 31, 2022
$ / shares
shares
Nov. 03, 2022
$ / shares
shares
Nov. 02, 2022
shares
Apr. 12, 2022
$ / shares
shares
SHAREHOLDERS' EQUITY              
Ordinary shares, shares authorized     500,000,000,000 500,000,000,000 500,000,000,000 50,000,000,000 50,000,000,000
Ordinary shares, par value | $ / shares     $ 0 $ 0 $ 0   $ 0
Number of vote for each ordinary share | Vote     1        
Number of years of income that limits distribution | Y     2        
Maximum period between date of financial statements and distribution date     6 months        
Threshold period for not to issue or proposed issuance of any ADSs or ordinary shares 90 days            
Threshold period for not to enter in to an agreement for variable rate transaction from the date of closing of the Offering 180 days            
Warrant Amendments              
SHAREHOLDERS' EQUITY              
Incremental fair value | $ $ 238,000            
Public offering              
SHAREHOLDERS' EQUITY              
Issuance of ADS and Pre-Funded Warrants, net (in shares) 24,750,000,000            
Public offering | Pre-Funded Warrants              
SHAREHOLDERS' EQUITY              
Warrants, number of securities called by warrants (in shares) 10,250,000,000            
ADS              
SHAREHOLDERS' EQUITY              
Issuance of ADS and Pre-Funded Warrants, net (in shares)   583,333          
Warrants, exercise price of warrants (in dollars per share) | $ / shares $ 60.00            
Shares warrants may purchase 280,000            
ADS | Warrant Amendments              
SHAREHOLDERS' EQUITY              
Warrants, exercise price of warrants (in dollars per share) | $ / shares $ 13.20            
Shares warrants may purchase 235,833            
ADS | Public offering              
SHAREHOLDERS' EQUITY              
Issuance of ADS and Pre-Funded Warrants, net (in shares) 412,500            
Purchase price | $ / shares $ 12.00            
ADS | Public offering | Pre-Funded Warrants              
SHAREHOLDERS' EQUITY              
Purchase price | $ / shares $ 11.9988            
Warrants, number of securities called by warrants (in shares) 170,833            
Gross proceeds from offering | $ $ 7,000,000.0            
Net proceeds from offering | $ $ 5,800,000            
ADS | Public offering | Common Warrants              
SHAREHOLDERS' EQUITY              
Warrants, exercise price of warrants (in dollars per share) | $ / shares $ 12.00            
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.2
SHAREHOLDERS' EQUITY - Warrants (Details)
6 Months Ended
Jun. 30, 2023
$ / shares
shares
Weighted Average Exercise Price Per Share  
Outstanding at December 31, 2022 | $ / shares $ 24.85
Outstanding and exercisable at June 30, 2023 | $ / shares 16.17
Common Warrants  
Weighted Average Exercise Price Per Share  
Granted | $ / shares $ 12.00
ADS  
ADSs Underlying Warrants  
Outstanding at December 31, 2022 280,735
Outstanding and exercisable at June 30, 2023 864,068
ADS | Common Warrants  
ADSs Underlying Warrants  
Granted 583,333
ADS | Pre-Funded Warrants  
ADSs Underlying Warrants  
Granted 170,833
Exercised Pre-Funded Warrants (170,833)
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.2
LICENSE AGREEMENTS (Details)
6 Months Ended
Jun. 30, 2023
USD ($)
agreement
LICENSE AGREEMENTS  
Number of license and supply agreements entered | agreement 8
Royalty revenues | $ $ 0
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.2
SUBSEQUENT EVENTS (Details) - ADS
Aug. 01, 2023
$ / shares
Jul. 18, 2023
shares
Apr. 05, 2023
$ / shares
SUBSEQUENT EVENTS      
Threshold number of consecutive business days for calculating closing bid price per ads     30 days
Minimum closing bid price required per ADS | $ / shares     $ 1.00
Subsequent Event      
SUBSEQUENT EVENTS      
Number of ordinary shares for each ADS | shares   5,000  
Number of ordinary shares for ADS | shares   60,000  
Reverse stock split   12  
Threshold number of consecutive business days for calculating closing bid price per ads 10 days    
Minimum closing bid price required per ADS | $ / shares $ 1.00    
XML 64 qnrx-20230630x10q_htm.xml IDEA: XBRL DOCUMENT 0001671502 qnrx:WarrantAmendmentsMember 2023-02-24 0001671502 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryBillSecuritiesMember 2023-06-30 0001671502 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryBillSecuritiesMember 2023-06-30 0001671502 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001671502 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001671502 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryBillSecuritiesMember 2022-12-31 0001671502 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryBillSecuritiesMember 2022-12-31 0001671502 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001671502 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001671502 dei:AdrMember qnrx:PublicOfferingMember 2023-02-24 2023-02-24 0001671502 qnrx:PublicOfferingMember 2023-02-24 2023-02-24 0001671502 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001671502 dei:AdrMember 2023-01-01 2023-03-31 0001671502 qnrx:ConvertibleNotesWarrantsCommonStockMember qnrx:Convertiblenotes2020Member 2021-01-01 2021-12-31 0001671502 dei:AdrMember us-gaap:SubsequentEventMember 2023-07-18 2023-07-18 0001671502 us-gaap:TreasuryStockCommonMember 2023-06-30 0001671502 us-gaap:RetainedEarningsMember 2023-06-30 0001671502 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001671502 us-gaap:TreasuryStockCommonMember 2023-03-31 0001671502 us-gaap:RetainedEarningsMember 2023-03-31 0001671502 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001671502 2023-03-31 0001671502 us-gaap:TreasuryStockCommonMember 2022-12-31 0001671502 us-gaap:RetainedEarningsMember 2022-12-31 0001671502 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001671502 us-gaap:TreasuryStockCommonMember 2022-06-30 0001671502 us-gaap:RetainedEarningsMember 2022-06-30 0001671502 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001671502 us-gaap:TreasuryStockCommonMember 2022-03-31 0001671502 us-gaap:RetainedEarningsMember 2022-03-31 0001671502 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001671502 2022-03-31 0001671502 us-gaap:TreasuryStockCommonMember 2021-12-31 0001671502 us-gaap:RetainedEarningsMember 2021-12-31 0001671502 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001671502 dei:AdrMember qnrx:PublicOfferingMember 2023-02-24 0001671502 qnrx:CommonWarrantsMember 2023-01-01 2023-06-30 0001671502 qnrx:AmendedAndRestatedEquityIncentivePlanMember 2023-01-01 2023-06-30 0001671502 qnrx:AmendedAndRestatedEquityIncentivePlanMember dei:AdrMember 2022-01-01 2022-12-31 0001671502 qnrx:AmendedAndRestatedEquityIncentivePlanMember dei:AdrMember 2022-12-31 0001671502 qnrx:PreFundedWarrantsMember dei:AdrMember 2023-01-01 2023-06-30 0001671502 qnrx:CommonWarrantsMember dei:AdrMember 2023-01-01 2023-06-30 0001671502 qnrx:AmendedAndRestatedEquityIncentivePlanMember dei:AdrMember 2023-01-01 2023-06-30 0001671502 qnrx:TherapeuticsInc.Member us-gaap:ResearchAndDevelopmentArrangementMember 2023-04-01 2023-06-30 0001671502 qnrx:SclerodermaMember us-gaap:ResearchAndDevelopmentArrangementMember 2023-04-01 2023-06-30 0001671502 qnrx:NethertonSyndromeMember us-gaap:ResearchAndDevelopmentArrangementMember 2023-04-01 2023-06-30 0001671502 qnrx:TherapeuticsInc.Member us-gaap:ResearchAndDevelopmentArrangementMember 2023-01-01 2023-06-30 0001671502 qnrx:SclerodermaMember us-gaap:ResearchAndDevelopmentArrangementMember 2023-01-01 2023-06-30 0001671502 qnrx:NethertonSyndromeMember us-gaap:ResearchAndDevelopmentArrangementMember 2023-01-01 2023-06-30 0001671502 qnrx:TherapeuticsInc.Member us-gaap:ResearchAndDevelopmentArrangementMember 2022-04-01 2022-06-30 0001671502 qnrx:SclerodermaMember us-gaap:ResearchAndDevelopmentArrangementMember 2022-04-01 2022-06-30 0001671502 qnrx:NethertonSyndromeMember us-gaap:ResearchAndDevelopmentArrangementMember 2022-04-01 2022-06-30 0001671502 qnrx:TherapeuticsInc.Member us-gaap:ResearchAndDevelopmentArrangementMember 2022-01-01 2022-06-30 0001671502 qnrx:SclerodermaMember us-gaap:ResearchAndDevelopmentArrangementMember 2022-01-01 2022-06-30 0001671502 qnrx:NethertonSyndromeMember us-gaap:ResearchAndDevelopmentArrangementMember 2022-01-01 2022-06-30 0001671502 qnrx:Ms.CarterMember 2023-04-01 2023-06-30 0001671502 qnrx:Dr.MyersMember 2023-04-01 2023-06-30 0001671502 qnrx:Ms.CarterMember 2022-04-01 2022-06-30 0001671502 qnrx:Dr.MyersMember 2022-04-01 2022-06-30 0001671502 qnrx:Ms.CarterMember 2022-01-01 2022-06-30 0001671502 qnrx:Dr.MyersMember 2022-01-01 2022-06-30 0001671502 qnrx:InvestorRelationsFirmMember qnrx:ConsultingAgreementMember 2023-04-01 2023-06-30 0001671502 qnrx:InvestorRelationsFirmMember qnrx:ConsultingAgreementMember 2023-01-01 2023-06-30 0001671502 qnrx:InvestorRelationsFirmMember qnrx:ConsultingAgreementMember 2022-04-01 2022-06-30 0001671502 qnrx:InvestorRelationsFirmMember qnrx:ConsultingAgreementMember 2022-01-01 2022-06-30 0001671502 qnrx:InvoicePaidOnBehalfOfCompanyMember 2023-06-30 0001671502 qnrx:Ms.CarterMember 2023-06-30 0001671502 qnrx:Dr.MyersMember 2023-06-30 0001671502 qnrx:SalaryAndOtherCompensationMember 2023-06-30 0001671502 qnrx:SalaryAndOtherCompensationMember 2022-12-31 0001671502 qnrx:InvoicePaidOnBehalfOfCompanyMember 2022-12-31 0001671502 qnrx:ConsultingExpenseMember 2023-04-01 2023-06-30 0001671502 qnrx:ConsultingExpenseMember 2023-01-01 2023-06-30 0001671502 qnrx:ConsultingExpenseMember 2022-04-01 2022-06-30 0001671502 qnrx:ConsultingExpenseMember 2022-01-01 2022-06-30 0001671502 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001671502 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001671502 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001671502 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001671502 qnrx:Convertiblenotes2020Member 2023-06-30 0001671502 qnrx:Convertiblenotes2020Member 2022-12-31 0001671502 qnrx:ConvertibleNotesWarrantsCommonStockMember 2021-12-31 0001671502 qnrx:Convertiblenotes2020Member 2023-04-01 2023-06-30 0001671502 qnrx:Convertiblenotes2020Member 2023-01-01 2023-06-30 0001671502 qnrx:Convertiblenotes2020Member 2022-04-01 2022-06-30 0001671502 qnrx:Convertiblenotes2020Member 2022-01-01 2022-06-30 0001671502 qnrx:InvestorRelationsFirmMember qnrx:ConsultingAgreementMember 2022-03-01 2022-03-31 0001671502 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-06-30 0001671502 us-gaap:LicensingAgreementsMember 2023-06-30 0001671502 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0001671502 us-gaap:LicensingAgreementsMember 2022-12-31 0001671502 dei:AdrMember 2023-04-01 2023-06-30 0001671502 dei:AdrMember 2023-01-01 2023-06-30 0001671502 dei:AdrMember 2022-01-01 2022-06-30 0001671502 us-gaap:CommonStockMember 2023-06-30 0001671502 us-gaap:CommonStockMember 2023-03-31 0001671502 dei:AdrMember 2023-03-31 0001671502 us-gaap:CommonStockMember 2022-12-31 0001671502 us-gaap:CommonStockMember 2022-06-30 0001671502 dei:AdrMember 2022-06-30 0001671502 us-gaap:CommonStockMember 2022-03-31 0001671502 dei:AdrMember 2022-03-31 0001671502 us-gaap:CommonStockMember 2021-12-31 0001671502 dei:AdrMember 2021-12-31 0001671502 dei:AdrMember 2023-06-30 0001671502 dei:AdrMember 2022-12-31 0001671502 2022-11-02 0001671502 2022-11-03 0001671502 2022-04-12 0001671502 qnrx:AmendedAndRestatedEquityIncentivePlanMember dei:AdrMember 2023-06-30 0001671502 qnrx:AmendedAndRestatedEquityIncentivePlanMember 2023-06-30 0001671502 qnrx:PreFundedWarrantsMember dei:AdrMember qnrx:PublicOfferingMember 2023-02-24 0001671502 qnrx:PreFundedWarrantsMember qnrx:PublicOfferingMember 2023-02-24 0001671502 qnrx:CommonWarrantsMember dei:AdrMember qnrx:PublicOfferingMember 2023-02-24 0001671502 qnrx:WarrantAmendmentsMember dei:AdrMember 2023-02-24 0001671502 dei:AdrMember 2023-02-24 0001671502 2022-06-30 0001671502 2021-12-31 0001671502 qnrx:SkinvisibleLicenseAgreementMember 2019-10-31 0001671502 us-gaap:EmployeeStockOptionMember dei:AdrMember 2023-01-01 2023-06-30 0001671502 qnrx:OutstandingWarrantsMember dei:AdrMember 2023-01-01 2023-06-30 0001671502 us-gaap:EmployeeStockOptionMember dei:AdrMember 2023-01-01 2023-03-31 0001671502 qnrx:OutstandingWarrantsMember dei:AdrMember 2023-01-01 2023-03-31 0001671502 us-gaap:EmployeeStockOptionMember dei:AdrMember 2022-01-01 2022-06-30 0001671502 qnrx:OutstandingWarrantsMember dei:AdrMember 2022-01-01 2022-06-30 0001671502 us-gaap:EmployeeStockOptionMember dei:AdrMember 2022-01-01 2022-03-31 0001671502 qnrx:OutstandingWarrantsMember dei:AdrMember 2022-01-01 2022-03-31 0001671502 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001671502 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001671502 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001671502 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001671502 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001671502 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001671502 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001671502 2022-01-01 2022-03-31 0001671502 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001671502 2023-04-01 2023-06-30 0001671502 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001671502 2023-01-01 2023-03-31 0001671502 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001671502 2022-04-01 2022-06-30 0001671502 qnrx:InvestorRelationsFirmMember qnrx:ConsultingAgreementMember 2021-12-31 0001671502 2023-02-24 2023-02-24 0001671502 dei:AdrMember us-gaap:SubsequentEventMember 2023-08-01 2023-08-01 0001671502 dei:AdrMember 2023-04-05 2023-04-05 0001671502 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001671502 dei:AdrMember 2022-04-01 2022-06-30 0001671502 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001671502 2023-07-18 2023-07-18 0001671502 qnrx:SecuritiesPurchaseAgreementInPolytherapeuticsincMember 2018-03-24 2018-03-24 0001671502 srt:MinimumMember 2023-07-18 0001671502 srt:MaximumMember 2023-07-18 0001671502 dei:AdrMember us-gaap:SubsequentEventMember 2023-07-18 0001671502 qnrx:PreFundedWarrantsMember dei:AdrMember qnrx:PublicOfferingMember 2023-02-24 2023-02-24 0001671502 qnrx:Ms.CarterMember 2023-01-01 2023-06-30 0001671502 qnrx:Dr.MyersMember 2023-01-01 2023-06-30 0001671502 dei:AdrMember us-gaap:SubsequentEventMember 2023-08-01 0001671502 dei:AdrMember 2023-04-05 0001671502 2022-01-01 2022-06-30 0001671502 2022-01-01 2022-12-31 0001671502 qnrx:InvestorRelationsFirmMember qnrx:ConsultingAgreementMember 2023-06-30 0001671502 qnrx:TherapeuticsInc.Member qnrx:ConsultingAgreementMember 2022-12-31 0001671502 qnrx:TherapeuticsInc.Member qnrx:ConsultingAgreementMember 2022-06-30 0001671502 qnrx:SclerodermaMember us-gaap:ResearchAndDevelopmentArrangementMember 2022-05-31 0001671502 qnrx:NethertonSyndromeMember qnrx:ConsultingAgreementMember 2021-11-30 0001671502 qnrx:SkinvisibleLicenseAgreementMember 2019-10-01 2019-10-31 0001671502 qnrx:TherapeuticsInc.Member qnrx:ConsultingAgreementMember 2020-11-01 2020-11-30 0001671502 2023-06-30 0001671502 2022-12-31 0001671502 us-gaap:CommonStockMember 2023-08-02 0001671502 dei:AdrMember 2023-08-02 0001671502 2023-01-01 2023-06-30 shares iso4217:USD pure qnrx:item iso4217:USD shares qnrx:agreement qnrx:Y qnrx:Vote qnrx:segment http://fasb.org/srt/2023#OfficerMember http://fasb.org/srt/2023#OfficerMember http://fasb.org/srt/2023#OfficerMember http://fasb.org/srt/2023#OfficerMember http://fasb.org/srt/2023#OfficerMember http://fasb.org/srt/2023#OfficerMember http://fasb.org/srt/2023#OfficerMember 0001671502 --12-31 2023 Q2 false http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/srt/2023#OfficerMember http://fasb.org/srt/2023#OfficerMember 987217 24233024799 59233024799 403884 25000 http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/srt/2023#OfficerMember http://fasb.org/srt/2023#OfficerMember http://fasb.org/srt/2023#OfficerMember http://fasb.org/srt/2023#OfficerMember http://fasb.org/srt/2023#OfficerMember P10D 10-Q true 2023-06-30 false 001-37846 QUOIN PHARMACEUTICALS LTD. L3 92-2593104 42127 Pleasant Forest Court Ashburn VA 20148 703 980-4182 American Depositary Shares QNRX NASDAQ Yes Yes Non-accelerated Filer true false false 59233024799 987217 4759129 2860628 10680160 9992900 234226 516584 15673515 13370112 383390 383390 652539 704561 16709444 14458063 707935 605600 1834653 1175705 1146251 1146251 725000 600000 4413839 3527556 3223733 3523733 7637572 7051289 0 0 500000000000 500000000000 59233024799 987217 24233024799 403884 0 0 2641693 2641693 2932000 2932000 54230635 47855521 -42226763 -37516747 9071872 7406774 16709444 14458063 1634960 1941473 3318777 3529943 625104 726694 1716837 1314263 2260064 2668167 5035614 4844206 416000 -77237 -34472 -14045 187589 339643 153117 325598 493237 -2106947 -2668167 -4710016 -4350969 -2.13 -38.91 -5.79 -69.90 -2.13 -38.91 -5.79 -69.90 987217 68573 813184 62242 987217 68573 813184 62242 3354650799 55911 -2932000 31659017 -28069985 657032 -1682802 -1682802 3200 296362 296362 3354653999 55911 -2932000 31955379 -29752787 -729408 -2668167 -2668167 229441 229441 1710500800 28508 5065154799 84419 -2932000 32184820 -32420954 -3168134 24233024799 403884 -2932000 47855521 -37516747 7406774 -2603069 -2603069 35000000000 583333 5849266 5849266 261472 261472 59233024799 987217 -2932000 53966259 -40119816 10914443 -2106947 -2106947 264376 264376 59233024799 987217 -2932000 54230635 -42226763 9071872 -4710016 -4350969 -77237 525848 229441 416000 52022 52021 -311670 230755 761283 440817 -282358 -188671 -3319260 -4244926 13491505 13035000 250000 -456505 -250000 175000 300000 5849266 5674266 -300000 1898501 -4794926 2860628 7482773 4759129 2687847 296362 238231 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1 – ORGANIZATION AND BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Quoin Pharmaceuticals Ltd. (“Quoin Ltd.,” or the “Company”), formerly known as Cellect Biotechnology Ltd. (“Cellect”), is the holding company for Quoin Pharmaceuticals, Inc., a Delaware corporation (“Quoin Inc.”). On October 28, 2021, Cellect completed the business combination with Quoin Inc., with Quoin Inc. surviving as a wholly-owned subsidiary of Cellect (the “Merger”). Immediately after completion of the Merger, Cellect changed its name to “Quoin Pharmaceuticals Ltd.”</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective July 18, 2023, the ratio of American Depositary Shares (“ADSs”) evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs (the “Ratio Change”). All ADSs and related option and warrant information presented in these financial statements and accompanying footnotes has been retroactively adjusted to reflect the number of ADSs resulting from the Ratio Change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Quoin Inc. was incorporated in Delaware on March 5, 2018. Quoin Inc. is clinical stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently no approved treatments or cures. The Company’s initial focus is on the development of products, using proprietary owned and in-licensed drug delivery technologies, that could help address rare skin diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary in-licensed Invisicare® technology, is under development as a potential treatment for Netherton Syndrome (“NS”), a rare hereditary genetic disease. QRX003 is currently being tested in two clinical studies in the United States (“U.S.”) under an open Investigational New Drug (“IND”) application with the Food and Drug Administration (“FDA”). Dosing of patients commenced in December 2022 for the first study and in March 2023 for the second study. The Company is also developing QRX004 as a potential treatment for Recessive Dystrophic Epidermolysis Bullosa (“RDEB”). In addition, the Company has entered into Research Agreements with the Queensland University of Technology (“QUT”), which include an option for global licenses to QRX007 for the potential treatment of NS and QRX008 for the potential treatment of scleroderma. To date, no products have been commercialized and revenue has not been generated.</p> 5000 60000 0.12 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 2 - LIQUIDITY RISKS AND OTHER UNCERTAINTIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”), which contemplates continuation of the Company as a going concern. The Company has incurred net losses every year since inception and has an accumulated deficit of approximately $42.2 million at June 30, 2023. The Company has limited operating history and has historically funded its operations through debt and equity financings. The Company incurred net losses of approximately $4.7 million, and negative cash flows from operations of $3.3 million for the six months ended June 30, 2023. At June 30, 2023, the Company had cash balances totaling $4.8 million and investments of $10.7 million. The Company has determined that it has sufficient cash and liquidity to effect its business plan for at least one year from the issuance of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additional financing will still be required to complete the research and development of the Company’s therapeutic targets and its other operating requirements until it achieves commercial profitability, if ever. Such financing may not be available at acceptable terms, if at all. If the Company is unable to obtain additional funding when it becomes necessary, the development of its product candidates will be impacted and the Company would likely be forced to delay, reduce, or terminate some or all of its development programs, all of which could have a material adverse effect on the Company’s business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other risks and uncertainties:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to development stage biopharmaceutical companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, pre-clinical and clinical trial outcome risks, regulatory approval risks, uncertainty of market acceptance and additional financing requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s products require approval or clearance from the FDA prior to commencing commercial sales in the United States. There can be no assurance that the Company’s products will receive all of the required approvals or clearances. Approvals or clearances are also required in foreign jurisdictions in which the Company may license or sell its products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the Company’s products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is also dependent on several third party suppliers, in some cases a single source supplier including the contract research organization managing both of the Company’s current clinical studies, the supplier of the active pharmaceutical ingredient (API), as well as the contract manufacturer of the drug substance for the expected clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Nasdaq Listing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 5, 2023, the Company received a letter from the Listing Qualifications staff of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that the closing bid price per ADS was below the required minimum of $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2). Pursuant to Nasdaq Rule 5810(c)(3)(A), the Company had a period of one hundred eighty (180) calendar days, or until October 2, 2023 (the “Compliance Period”), to regain compliance with Nasdaq’s minimum bid price requirement. On August 1, 2023, the Company received a letter from Nasdaq stating that the Company’s closing bid price per ADS was at $1.00 or greater for the last 10 consecutive business days. Accordingly, the Company regained compliance with Listing Rule 5550(a)(2) and the matter was closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the Company will be able to maintain compliance with Nasdaq’s minimum bid-price requirement for continued listing. If the Company’s ADSs are delisted from Nasdaq, it will have a material negative impact on the actual and potential liquidity of the Company’s securities, as well as a material negative impact on the Company’s ability to raise future capital.</p> 42200000 -4700000 -3300000 4800000 10700000 1.00 P30D 1.00 P10D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basis of Presentation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of June 30, 2023 and for the three and six months then ended. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of December 31, 2022 and for the year then ended which are included in the Company’s Annual Report on Form 10- K, filed with the SEC on March 15, 2023. The Company operates in one segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">research and development expense recognition, intangible asset estimated useful lives and impairment assessments, allowances of deferred tax assets, and cash flow assumptions regarding going concern considerations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents. The Company, from time to time during the periods presented, has had bank account balances in excess of federally insured limits where substantially all cash is held in the United States. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Warrants:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) provided that such contracts are indexed to the Company’s own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company assesses classification of its warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets, liabilities and equity is required. The Company evaluated the warrants to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that such warrants meet the criteria for equity classification in the accompanying unaudited condensed consolidated balance sheets as of June 30, 2023 and December 31, 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Investments:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Investments as of June 30, 2023 and December 31, 2022 consist of U.S. Treasury Bills, which are classified as trading securities, totaling $</span><span style="font-weight:normal;">10.7</span><span style="font-weight:normal;"> million and </span><span style="font-weight:normal;">$10.0</span><span style="font-weight:normal;"> million, respectively. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Long-lived assets:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Long-lived assets are comprised of acquired technology and licensed rights to use technology, which are considered platform technology with alternative future uses beyond the current products in development. Such intangible assets are being amortized on a straight-line basis over their expected useful life of 10 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company assesses the impairment for long-lived assets whenever events or circumstances indicate the carrying value may not be recoverable. Factors we consider that could trigger an impairment review include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Significant changes in the manner of the Company’s use of the acquired assets or the strategy for its overall business,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Significant underperformance relative to expected historical or projected development milestones,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Significant negative regulatory or economic trends, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Significant technological changes which could render the platform technology obsolete.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the three and six months ended June 30, 2023 and 2022, there were no impairment indicators which required an impairment loss measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials when applicable, administrative costs incurred by third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expenses in future periods as the related services are rendered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Income taxes:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for its income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company maintains a full valuation allowance on its existing deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also accounts for uncertain tax positions using the more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company’s income tax returns. As of June 30, 2023 and December 31, 2022, the Company had no uncertain tax positions which affected its financial position and its results of operations or its cash flows and will continue to evaluate for uncertain tax positions in the future. If at any time the Company should record interest and penalties in connection with income taxes, the interest and the penalties will be expensed within the interest and general and administrative expenses, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock based compensation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s expected stock volatility is based on the historical data regarding the volatility of a publicly traded set of peer companies, since it has a limited history of trading as a public company. The Company utilizes the simplified method to estimate the expected term. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield was assumed to be zero as the Company has not paid and dividends since its inception and does not anticipate paying dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fair value of financial instruments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers its cash and cash equivalents, investments, accounts payable, accrued expenses to meet the definition of financial instruments. The carrying amounts of these financial instruments approximated their fair values due to the short maturities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company measures fair value as required by ASC Topic 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i> (“ASC Topic 820”). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Earnings (loss) per share:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company reports loss per share in accordance with ASC 260-10, <i style="font-style:italic;">Earnings Per Share</i>, which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives effect to ordinary shares equivalents; however, potential common shares are excluded if their effect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three and six months ended June 30, 2023, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 864,068 ADS and outstanding stock options to purchase 25,595 ADS. For the three and six months ended June 30, 2022, the number of shares excluded from the diluted net earnings (loss) per share included warrants to purchase 87,742 ADSs and outstanding options to purchase 25,760 ADSs, respectively. The inclusion of these stock options and warrants from both periods in 2023 and 2022 in the denominator would be anti-dilutive.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basis of Presentation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of June 30, 2023 and for the three and six months then ended. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of December 31, 2022 and for the year then ended which are included in the Company’s Annual Report on Form 10- K, filed with the SEC on March 15, 2023. The Company operates in one segment.</p> 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">research and development expense recognition, intangible asset estimated useful lives and impairment assessments, allowances of deferred tax assets, and cash flow assumptions regarding going concern considerations.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents. The Company, from time to time during the periods presented, has had bank account balances in excess of federally insured limits where substantially all cash is held in the United States. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Warrants:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) provided that such contracts are indexed to the Company’s own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company assesses classification of its warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets, liabilities and equity is required. The Company evaluated the warrants to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that such warrants meet the criteria for equity classification in the accompanying unaudited condensed consolidated balance sheets as of June 30, 2023 and December 31, 2022, respectively.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Investments:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Investments as of June 30, 2023 and December 31, 2022 consist of U.S. Treasury Bills, which are classified as trading securities, totaling $</span><span style="font-weight:normal;">10.7</span><span style="font-weight:normal;"> million and </span><span style="font-weight:normal;">$10.0</span><span style="font-weight:normal;"> million, respectively. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date.</span></p> 10700000 10000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Long-lived assets:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Long-lived assets are comprised of acquired technology and licensed rights to use technology, which are considered platform technology with alternative future uses beyond the current products in development. Such intangible assets are being amortized on a straight-line basis over their expected useful life of 10 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company assesses the impairment for long-lived assets whenever events or circumstances indicate the carrying value may not be recoverable. Factors we consider that could trigger an impairment review include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Significant changes in the manner of the Company’s use of the acquired assets or the strategy for its overall business,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Significant underperformance relative to expected historical or projected development milestones,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Significant negative regulatory or economic trends, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Significant technological changes which could render the platform technology obsolete.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the three and six months ended June 30, 2023 and 2022, there were no impairment indicators which required an impairment loss measurement.</p> P10Y 0 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials when applicable, administrative costs incurred by third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expenses in future periods as the related services are rendered.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Income taxes:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for its income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company maintains a full valuation allowance on its existing deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also accounts for uncertain tax positions using the more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company’s income tax returns. As of June 30, 2023 and December 31, 2022, the Company had no uncertain tax positions which affected its financial position and its results of operations or its cash flows and will continue to evaluate for uncertain tax positions in the future. If at any time the Company should record interest and penalties in connection with income taxes, the interest and the penalties will be expensed within the interest and general and administrative expenses, respectively.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock based compensation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s expected stock volatility is based on the historical data regarding the volatility of a publicly traded set of peer companies, since it has a limited history of trading as a public company. The Company utilizes the simplified method to estimate the expected term. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield was assumed to be zero as the Company has not paid and dividends since its inception and does not anticipate paying dividends in the foreseeable future.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fair value of financial instruments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers its cash and cash equivalents, investments, accounts payable, accrued expenses to meet the definition of financial instruments. The carrying amounts of these financial instruments approximated their fair values due to the short maturities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company measures fair value as required by ASC Topic 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i> (“ASC Topic 820”). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Earnings (loss) per share:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company reports loss per share in accordance with ASC 260-10, <i style="font-style:italic;">Earnings Per Share</i>, which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives effect to ordinary shares equivalents; however, potential common shares are excluded if their effect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three and six months ended June 30, 2023, the number of shares excluded from the diluted net earnings (loss) per share included outstanding warrants to purchase 864,068 ADS and outstanding stock options to purchase 25,595 ADS. For the three and six months ended June 30, 2022, the number of shares excluded from the diluted net earnings (loss) per share included warrants to purchase 87,742 ADSs and outstanding options to purchase 25,760 ADSs, respectively. The inclusion of these stock options and warrants from both periods in 2023 and 2022 in the denominator would be anti-dilutive.</p> 864068 864068 25595 25595 87742 87742 25760 25760 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 4 – ACCRUED INTEREST AND FINANCING EXPENSE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 2, 2020, Quoin Inc. commenced an offering of promissory notes (the “2020 Notes”) and warrants to certain investors (“2020 Noteholders”). 2020 Notes were mandatorily convertible into 432 ADSs in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The ADSs issued to the 2020 Noteholders did not include the accrued interest which was estimated to be approximately $744,000 at December 31, 2021 of which $312,000 was paid to two of the five 2020 Noteholders during the year ended December 31, 2022. Based on the terms of the cash settlement with these two 2020 Noteholders, the Company’s estimate of the liability to the remaining three 2020 Noteholders was $1,146,000 as of June 30, 2023 and December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There was no interest expense recognized in both the three and six month periods ended June 30, 2023 and 2022.</p> 432 744000 312000 2 5 2 2 3 3 1146000 1146000 0 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 5 - FAIR VALUE OF FINANCIAL INSTRUMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company applies fair value accounting for all assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. For certain instruments, including cash and cash equivalents, accounts payable, and accrued expenses, it was estimated that the carrying amount approximated fair value because of the short maturities of these instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fair value is estimated using various valuation models, which utilize certain inputs and assumptions that market participants would use in pricing the asset or liability. The inputs and assumptions used in valuation models are classified in the fair value hierarchy as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">Level 2: Quoted market prices for similar instruments in an active market; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations inputs of which are observable and can be corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">Level 3: Unobservable inputs and assumptions that are supported by little or no market activity and that are significant to the fair value of the asset and liability. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In determining the appropriate hierarchy levels, the Company analyzes the assets and liabilities that are subject to fair value disclosure. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to their fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis by fair value hierarchy at June 30, 2023 and December 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US Treasury Bills </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,680,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,680,160</p></td></tr><tr><td style="vertical-align:bottom;width:49.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total US Treasury Bills Asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,680,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,680,160</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US Treasury Bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,992,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,992,900</p></td></tr><tr><td style="vertical-align:bottom;width:48.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total US Treasury Bills Asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,992,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,992,900</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US Treasury Bills </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,680,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,680,160</p></td></tr><tr><td style="vertical-align:bottom;width:49.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total US Treasury Bills Asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,680,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,680,160</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">US Treasury Bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,992,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,992,900</p></td></tr><tr><td style="vertical-align:bottom;width:48.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total US Treasury Bills Asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,992,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,992,900</p></td></tr></table> 10680160 10680160 10680160 10680160 9992900 9992900 9992900 9992900 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 6 – STOCK BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March 2022, the Board of Directors of the Company approved the Amended and Restated Equity Incentive Plan (the “Amended Plan”), which was approved by the shareholders at the Company’s Annual General Meeting of Shareholders held on April 12, 2022. The Amended Plan increased the number of ordinary shares reserved for issuance under such equity incentive plan to 15% of the Company’s outstanding ordinary shares on a fully-diluted basis, or 16,891,925,220 ordinary shares represented by 281,532 ADSs as of June 30, 2023. Under the Amended Plan, the Company may grant options to its directors, officers, employees, consultants, advisers and service providers. As of June 30, 2023, 255,937 ADSs remained available for grant under the Amended Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes stock-based activities under the Amended Plan:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ADS Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Terms</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 210.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.28</p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 25,595</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 210.00</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8.78</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable options at June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 210.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.78</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The intrinsic value of outstanding options at June 30, 2023 was $0.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock based compensation expense was approximately $264,000 ($34,000 included in research and development expense and $230,000 included in general and administrative expenses) in the three months ended June 30, 2023 and approximately $526,000 ($69,000 included in research and development expense and $457,000 included in general and administrative expenses) in the six months ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock based compensation expense was approximately $229,000 ($30,000 included in research and development expense and $199,000 included in general and administrative expenses) in both the three and six months ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At June 30, 2023, the total unrecognized compensation expense related to non-vested options was approximately $2,679,000 and is expected to be recognized over the remaining weighted average service period of approximately 2.60 years.</p> 0.15 16891925220 281532 255937 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ADS Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Terms</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 210.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.28</p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding at June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 25,595</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 210.00</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8.78</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable options at June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 210.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.78</p></td></tr></table> 25595 210.00 P9Y3M10D 25595 210.00 P8Y9M10D 6845 210.00 P8Y9M10D 0 264000 34000 230000 526000 69000 457000 229000 30000 199000 2679000 P2Y7M6D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 7 – PREPAID EXPENSES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prepaid expenses are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid R&amp;D costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 383,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 383,390</p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202,226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 508,084</p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,500</p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 617,616</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 899,974</p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Short-term portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (234,226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (516,584)</p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 383,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 383,390</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid R&amp;D costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 383,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 383,390</p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202,226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 508,084</p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,500</p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 617,616</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 899,974</p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Short-term portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (234,226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (516,584)</p></td></tr><tr><td style="vertical-align:bottom;width:74.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 383,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 383,390</p></td></tr></table> 383390 383390 202226 508084 32000 8500 617616 899974 234226 516584 383390 383390 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 8 - ACCRUED EXPENSES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accrued expenses are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research contract expenses (note 12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 343,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,071</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll (note 11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,168,486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 788,169</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll taxes (note 11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 199,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 159,593</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,278</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,594</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,834,653</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,175,705</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research contract expenses (note 12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 343,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,071</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll (note 11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,168,486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 788,169</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll taxes (note 11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 199,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 159,593</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,278</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,594</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,834,653</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,175,705</b></p></td></tr></table> 343152 105071 1168486 788169 199408 159593 85299 44278 38308 78594 1834653 1175705 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 9 – IN-LICENSED TECHNOLOGY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Polytherapeutics:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 24, 2018, Quoin Inc. entered into a securities purchase agreement (the “Acquisition Agreement”), in which it agreed to acquire all of the equity interests in Polytherapeutics, Inc. (the “Seller” or “Polytherapeutics”) for $40,833 and future royalties provided Quoin Inc. commercializes products using the technology developed by the Seller. The terms of any royalty payments to the Seller are 4.0% of the net revenue of royalty products, as defined in the Acquisition Agreement during the ten (10) year period commencing from the date of first sale of a royalty product. If a generic product is introduced by a third party to the market, during the royalty period, the royalty fees shall be reduced from 4% to 2%. If, during the royalty period, two or more generic products are introduced, the royalty fees shall be reduced from 2% to 0%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Skinvisible:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In October 2019, Quoin Inc. entered into the Exclusive Licensing Agreement (as amended from time to time, the “License Agreement”) with Skinvisible Pharmaceuticals, Inc. (“Skinvisible”), under which Skinvisible granted the Company an exclusive royalty-bearing license relating to the production and manufacture of prescription drug products related to certain patents held by Skinvisible, including those related to QRX003 and QRX004. The Company made Skinvisible a one-time non-refundable, non-creditable license fee of $1 million (the “License Fee”). In addition, the Company agreed to pay Skinvisible a single digit royalty percentage of the Company’s net sales revenues for any licensed product covered by the patent rights licensed under the License Agreement. The Company also agreed </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to pay Skinvisible 25% of any revenues the Company receives as royalties in the event that the Company sublicense any licensed products to a third party. The License Agreement also requires that the Company make a $5 million payment to Skinvisible upon receiving approval in the U.S. or European Union, whichever occurs first, for the first drug product developed using intellectual property licensed thereunder.</p> 40833 0.040 P10Y 0.04 0.02 0.02 0 1000000 0.25 5000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 10 - INTANGIBLE ASSETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Intangible assets are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Acquired technology – Polytherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,433</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Technology license – Skinvisible</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,040,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,040,433</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (387,894)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (335,872)</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net book value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 652,539</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 704,561</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recorded amortization expense of approximately $52,000 for the six months ended June 30, 2023 and 2022. The Company recorded amortization expense of approximately $26,000 for the three months ended June 30, 2023 and 2022. The annual amortization expense expected to be recorded for existing intangible assets for the years 2023 through 2026, and thereafter, is approximately $52,000, $104,000, $104,000, $104,000 and $288,000, respectively.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Acquired technology – Polytherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,433</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Technology license – Skinvisible</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,040,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,040,433</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (387,894)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (335,872)</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net book value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 652,539</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 704,561</b></p></td></tr></table> 40433 40433 1000000 1000000 1040433 1040433 387894 335872 652539 704561 52000 52000 26000 26000 52000 104000 104000 104000 104000 288000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 11 - RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Employment Agreements and Due to Officers/Founders:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Due to the limited funding of Quoin Inc. prior to the consummation of the Merger, the compensation, including salary, office and car allowances and other benefits, due to Dr. Myers and Ms. Carter under their respective employment agreements, as well as reimbursement of expenses and other amounts paid to third parties on behalf of Quoin Inc., were accrued as indebtedness to Dr. Myers and Ms. Carter. Following the closing of the Merger, Quoin Inc. began making payments of $25,000 per month to each of Dr. Myers and Ms. Carter to <span style="-sec-ix-hidden:Hidden_FCS2oM2KZkeQTnHy_pzd-A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">repay</span></span> the above-described non-interest-bearing indebtedness. The Company repaid $75,000 and $75,000 of such indebtedness to Dr. Myers and $0 and $75,000 to Ms. Carter in the three months ended June 30, 2023 and 2022, respectively. The Company repaid $150,000 and $150,000 of such indebtedness to Dr. Myers and $25,000 and $150,000 to Ms. Carter in the six months ended June 30, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, approximately $2,109,000 and $1,840,000 of <span style="-sec-ix-hidden:Hidden_a4xLBMD0SEmPlbvE-3Iiog;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such</span></span> <span style="-sec-ix-hidden:Hidden_9FeleDds4E6kkurh5uwA9w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">indebtedness</span></span> was outstanding to Dr. Myers and Ms. Carter, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Amounts due to officers at June 30, 2023 and December 31, 2022 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_UuaTlB5kdEOAWrq98XPh6w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Salaries and other compensation</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,948,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,108,500</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_TrJS3VxVH0qQdex4DlbbFQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Invoices paid on behalf of the Company</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,232</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_dlMbOo6ZaEaGvwLfa1E-nA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Total</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,948,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,123,732</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_cc3mFEIPvka9jv9j4L95eQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Less: Short-term portion</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (725,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (600,000)</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_a7n7oNzvkUW9WW37B9zqvw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Long-term portion</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,223,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,523,733</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Expenses:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expense, incurred in the three months ended June 30, 2023 and 2022, was $0 and $12,000 and it was $12,000 and $24,000 in the six months ended June 30, 2023 and 2022, respectively, for payments to the CEO Dr. Myers’ son, who had been consulting for the Company on research and development matters from time to time. As of March 31, 2023, Dr. Myers’ son no longer provided consulting services to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interest Payable:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 4 for interest payable on the 2020 Notes.</p> 25000 75000 75000 0 75000 150000 150000 25000 150000 2109000 1840000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_UuaTlB5kdEOAWrq98XPh6w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Salaries and other compensation</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,948,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,108,500</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_TrJS3VxVH0qQdex4DlbbFQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Invoices paid on behalf of the Company</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,232</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_dlMbOo6ZaEaGvwLfa1E-nA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Total</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,948,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,123,732</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_cc3mFEIPvka9jv9j4L95eQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Less: Short-term portion</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (725,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (600,000)</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_a7n7oNzvkUW9WW37B9zqvw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Long-term portion</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,223,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,523,733</p></td></tr></table> 3948733 4108500 15232 3948733 4123732 725000 600000 3223733 3523733 0 12000 12000 24000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 12 – RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2020, Quoin Inc. entered into a Master Service Agreement for an initial term of three years with Therapeutics Inc. for managing preclinical and clinical development for new products in the field of dermatology. The agreement required the execution of individual work orders. Quoin Inc. may terminate any work order for any reason with 90 days written notice subject to costs incurred through termination and a defined termination fee, unless there is a material breach by Therapeutics Inc. A work order was entered into in June 2022 for the first QRX003 clinical study at an expected estimated cost of approximately $4.4 million through 2024. A further work order was entered into in December 2022 for the second QRX003 clinical study at an expected estimated cost of approximately $830,000 through 2024. For the three and six months ended June 30, 2023 and 2022, the Company incurred a research and development expense under these agreements of approximately $360,000 and $959,000, and $309,000 and $480,000 respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2021, the Company entered into a commitment with Queensland University of Technology for research related services associated with Netherton Syndrome of approximately $250,000 for an expected period of eighteen months. For the three and six months ended June 30, 2023 and 2022, the Company incurred research and development costs related to this agreement of approximately $0 and $50,000, and $77,000 and $77,000 respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2022, the Company entered into a commitment with Queensland University of Technology for research related services associated with Scleroderma of approximately $610,000 for an expected period of eighteen months. For the three and six months ended June 30, 2023 and 2022, the Company incurred research and development costs related to this agreement of approximately $138,000 and $226,000, and $-0- and $-0- respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Consulting agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Quoin Inc. entered into a consulting agreement with an Investor Relations (IR) firm, which provided for a monthly fee of $14,000. The agreement had an automatic annual renewal clause and was in effect in November 2017. The Company owed the IR firm $584,000 as of December 31, 2021. Effective March 31, 2022, the Company entered into a settlement agreement with the IR firm reducing the liability to $168,000 and recognized $416,000 as other income in the accompanying consolidated statement of operations. The liability was fully repaid as of April 1, 2023. No expenses were incurred in both the three and six months ended June 30, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Performance milestones and Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 9 for asset and in-licensed technology commitments.</p> P3Y P90D 4400000 830000 360000 959000 309000 480000 250000 0 50000 77000 77000 610000 138000 226000 0 0 14000 584000 168000 416000 0 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;"> </span>NOTE 13 – SHAREHOLDERS’ EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company held its Annual General Meeting on April 12, 2022, at which the Company’s shareholders approved an increase to the authorized share capital to 50,000,000,000, no par value. The Company held a further Annual General Meeting on November 3, 2022, at which the Company’s shareholders approved an increase to the authorized share capital to 500,000,000,000 ordinary shares from 50,000,000,000, no par value. These ordinary shares are not redeemable and do not have any preemptive rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Holders of the Company’s ordinary shares have one vote for each ordinary share held on all matters submitted to a vote of shareholders at a shareholders meeting. The board of directors shall determine and provide a record date for each shareholders meeting and all shareholders at such record date may vote. Unless stipulated differently in the Companies Law or in the articles of association, all shareholders’ resolutions shall be approved by a simple majority vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under Israeli law, the Company may declare and pay dividends only if, upon the determination of its board of directors, there is no reasonable concern that the distribution will prevent the Company from being able to meet the terms of its existing and foreseeable obligations as they become due. Under the Companies Law, the distribution amount is further limited to the greater of retained earnings or earnings generated over the two most recent years legally available for distribution according to the Company’s then last reviewed or audited financial statements, provided that the date of the financial statements is not more than six months prior to the date of distribution. In the event that the Company does not have retained earnings or earnings generated over the two most recent years legally available for distribution, the Company may seek the approval of the court in order to distribute a dividend. The court may approve the Company’s request if it determines that there is no reasonable concern that the payment of a dividend will prevent the Company from satisfying existing and foreseeable obligations as they become due.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each ADS will also represent any other securities, cash or other property which may be held by the depositary. ADSs may be held either (a) directly (1) by having an American Depositary Receipt, also referred to as an ADR, which is a certificate evidencing a specific number of ADSs or (2) by having uncertificated ADSs, or (b) indirectly by holding a security entitlement in ADSs through a broker or other financial institution that is a direct or indirect participant in The Depository Trust Company, also called DTC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">February 2023 Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 24, 2023 (the “February Closing Date”), the Company completed an offering (the “February Offering”) of 24,750,000,000 ordinary shares represented by 412,500 ADSs at a purchase price of $12.00 per ADS and a pre-funded warrant (the “February Pre-Funded Warrant”) to purchase 10,250,000,000 ordinary shares represented by 170,833 ADSs at a per pre-funded warrant price of $11.9988, with each ADS and February Pre-Funded Warrant accompanied by an ordinary warrant (the “February Common Warrant”) for aggregate gross proceeds of $7.0 million, resulting in net proceeds of approximately $5.8 million, after deducting the placement agent’s fees and offering expenses. Each February Common Warrant has an exercise price of $12.00 per ADS and expires on the fifth anniversary of the February Closing Date. On the February Closing Date, the holder of the February Pre-Funded Warrant exercised its Pre-Funded Warrant in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the February Offering, the Company entered into a Securities Purchase Agreement (the “February Purchase Agreement”) with certain institutional investors. Under the February Purchase Agreement, subject to certain exemptions, the Company agreed not to: (i) for a period of ninety (90) days after the closing date of the February Offering, issue, enter into any agreement to issue or announce the issuance or proposed issuance of any ADSs, ordinary shares or ordinary share equivalents or (ii) file any registration statement or amendment or supplement thereto, other than a registration statement on Form S-8 in connection with any employee benefit plan or any post-effective amendment to a registration statement declared effective by the Securities and Exchange Commission (the “SEC”) and (ii) for a period of 180 days after the closing date of the February Offering, enter into an agreement to effect a “variable rate transaction” as defined in the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the February Offering, the Company entered into an Amendment No. 1 to Warrant to Purchase Ordinary Shares Represented by American Depositary Shares, dated February 24, 2023 (collectively, the “Warrant Amendments”), with each of the purchasers (the “2022 Purchasers”) who participated in both the Company’s offering completed in August 2022 (the “August Offering”) and February Offering. The Warrant Amendments amended certain terms of the Common Warrants issued in the August Offering to such 2022 Purchasers. Specifically, the Warrant Amendments reduced the exercise price of Common Warrants to purchase 235,833 ADSs out of the total 280,000 issued in the August Offering from $60.00 to $13.20 and extended the term during which those warrants could remain exercisable until February 24, 2028. The incremental fair value of the modified warrants was approximately $238,000, which was accounted for as an offering expense in connection with the February Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes warrant activities during the six months ended June 30, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ADSs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per ADS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 280,735</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 583,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted Pre-Funded Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised Pre-Funded Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (170,833)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding and exercisable at June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 864,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">*</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes the reduction of the exercise price from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$60.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per ADS to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$13.20</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per ADS for Common Warrants issued in the August Offering to investors who participated in both the Company’s August Offering and February Offering, see above.</span></td></tr></table><div style="margin-top:12pt;"></div> 50000000000 0 500000000000 50000000000 0 1 2 P6M 2 24750000000 412500 12.00 10250000000 170833 11.9988 7000000.0 5800000 12.00 P90D P180D 235833 280000 60.00 13.20 238000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ADSs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per ADS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 280,735</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 583,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted Pre-Funded Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised Pre-Funded Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (170,833)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding and exercisable at June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 864,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">*</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes the reduction of the exercise price from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$60.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per ADS to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$13.20</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per ADS for Common Warrants issued in the August Offering to investors who participated in both the Company’s August Offering and February Offering, see above.</span></td></tr></table><div style="margin-top:12pt;"></div> 280735 24.85 583333 12.00 170833 170833 864068 16.17 60.00 13.20 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 14 – CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may become involved in various legal matters arising in the ordinary course of business. Management is unaware of any matters requiring accrual for related losses in the financial statements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 15 – LICENSE AGREEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, the Company has entered into eight license and supply agreements, whereby the Company will receive a royalty or other proceeds from the specified product revenues in select non-US markets from the licensor, if and when the underlying products are approved and commercialized. No royalty revenues have been received through June 30, 2023 under any of these agreements. </p> 8 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 16 - SUBSEQUENT EVENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective July 18, 2023, the ratio of ADSs evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs. See Note 1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 1, 2023, the Company received a letter from Nasdaq stating that the Company’s closing bid price per ADS was at $1.00 or greater for the last <span style="-sec-ix-hidden:Hidden_4oQzdjI270ap8KKUYfvOnA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10</span></span> consecutive business days. Accordingly, the Company regained compliance with Listing Rule 5550(a)(2) and the matter was closed. See Note 2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 5000 60000 12 1.00 EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end
XML 66 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 172 211 1 false 38 0 false 9 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Statements of Shareholders' Equity Sheet http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity Condensed Consolidated Statements of Shareholders' Equity Statements 5 false false R6.htm 00400 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 10101 - Disclosure - ORGANIZATION AND BUSINESS Sheet http://www.quoinpharma.com/role/DisclosureOrganizationAndBusiness ORGANIZATION AND BUSINESS Notes 7 false false R8.htm 10201 - Disclosure - LIQUIDITY RISKS AND OTHER UNCERTAINTIES Sheet http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertainties LIQUIDITY RISKS AND OTHER UNCERTAINTIES Notes 8 false false R9.htm 10301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 10401 - Disclosure - ACCRUED INTEREST AND FINANCING EXPENSE Sheet http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpense ACCRUED INTEREST AND FINANCING EXPENSE Notes 10 false false R11.htm 10501 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS Sheet http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstruments FAIR VALUE OF FINANCIAL INSTRUMENTS Notes 11 false false R12.htm 10601 - Disclosure - STOCK BASED COMPENSATION Sheet http://www.quoinpharma.com/role/DisclosureStockBasedCompensation STOCK BASED COMPENSATION Notes 12 false false R13.htm 10701 - Disclosure - PREPAID EXPENSES Sheet http://www.quoinpharma.com/role/DisclosurePrepaidExpenses PREPAID EXPENSES Notes 13 false false R14.htm 10801 - Disclosure - ACCRUED EXPENSES Sheet http://www.quoinpharma.com/role/DisclosureAccruedExpenses ACCRUED EXPENSES Notes 14 false false R15.htm 10901 - Disclosure - IN-LICENSED TECHNOLOGY Sheet http://www.quoinpharma.com/role/DisclosureInLicensedTechnology IN-LICENSED TECHNOLOGY Notes 15 false false R16.htm 11001 - Disclosure - INTANGIBLE ASSETS Sheet http://www.quoinpharma.com/role/DisclosureIntangibleAssets INTANGIBLE ASSETS Notes 16 false false R17.htm 11101 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 17 false false R18.htm 11201 - Disclosure - RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS Sheet http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitments RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS Notes 18 false false R19.htm 11301 - Disclosure - SHAREHOLDERS' EQUITY Sheet http://www.quoinpharma.com/role/DisclosureShareholdersEquity SHAREHOLDERS' EQUITY Notes 19 false false R20.htm 11401 - Disclosure - CONTINGENCIES Sheet http://www.quoinpharma.com/role/DisclosureContingencies CONTINGENCIES Notes 20 false false R21.htm 11501 - Disclosure - LICENSE AGREEMENTS Sheet http://www.quoinpharma.com/role/DisclosureLicenseAgreements LICENSE AGREEMENTS Notes 21 false false R22.htm 11601 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.quoinpharma.com/role/DisclosureSubsequentEvents SUBSEQUENT EVENTS Notes 22 false false R23.htm 20302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 23 false false R24.htm 30503 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Sheet http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTables FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Tables http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstruments 24 false false R25.htm 30603 - Disclosure - STOCK BASED COMPENSATION (Tables) Sheet http://www.quoinpharma.com/role/DisclosureStockBasedCompensationTables STOCK BASED COMPENSATION (Tables) Tables http://www.quoinpharma.com/role/DisclosureStockBasedCompensation 25 false false R26.htm 30703 - Disclosure - PREPAID EXPENSES (Tables) Sheet http://www.quoinpharma.com/role/DisclosurePrepaidExpensesTables PREPAID EXPENSES (Tables) Tables http://www.quoinpharma.com/role/DisclosurePrepaidExpenses 26 false false R27.htm 30803 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://www.quoinpharma.com/role/DisclosureAccruedExpensesTables ACCRUED EXPENSES (Tables) Tables http://www.quoinpharma.com/role/DisclosureAccruedExpenses 27 false false R28.htm 31003 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://www.quoinpharma.com/role/DisclosureIntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://www.quoinpharma.com/role/DisclosureIntangibleAssets 28 false false R29.htm 31103 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) Sheet http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsTables RELATED PARTY TRANSACTIONS (Tables) Tables http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactions 29 false false R30.htm 31303 - Disclosure - SHAREHOLDERS' EQUITY (Tables) Sheet http://www.quoinpharma.com/role/DisclosureShareholdersEquityTables SHAREHOLDERS' EQUITY (Tables) Tables http://www.quoinpharma.com/role/DisclosureShareholdersEquity 30 false false R31.htm 40101 - Disclosure - ORGANIZATION AND BUSINESS (Details) Sheet http://www.quoinpharma.com/role/DisclosureOrganizationAndBusinessDetails ORGANIZATION AND BUSINESS (Details) Details http://www.quoinpharma.com/role/DisclosureOrganizationAndBusiness 31 false false R32.htm 40201 - Disclosure - LIQUIDITY RISKS AND OTHER UNCERTAINTIES (Details) Sheet http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails LIQUIDITY RISKS AND OTHER UNCERTAINTIES (Details) Details http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertainties 32 false false R33.htm 40301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Sheet http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Details 33 false false R34.htm 40302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-lived assets & Income taxes (Details) Sheet http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsIncomeTaxesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-lived assets & Income taxes (Details) Details 34 false false R35.htm 40303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (loss) per share (Details) Sheet http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (loss) per share (Details) Details 35 false false R36.htm 40401 - Disclosure - ACCRUED INTEREST AND FINANCING EXPENSE (Details) Sheet http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails ACCRUED INTEREST AND FINANCING EXPENSE (Details) Details http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpense 36 false false R37.htm 40501 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair value on a recurring basis (Details) Sheet http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair value on a recurring basis (Details) Details 37 false false R38.htm 40601 - Disclosure - STOCK BASED COMPENSATION (Details) Sheet http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails STOCK BASED COMPENSATION (Details) Details http://www.quoinpharma.com/role/DisclosureStockBasedCompensationTables 38 false false R39.htm 40602 - Disclosure - STOCK BASED COMPENSATION - Option activity (Details) Sheet http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails STOCK BASED COMPENSATION - Option activity (Details) Details 39 false false R40.htm 40603 - Disclosure - STOCK BASED COMPENSATION - Stock based compensation expense (Details) Sheet http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails STOCK BASED COMPENSATION - Stock based compensation expense (Details) Details 40 false false R41.htm 40701 - Disclosure - PREPAID EXPENSES (Details) Sheet http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails PREPAID EXPENSES (Details) Details http://www.quoinpharma.com/role/DisclosurePrepaidExpensesTables 41 false false R42.htm 40801 - Disclosure - ACCRUED EXPENSES (Details) Sheet http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails ACCRUED EXPENSES (Details) Details http://www.quoinpharma.com/role/DisclosureAccruedExpensesTables 42 false false R43.htm 40901 - Disclosure - IN-LICENSED TECHNOLOGY - Polytherapeutics (Details) Sheet http://www.quoinpharma.com/role/DisclosureInLicensedTechnologyPolytherapeuticsDetails IN-LICENSED TECHNOLOGY - Polytherapeutics (Details) Details 43 false false R44.htm 40902 - Disclosure - IN-LICENSED TECHNOLOGY - Skinvisible (Details) Sheet http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails IN-LICENSED TECHNOLOGY - Skinvisible (Details) Details 44 false false R45.htm 41001 - Disclosure - INTANGIBLE ASSETS (Details) Sheet http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails INTANGIBLE ASSETS (Details) Details http://www.quoinpharma.com/role/DisclosureIntangibleAssetsTables 45 false false R46.htm 41002 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details) Sheet http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails INTANGIBLE ASSETS - Additional Information (Details) Details 46 false false R47.htm 41101 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details) Sheet http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails RELATED PARTY TRANSACTIONS - Narrative (Details) Details 47 false false R48.htm 41102 - Disclosure - RELATED PARTY TRANSACTIONS - Amounts due to officers (Details) Sheet http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails RELATED PARTY TRANSACTIONS - Amounts due to officers (Details) Details 48 false false R49.htm 41201 - Disclosure - RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS (Details) Sheet http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS (Details) Details http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitments 49 false false R50.htm 41301 - Disclosure - SHAREHOLDERS' EQUITY - Share Capital (Details) Sheet http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails SHAREHOLDERS' EQUITY - Share Capital (Details) Details 50 false false R51.htm 41302 - Disclosure - SHAREHOLDERS' EQUITY - Warrants (Details) Sheet http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails SHAREHOLDERS' EQUITY - Warrants (Details) Details 51 false false R52.htm 41501 - Disclosure - LICENSE AGREEMENTS (Details) Sheet http://www.quoinpharma.com/role/DisclosureLicenseAgreementsDetails LICENSE AGREEMENTS (Details) Details http://www.quoinpharma.com/role/DisclosureLicenseAgreements 52 false false R53.htm 41601 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.quoinpharma.com/role/DisclosureSubsequentEventsDetails SUBSEQUENT EVENTS (Details) Details http://www.quoinpharma.com/role/DisclosureSubsequentEvents 53 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: qnrx:MonthlyPaymentAmountsDueToRelatedParty, qnrx:ThresholdNumberOfConsecutiveBusinessDaysForCalculatingClosingBidPricePerAds, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding - qnrx-20230630x10q.htm 9 [ix-0514-Hidden-Fact-Not-Referenced] WARN: 11 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies, us-gaap:OperatingCostAndExpenseRelatedPartyTypeExtensibleEnumeration, us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration, us-gaap:OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration, us-gaap:OtherLiabilityRelatedPartyTypeExtensibleEnumeration - qnrx-20230630x10q.htm 9 qnrx-20230630x10q.htm qnrx-20230630.xsd qnrx-20230630_cal.xml qnrx-20230630_def.xml qnrx-20230630_lab.xml qnrx-20230630_pre.xml qnrx-20230630xex31d1.htm qnrx-20230630xex31d2.htm qnrx-20230630xex32d1.htm qnrx-20230630xex32d2.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 71 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "qnrx-20230630x10q.htm": { "axisCustom": 0, "axisStandard": 20, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 401, "http://xbrl.sec.gov/dei/2023": 30 }, "contextCount": 172, "dts": { "calculationLink": { "local": [ "qnrx-20230630_cal.xml" ] }, "definitionLink": { "local": [ "qnrx-20230630_def.xml" ] }, "inline": { "local": [ "qnrx-20230630x10q.htm" ] }, "labelLink": { "local": [ "qnrx-20230630_lab.xml" ] }, "presentationLink": { "local": [ "qnrx-20230630_pre.xml" ] }, "schema": { "local": [ "qnrx-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 360, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 24, "http://www.quoinpharma.com/20230630": 2, "http://xbrl.sec.gov/dei/2023": 5, "total": 31 }, "keyCustom": 44, "keyStandard": 167, "memberCustom": 20, "memberStandard": 17, "nsprefix": "qnrx", "nsuri": "http://www.quoinpharma.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "qnrx:AccruedInterestAndFinancingExpenseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - ACCRUED INTEREST AND FINANCING EXPENSE", "menuCat": "Notes", "order": "10", "role": "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpense", "shortName": "ACCRUED INTEREST AND FINANCING EXPENSE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "qnrx:AccruedInterestAndFinancingExpenseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS", "menuCat": "Notes", "order": "11", "role": "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstruments", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - STOCK BASED COMPENSATION", "menuCat": "Notes", "order": "12", "role": "http://www.quoinpharma.com/role/DisclosureStockBasedCompensation", "shortName": "STOCK BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "qnrx:PrepaidExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - PREPAID EXPENSES", "menuCat": "Notes", "order": "13", "role": "http://www.quoinpharma.com/role/DisclosurePrepaidExpenses", "shortName": "PREPAID EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "qnrx:PrepaidExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - ACCRUED EXPENSES", "menuCat": "Notes", "order": "14", "role": "http://www.quoinpharma.com/role/DisclosureAccruedExpenses", "shortName": "ACCRUED EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - IN-LICENSED TECHNOLOGY", "menuCat": "Notes", "order": "15", "role": "http://www.quoinpharma.com/role/DisclosureInLicensedTechnology", "shortName": "IN-LICENSED TECHNOLOGY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - INTANGIBLE ASSETS", "menuCat": "Notes", "order": "16", "role": "http://www.quoinpharma.com/role/DisclosureIntangibleAssets", "shortName": "INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "17", "role": "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS", "menuCat": "Notes", "order": "18", "role": "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitments", "shortName": "RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - SHAREHOLDERS' EQUITY", "menuCat": "Notes", "order": "19", "role": "http://www.quoinpharma.com/role/DisclosureShareholdersEquity", "shortName": "SHAREHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": "0", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDisclosures", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - CONTINGENCIES", "menuCat": "Notes", "order": "20", "role": "http://www.quoinpharma.com/role/DisclosureContingencies", "shortName": "CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDisclosures", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "qnrx:LicenseAgreementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - LICENSE AGREEMENTS", "menuCat": "Notes", "order": "21", "role": "http://www.quoinpharma.com/role/DisclosureLicenseAgreements", "shortName": "LICENSE AGREEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "qnrx:LicenseAgreementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11601 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "22", "role": "http://www.quoinpharma.com/role/DisclosureSubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "23", "role": "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTables", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - STOCK BASED COMPENSATION (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationTables", "shortName": "STOCK BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "qnrx:PrepaidExpenseDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - PREPAID EXPENSES (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesTables", "shortName": "PREPAID EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "qnrx:PrepaidExpenseDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - ACCRUED EXPENSES (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.quoinpharma.com/role/DisclosureAccruedExpensesTables", "shortName": "ACCRUED EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - INTANGIBLE ASSETS (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsTables", "shortName": "INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsTables", "shortName": "RELATED PARTY TRANSACTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_6-SvsQUDukCSOaXCn741pw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_OdFUuGvb9UuMJdvhZ_Zjvg", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "qnrx:SummaryOfWarrantActivitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31303 - Disclosure - SHAREHOLDERS' EQUITY (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.quoinpharma.com/role/DisclosureShareholdersEquityTables", "shortName": "SHAREHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "qnrx:SummaryOfWarrantActivitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_7_18_2023_To_7_18_2023_j4WXu3bhmkKrYLbwtUTufw", "decimals": "2", "first": true, "lang": null, "name": "qnrx:SharesOwnedPercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_ClP0jEMbGkSnt3GNRNbrHQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - ORGANIZATION AND BUSINESS (Details)", "menuCat": "Details", "order": "31", "role": "http://www.quoinpharma.com/role/DisclosureOrganizationAndBusinessDetails", "shortName": "ORGANIZATION AND BUSINESS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_7_18_2023_To_7_18_2023_j4WXu3bhmkKrYLbwtUTufw", "decimals": "2", "first": true, "lang": null, "name": "qnrx:SharesOwnedPercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_ClP0jEMbGkSnt3GNRNbrHQ", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - LIQUIDITY RISKS AND OTHER UNCERTAINTIES (Details)", "menuCat": "Details", "order": "32", "role": "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails", "shortName": "LIQUIDITY RISKS AND OTHER UNCERTAINTIES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_bNVMxipIYEilxfz65K32aQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "menuCat": "Details", "order": "33", "role": "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_bNVMxipIYEilxfz65K32aQ", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-lived assets & Income taxes (Details)", "menuCat": "Details", "order": "34", "role": "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsIncomeTaxesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Long-lived assets & Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_iJi3UnNMnUC1zbPEUNrruA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_OdFUuGvb9UuMJdvhZ_Zjvg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (loss) per share (Details)", "menuCat": "Details", "order": "35", "role": "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (loss) per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_iJi3UnNMnUC1zbPEUNrruA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_OdFUuGvb9UuMJdvhZ_Zjvg", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "qnrx:AccruedInterestAndFinancingExpenseTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2022_To_12_31_2022_qmuyK5a_fEy37pvNl_eLQQ", "decimals": "0", "first": true, "lang": null, "name": "qnrx:ExpectedAccruedInterestOnWarrantsIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - ACCRUED INTEREST AND FINANCING EXPENSE (Details)", "menuCat": "Details", "order": "36", "role": "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails", "shortName": "ACCRUED INTEREST AND FINANCING EXPENSE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "qnrx:AccruedInterestAndFinancingExpenseTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2022_To_12_31_2022_qmuyK5a_fEy37pvNl_eLQQ", "decimals": "0", "first": true, "lang": null, "name": "qnrx:ExpectedAccruedInterestOnWarrantsIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_llxB7OAPEk2jQFd7qNh1vQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair value on a recurring basis (Details)", "menuCat": "Details", "order": "37", "role": "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair value on a recurring basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_llxB7OAPEk2jQFd7qNh1vQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_qnrx_AmendedAndRestatedEquityIncentivePlanMember_0K3seMydl0CTUfE4Nr7Klw", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_ClP0jEMbGkSnt3GNRNbrHQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - STOCK BASED COMPENSATION (Details)", "menuCat": "Details", "order": "38", "role": "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "shortName": "STOCK BASED COMPENSATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_qnrx_AmendedAndRestatedEquityIncentivePlanMember_0K3seMydl0CTUfE4Nr7Klw", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_ClP0jEMbGkSnt3GNRNbrHQ", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "qnrx:SummaryOfWarrantActivitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_12_31_2022_RcUh8ClR70ixBOYKhBjjEg", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_6-SvsQUDukCSOaXCn741pw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - STOCK BASED COMPENSATION - Option activity (Details)", "menuCat": "Details", "order": "39", "role": "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails", "shortName": "STOCK BASED COMPENSATION - Option activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_us-gaap_PlanNameAxis_qnrx_AmendedAndRestatedEquityIncentivePlanMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_68L2pGpveEmnflYhQZNYtg", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_OdFUuGvb9UuMJdvhZ_Zjvg", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_xYDXEc0OX0eUFwrglRSUCw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Condensed Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_xYDXEc0OX0eUFwrglRSUCw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40603 - Disclosure - STOCK BASED COMPENSATION - Stock based compensation expense (Details)", "menuCat": "Details", "order": "40", "role": "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails", "shortName": "STOCK BASED COMPENSATION - Stock based compensation expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_xYDXEc0OX0eUFwrglRSUCw", "decimals": "0", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "qnrx:PrepaidExpenseDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": "0", "first": true, "lang": null, "name": "qnrx:PrepaidResearchAndDevelopmentCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - PREPAID EXPENSES (Details)", "menuCat": "Details", "order": "41", "role": "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails", "shortName": "PREPAID EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "qnrx:PrepaidExpenseDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": "0", "first": true, "lang": null, "name": "qnrx:PrepaidResearchAndDevelopmentCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": "0", "first": true, "lang": null, "name": "qnrx:AccruedResearchContractExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - ACCRUED EXPENSES (Details)", "menuCat": "Details", "order": "42", "role": "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails", "shortName": "ACCRUED EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": "0", "first": true, "lang": null, "name": "qnrx:AccruedResearchContractExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_3_24_2018_To_3_24_2018_us-gaap_AssetAcquisitionAxis_qnrx_SecuritiesPurchaseAgreementInPolytherapeuticsincMember_Y_R7xnwDy06ZgKBjt1JrXw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - IN-LICENSED TECHNOLOGY - Polytherapeutics (Details)", "menuCat": "Details", "order": "43", "role": "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologyPolytherapeuticsDetails", "shortName": "IN-LICENSED TECHNOLOGY - Polytherapeutics (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_3_24_2018_To_3_24_2018_us-gaap_AssetAcquisitionAxis_qnrx_SecuritiesPurchaseAgreementInPolytherapeuticsincMember_Y_R7xnwDy06ZgKBjt1JrXw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_10_1_2019_To_10_31_2019_us-gaap_AssetAcquisitionAxis_qnrx_SkinvisibleLicenseAgreementMember_GRFg6dGcAEmZcs3tgyYARw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - IN-LICENSED TECHNOLOGY - Skinvisible (Details)", "menuCat": "Details", "order": "44", "role": "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails", "shortName": "IN-LICENSED TECHNOLOGY - Skinvisible (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_10_1_2019_To_10_31_2019_us-gaap_AssetAcquisitionAxis_qnrx_SkinvisibleLicenseAgreementMember_GRFg6dGcAEmZcs3tgyYARw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - INTANGIBLE ASSETS (Details)", "menuCat": "Details", "order": "45", "role": "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails", "shortName": "INTANGIBLE ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "us-gaap:AmortizationOfIntangibleAssets", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_xYDXEc0OX0eUFwrglRSUCw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details)", "menuCat": "Details", "order": "46", "role": "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "shortName": "INTANGIBLE ASSETS - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfRelatedPartyDebt", "reportCount": 1, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)", "menuCat": "Details", "order": "47", "role": "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "shortName": "RELATED PARTY TRANSACTIONS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_us-gaap_RelatedPartyTransactionAxis_qnrx_ConsultingExpenseMember_UPq5wix-N06WXt3CvCh9AA", "decimals": "0", "lang": null, "name": "us-gaap:OperatingCostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41102 - Disclosure - RELATED PARTY TRANSACTIONS - Amounts due to officers (Details)", "menuCat": "Details", "order": "48", "role": "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "shortName": "RELATED PARTY TRANSACTIONS - Amounts due to officers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_xYDXEc0OX0eUFwrglRSUCw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS (Details)", "menuCat": "Details", "order": "49", "role": "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails", "shortName": "RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_qnrx_NethertonSyndromeMember_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_us-gaap_ResearchAndDevelopmentArrangementMember_AWBFPiibbU-NSbHdGDbzUg", "decimals": "0", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_pekTkHGdHkybTx_nYq9WjA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Condensed Consolidated Statements of Shareholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity", "shortName": "Condensed Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UmDIyzLRekugPcqkiChIwg", "decimals": "0", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_ZvOkE8zQc0GVxWJ1e3jrbA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_OdFUuGvb9UuMJdvhZ_Zjvg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - SHAREHOLDERS' EQUITY - Share Capital (Details)", "menuCat": "Details", "order": "50", "role": "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "shortName": "SHAREHOLDERS' EQUITY - Share Capital (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_11_3_2022_mVLO2W7xbkW6qeGv3NuvXQ", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_OdFUuGvb9UuMJdvhZ_Zjvg", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "qnrx:SummaryOfWarrantActivitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_12_31_2022_RcUh8ClR70ixBOYKhBjjEg", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_6-SvsQUDukCSOaXCn741pw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41302 - Disclosure - SHAREHOLDERS' EQUITY - Warrants (Details)", "menuCat": "Details", "order": "51", "role": "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "shortName": "SHAREHOLDERS' EQUITY - Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "qnrx:SummaryOfWarrantActivitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_qnrx_CommonWarrantsMember_wOPj51oeVkWXoY9B_DL7OQ", "decimals": "2", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_6-SvsQUDukCSOaXCn741pw", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "qnrx:LicenseAgreementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": "INF", "first": true, "lang": null, "name": "qnrx:NumberOfLicenseAndSupplyAgreementsEntered", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_agreement_Ef58XZUIy0mIjOjXu6bu9A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - LICENSE AGREEMENTS (Details)", "menuCat": "Details", "order": "52", "role": "http://www.quoinpharma.com/role/DisclosureLicenseAgreementsDetails", "shortName": "LICENSE AGREEMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "qnrx:LicenseAgreementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": "INF", "first": true, "lang": null, "name": "qnrx:NumberOfLicenseAndSupplyAgreementsEntered", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_agreement_Ef58XZUIy0mIjOjXu6bu9A", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_4_5_2023_To_4_5_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_SYTJ8GWQ7Eqxu-l3HHyB3A", "decimals": null, "first": true, "lang": "en-US", "name": "qnrx:ThresholdNumberOfConsecutiveBusinessDaysForCalculatingClosingBidPricePerAds", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41601 - Disclosure - SUBSEQUENT EVENTS (Details)", "menuCat": "Details", "order": "53", "role": "http://www.quoinpharma.com/role/DisclosureSubsequentEventsDetails", "shortName": "SUBSEQUENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "As_Of_7_18_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fNfNqdDUcES3rh_5s8_Rqg", "decimals": "INF", "lang": null, "name": "qnrx:NumberOfOrdinarySharesForEachAmericanDepositaryShares", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_OdFUuGvb9UuMJdvhZ_Zjvg", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mkeQm1ush06IWES_sPiG9A", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - ORGANIZATION AND BUSINESS", "menuCat": "Notes", "order": "7", "role": "http://www.quoinpharma.com/role/DisclosureOrganizationAndBusiness", "shortName": "ORGANIZATION AND BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - LIQUIDITY RISKS AND OTHER UNCERTAINTIES", "menuCat": "Notes", "order": "8", "role": "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertainties", "shortName": "LIQUIDITY RISKS AND OTHER UNCERTAINTIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "9", "role": "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "qnrx-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_tv6eMXcIT0C_FIc0sUD88A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 38, "tag": { "dei_AdrMember": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "American Depositary Receipt (or American Depositary Share, ADS).", "label": "ADR [Member]", "terseLabel": "ADS" } } }, "localname": "AdrMember", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails", "http://www.quoinpharma.com/role/DisclosureSubsequentEventsDetails", "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails", "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r612" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Addresses [Line Items]", "terseLabel": "Document and Entity Information" } } }, "localname": "EntityAddressesLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesTable": { "auth_ref": [ "r607" ], "lang": { "en-us": { "role": { "documentation": "Container of address information for the entity", "label": "Entity Addresses [Table]" } } }, "localname": "EntityAddressesTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r607" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r607" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r607" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r607" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r607" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r607" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r607" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "qnrx_AccruedInterestAndFinancingExpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "ACCRUED INTEREST AND FINANCING EXPENSE[Line Items]", "terseLabel": "ACCRUED INTEREST AND FINANCING EXPENSE" } } }, "localname": "AccruedInterestAndFinancingExpenseLineItems", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails" ], "xbrltype": "stringItemType" }, "qnrx_AccruedInterestAndFinancingExpenseTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure pertaining to accrued interest and financing expense.", "label": "Accrued Interest and Financing Expense[Text Block]", "terseLabel": "ACCRUED INTEREST AND FINANCING EXPENSE" } } }, "localname": "AccruedInterestAndFinancingExpenseTextBlock", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpense" ], "xbrltype": "textBlockItemType" }, "qnrx_AccruedResearchContractExpenseCurrent": { "auth_ref": [], "calculation": { "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research contract expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Research Contract Expense Current", "terseLabel": "Research contract expenses" } } }, "localname": "AccruedResearchContractExpenseCurrent", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "qnrx_AgreementInitialTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of between signing and termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Agreement, Initial Term", "terseLabel": "Initial term" } } }, "localname": "AgreementInitialTerm", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "durationItemType" }, "qnrx_AgreementWrittenTerminationNotice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of between written notice of termination and actual termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Agreement Written Termination Notice", "terseLabel": "Written termination notice period" } } }, "localname": "AgreementWrittenTerminationNotice", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "durationItemType" }, "qnrx_AmendedAndRestatedEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the amended and restated equity incentive Plan (the \"Amended Plan\").", "label": "Amended Plan [Member]", "terseLabel": "Amended plan" } } }, "localname": "AmendedAndRestatedEquityIncentivePlanMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails" ], "xbrltype": "domainItemType" }, "qnrx_AssetAcquisitionPercentageOfRevenuesToBePaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of revenues to be paid under asset acquisition.", "label": "Asset Acquisition, Percentage of Revenues to be Paid", "terseLabel": "Percentage of revenues to be paid" } } }, "localname": "AssetAcquisitionPercentageOfRevenuesToBePaid", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails" ], "xbrltype": "percentItemType" }, "qnrx_CommonWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Warrants [Member]", "label": "Common Warrants [Member]", "terseLabel": "Common Warrants" } } }, "localname": "CommonWarrantsMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails" ], "xbrltype": "domainItemType" }, "qnrx_ConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents consulting agreement.", "label": "Consulting Agreement [Member]", "terseLabel": "Consulting agreements" } } }, "localname": "ConsultingAgreementMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "qnrx_ConsultingExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to consulting expense.", "label": "Consulting Expense [Member]", "terseLabel": "Consulting expense" } } }, "localname": "ConsultingExpenseMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "qnrx_ConsultingOrServiceAgreementAgreedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of fee per consulting or service agreement.", "label": "Consulting or Service Agreement, Agreed Amount", "terseLabel": "Total amount of agreement" } } }, "localname": "ConsultingOrServiceAgreementAgreedAmount", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "qnrx_ConsultingOrServiceAgreementMonthlyPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of monthly fee or payments per consulting or service agreement.", "label": "Consulting or Service Agreement, Monthly Payment", "terseLabel": "Monthly payments" } } }, "localname": "ConsultingOrServiceAgreementMonthlyPayment", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "qnrx_ConvertibleNotesPayableNumberOfNoteholders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of noteholders.", "label": "Convertible Notes Payable, Number of Noteholders", "terseLabel": "Total number of notes holders" } } }, "localname": "ConvertibleNotesPayableNumberOfNoteholders", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails" ], "xbrltype": "integerItemType" }, "qnrx_ConvertibleNotesPayableNumberOfNoteholdersWhoReceivedConsideration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of noteholders who received consideration.", "label": "Convertible Notes Payable, Number of Noteholders Who Received Consideration", "terseLabel": "Number of notes holders who received consideration" } } }, "localname": "ConvertibleNotesPayableNumberOfNoteholdersWhoReceivedConsideration", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails" ], "xbrltype": "integerItemType" }, "qnrx_ConvertibleNotesPayableNumberOfRemainingNoteholdersReceiveConsideration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of remaining noteholders who received consideration.", "label": "Convertible Notes Payable, Number Of Remaining Noteholders Receive Consideration", "terseLabel": "Number of remaining noteholders" } } }, "localname": "ConvertibleNotesPayableNumberOfRemainingNoteholdersReceiveConsideration", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails" ], "xbrltype": "integerItemType" }, "qnrx_ConvertibleNotesWarrantsCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes Warrants, Common Stock.", "label": "Convertible Notes Warrants, Common Stock" } } }, "localname": "ConvertibleNotesWarrantsCommonStockMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails" ], "xbrltype": "domainItemType" }, "qnrx_Convertiblenotes2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes issued in 2020.", "label": "Convertible notes 2020" } } }, "localname": "Convertiblenotes2020Member", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails" ], "xbrltype": "domainItemType" }, "qnrx_DateOfFinancialStatementsAndDistributionPeriodMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum period of between date of financial statements and distribution, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Date of Financial Statements and Distribution Period, Maximum", "terseLabel": "Maximum period between date of financial statements and distribution date" } } }, "localname": "DateOfFinancialStatementsAndDistributionPeriodMaximum", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "durationItemType" }, "qnrx_Dr.MyersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Dr. Myers.", "label": "Dr. Myers [Member]", "terseLabel": "Dr. Myers" } } }, "localname": "Dr.MyersMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "qnrx_ExpectedAccruedInterestOnWarrantsIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected accrued interest on warrants issued.", "label": "Expected Accrued Interest on Warrants Issued", "terseLabel": "Expected accrued interest" } } }, "localname": "ExpectedAccruedInterestOnWarrantsIssued", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "qnrx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This amount represents finite lived intangible assets amortization after year four.", "label": "Finite Lived Intangible Assets Amortization Expense After Year Four", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "qnrx_IncreaseDecreaseInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Expenses", "terseLabel": "Increase in accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedExpenses", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "qnrx_IncreaseInAccruedInterestAndFinancingExpenses": { "auth_ref": [], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in accrued interest and finance expenses.", "label": "Increase In Accrued Interest And Financing Expenses", "terseLabel": "Increase in accrued interest and financing expense" } } }, "localname": "IncreaseInAccruedInterestAndFinancingExpenses", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "qnrx_InvestorRelationsFirmMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Investor Relations (IR) firm.", "label": "Investor Relations Firm [Member]", "terseLabel": "Investor Relations firm" } } }, "localname": "InvestorRelationsFirmMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "qnrx_InvoicePaidOnBehalfOfCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to invoices paid on behalf of the Company, due to offices.", "label": "Invoice Paid On Behalf Of The Company [Member]", "terseLabel": "Invoices paid on behalf of the Company" } } }, "localname": "InvoicePaidOnBehalfOfCompanyMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails" ], "xbrltype": "domainItemType" }, "qnrx_LicenseAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "LICENSE AGREEMENTS" } } }, "localname": "LicenseAgreementsAbstract", "nsuri": "http://www.quoinpharma.com/20230630", "xbrltype": "stringItemType" }, "qnrx_LicenseAgreementsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for license agreements.", "label": "License Agreements [Disclosure Text Block]", "terseLabel": "LICENSE AGREEMENTS" } } }, "localname": "LicenseAgreementsDisclosureTextBlock", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLicenseAgreements" ], "xbrltype": "textBlockItemType" }, "qnrx_MinimumClosingBidPriceRequiredPerAds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum closing bid price required per ADS.", "label": "Minimum Closing Bid Price Required Per ADS", "terseLabel": "Minimum closing bid price required per ADS" } } }, "localname": "MinimumClosingBidPriceRequiredPerAds", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails", "http://www.quoinpharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "qnrx_MonthlyPaymentAmountsDueToRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of monthly payment amounts due to related party.", "label": "Monthly Payment Amounts Due To Related Party", "terseLabel": "Monthly payment amounts due to related party" } } }, "localname": "MonthlyPaymentAmountsDueToRelatedParty", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "qnrx_Ms.CarterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Ms. Carter.", "label": "Ms. Carter [Member]", "terseLabel": "Ms. Carter" } } }, "localname": "Ms.CarterMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "qnrx_NetProceedsFromIssuanceOfCommonStock": { "auth_ref": [], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow from the additional capital contribution to the entity.", "label": "Net Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from sale of equity securities, net" } } }, "localname": "NetProceedsFromIssuanceOfCommonStock", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "qnrx_NetProceedsFromIssuancePublicOfferingAfterIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's offering of stock to the public net of issuance costs.", "label": "Net Proceeds From Issuance Public Offering After Issuance Costs", "terseLabel": "Net proceeds from offering" } } }, "localname": "NetProceedsFromIssuancePublicOfferingAfterIssuanceCosts", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "monetaryItemType" }, "qnrx_NethertonSyndromeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Netherton Syndrome.", "label": "Netherton Syndrome [Member]", "terseLabel": "Netherton Syndrome" } } }, "localname": "NethertonSyndromeMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "qnrx_NumberOfLicenseAndSupplyAgreementsEntered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new license and supply agreements entered during the period.", "label": "Number Of License And Supply Agreements Entered", "terseLabel": "Number of license and supply agreements entered" } } }, "localname": "NumberOfLicenseAndSupplyAgreementsEntered", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "integerItemType" }, "qnrx_NumberOfOrdinarySharesForAmericanDepositaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of ordinary shares for each American Depositary Shares.", "label": "Number of Ordinary Shares for American Depositary Shares", "terseLabel": "Number of ordinary shares for ADS" } } }, "localname": "NumberOfOrdinarySharesForAmericanDepositaryShares", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "qnrx_NumberOfOrdinarySharesForEachAmericanDepositaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of ordinary shares for each American Depositary Shares.", "label": "Number Of Ordinary Shares For Each American Depositary Shares", "terseLabel": "Number of ordinary shares for each ADS" } } }, "localname": "NumberOfOrdinarySharesForEachAmericanDepositaryShares", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "qnrx_NumberOfSharesRepresentedForOneAmericanDepositaryShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares represented for one American depositary share.", "label": "Number of Shares Represented for One American Depositary Share", "terseLabel": "Number of shares represented for one ADS" } } }, "localname": "NumberOfSharesRepresentedForOneAmericanDepositaryShare", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureOrganizationAndBusinessDetails" ], "xbrltype": "sharesItemType" }, "qnrx_NumberOfYearsIncomeForDistributionLimit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The of number of most recent years prior to the current period the income of which limits the distribution.", "label": "Number of Years Income For Distribution Limit", "terseLabel": "Number of years of income that limits distribution" } } }, "localname": "NumberOfYearsIncomeForDistributionLimit", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "integerItemType" }, "qnrx_OfferingExpensesAssociatedWithWarrantModification": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of offering expenses associated with warrant modification.", "label": "Offering Expenses Associated with Warrant Modification", "terseLabel": "Offering expenses associated with warrant modification" } } }, "localname": "OfferingExpensesAssociatedWithWarrantModification", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "qnrx_OutstandingWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member represents outstanding warrants.", "label": "Outstanding Warrants [Member]", "terseLabel": "Outstanding warrants" } } }, "localname": "OutstandingWarrantsMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "qnrx_PaymentsForPreviousIntangibleAssetAcquisition": { "auth_ref": [], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow representing payments of amounts due on the previous purchase of intangible assets.", "label": "Payments for Previous Intangible Asset Acquisition", "negatedLabel": "Payment for license acquisition" } } }, "localname": "PaymentsForPreviousIntangibleAssetAcquisition", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "qnrx_PreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to pre-funded warrants.", "label": "Pre Funded Warrants [Member]", "terseLabel": "Pre-Funded Warrants" } } }, "localname": "PreFundedWarrantsMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails" ], "xbrltype": "domainItemType" }, "qnrx_PrepaidExpenseDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for current prepaid expenses.", "label": "Prepaid Expense Disclosure Text Block", "terseLabel": "PREPAID EXPENSES" } } }, "localname": "PrepaidExpenseDisclosureTextBlock", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosurePrepaidExpenses" ], "xbrltype": "textBlockItemType" }, "qnrx_PrepaidResearchAndDevelopmentCosts": { "auth_ref": [], "calculation": { "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to research and development costs paid in advance that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Research And Development Costs", "terseLabel": "Prepaid R&D costs" } } }, "localname": "PrepaidResearchAndDevelopmentCosts", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "qnrx_ProceedsFromIssuanceOfPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's offering of stock to the public.", "label": "Proceeds From Issuance Of Public Offering", "terseLabel": "Gross proceeds from offering" } } }, "localname": "ProceedsFromIssuanceOfPublicOffering", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "monetaryItemType" }, "qnrx_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to public offering.", "label": "Public Offering [Member]", "terseLabel": "Public offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "domainItemType" }, "qnrx_ReclassificationOfWarrantLiabilityToEquityUponIssuanceOfExchangeWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of reclassification of warrant liability to equity upon issuance of \"Exchange Warrants\" in noncash investing or financing activities.", "label": "Reclassification of Warrant Liability to Equity Upon Issuance of Exchange Warrants", "terseLabel": "Reclassification of warrant liability to equity upon issuance of \"Exchange warrants\"" } } }, "localname": "ReclassificationOfWarrantLiabilityToEquityUponIssuanceOfExchangeWarrants", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "qnrx_RoyaltyAsPercentageOfNetRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of royalty as percentage of net revenue.", "label": "Royalty as Percentage of Net Revenue", "terseLabel": "Percentage of royalty payments of net revenue" } } }, "localname": "RoyaltyAsPercentageOfNetRevenue", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologyPolytherapeuticsDetails" ], "xbrltype": "percentItemType" }, "qnrx_RoyaltyAsPercentageOfNetRevenueIfGenericProductIsIntroduced": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of royalty as royalty as percentage of net revenue, if a generic product is introduced.", "label": "Royalty as Percentage of Net Revenue, If a Generic Product Is Introduced", "terseLabel": "Royalty payments with generic product introduced, as a percent of net revenue" } } }, "localname": "RoyaltyAsPercentageOfNetRevenueIfGenericProductIsIntroduced", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologyPolytherapeuticsDetails" ], "xbrltype": "percentItemType" }, "qnrx_RoyaltyAsPercentageOfNetRevenueIfTwoOrMoreGenericProductAreIntroduced": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of royalty as royalty as percentage of net revenue, if two or more generic product are introduced.", "label": "Royalty as Percentage of Net Revenue, If Two or More Generic Product are Introduced", "terseLabel": "Royalty payments with two or more generic product introduced, as a percent of net revenue" } } }, "localname": "RoyaltyAsPercentageOfNetRevenueIfTwoOrMoreGenericProductAreIntroduced", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologyPolytherapeuticsDetails" ], "xbrltype": "percentItemType" }, "qnrx_RoyaltyPaymentsPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the royalty payment period under as defined by the contract.", "label": "Royalty Payments Period", "terseLabel": "Royalty payment period" } } }, "localname": "RoyaltyPaymentsPeriod", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologyPolytherapeuticsDetails" ], "xbrltype": "durationItemType" }, "qnrx_SalaryAndOtherCompensationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to salary and other compensation due to officers.", "label": "Salary And Other Compensation [Member]", "terseLabel": "Salaries and other compensation" } } }, "localname": "SalaryAndOtherCompensationMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails" ], "xbrltype": "domainItemType" }, "qnrx_SclerodermaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Scleroderma.", "label": "Scleroderma [Member]", "terseLabel": "Scleroderma" } } }, "localname": "SclerodermaMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "qnrx_SecuritiesPurchaseAgreementInPolytherapeuticsincMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to the securities purchase agreement in Polytherapeutics, Inc.", "label": "Securities Purchase Agreement in Polytherapeutics Inc [Member]", "terseLabel": "Polytherapeutics" } } }, "localname": "SecuritiesPurchaseAgreementInPolytherapeuticsincMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologyPolytherapeuticsDetails" ], "xbrltype": "domainItemType" }, "qnrx_SharesNumberOfVotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of votes each share is entitled to.", "label": "Shares, Number of Votes", "terseLabel": "Number of vote for each ordinary share" } } }, "localname": "SharesNumberOfVotes", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "integerItemType" }, "qnrx_SharesOwnedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of entity's shares owned.", "label": "Shares Owned, Percentage", "terseLabel": "Shares owned (as a percent)" } } }, "localname": "SharesOwnedPercentage", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureOrganizationAndBusinessDetails" ], "xbrltype": "percentItemType" }, "qnrx_SkinvisibleLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for skinvisible license agreement.", "label": "Skinvisible License Agreement [Member]", "terseLabel": "Skinvisible Licensing agreement" } } }, "localname": "SkinvisibleLicenseAgreementMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails" ], "xbrltype": "domainItemType" }, "qnrx_StockIssuedDuringPeriodSharesCashlessWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period Shares Cashless Warrants Exercised", "terseLabel": "Cashless exercise of warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesCashlessWarrantsExercised", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "qnrx_SubstantialDoubtAboutGoingConcernAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "LIQUIDITY RISKS AND OTHER UNCERTAINTIES" } } }, "localname": "SubstantialDoubtAboutGoingConcernAbstract", "nsuri": "http://www.quoinpharma.com/20230630", "xbrltype": "stringItemType" }, "qnrx_SubstantialDoubtAboutGoingConcernLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "LIQUIDITY RISKS AND OTHER UNCERTAINTIES [Line Items]", "terseLabel": "LIQUIDITY RISKS AND OTHER UNCERTAINTIES" } } }, "localname": "SubstantialDoubtAboutGoingConcernLineItems", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails" ], "xbrltype": "stringItemType" }, "qnrx_SubstantialDoubtAboutGoingConcernTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Substantial Doubt About Going Concern [Table]" } } }, "localname": "SubstantialDoubtAboutGoingConcernTable", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails" ], "xbrltype": "stringItemType" }, "qnrx_SummaryOfWarrantActivitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrant activities.", "label": "Summary Of Warrant Activities [Table Text Block]", "terseLabel": "Schedule of warrant activities" } } }, "localname": "SummaryOfWarrantActivitiesTableTextBlock", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "qnrx_TherapeuticsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Therapeutics Inc.", "label": "Therapeutics Inc. [Member]", "terseLabel": "Therapeutics Inc." } } }, "localname": "TherapeuticsInc.Member", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "qnrx_ThresholdNumberOfConsecutiveBusinessDaysForCalculatingClosingBidPricePerAds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of consecutive business days, closing bid price per ADS.", "label": "Threshold Number Of Consecutive Business Days For Calculating Closing Bid Price Per Ads", "terseLabel": "Threshold number of consecutive business days for calculating closing bid price per ads" } } }, "localname": "ThresholdNumberOfConsecutiveBusinessDaysForCalculatingClosingBidPricePerAds", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails", "http://www.quoinpharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "qnrx_ThresholdPeriodForNotToEnterInToAgreementForVariableRateTransactionFromDateOfClosingOfOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The threshold period for not to enter in to an agreement for variable rate transaction from the date of closing of the offering.", "label": "Threshold Period For Not To Enter In To Agreement For Variable Rate Transaction From Date Of Closing Of Offering", "terseLabel": "Threshold period for not to enter in to an agreement for variable rate transaction from the date of closing of the Offering" } } }, "localname": "ThresholdPeriodForNotToEnterInToAgreementForVariableRateTransactionFromDateOfClosingOfOffering", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "durationItemType" }, "qnrx_ThresholdPeriodForNotToIssueOrProposedIssuanceOfAnyAdsSOrOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The threshold period for not to issue or proposed issuance of any ADSs or ordinary shares.", "label": "Threshold Period For Not To Issue Or Proposed Issuance Of Any ADS's Or Ordinary Shares", "terseLabel": "Threshold period for not to issue or proposed issuance of any ADSs or ordinary shares" } } }, "localname": "ThresholdPeriodForNotToIssueOrProposedIssuanceOfAnyAdsSOrOrdinaryShares", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "durationItemType" }, "qnrx_WarrantAmendmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to warrant amendments member.", "label": "Warrant Amendments [Member]", "terseLabel": "Warrant Amendments" } } }, "localname": "WarrantAmendmentsMember", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "domainItemType" }, "qnrx_WarrantLiabilityIncomeExpenseValue": { "auth_ref": [], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Warrant Liability (Income) Expense, Value", "terseLabel": "Warrant liability (income) expense" } } }, "localname": "WarrantLiabilityIncomeExpenseValue", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "qnrx_WarrantsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for warrants.", "label": "Warrants Policy [Policy Text Block]", "terseLabel": "Warrants:" } } }, "localname": "WarrantsPolicyPolicyTextBlock", "nsuri": "http://www.quoinpharma.com/20230630", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r139", "r140", "r248", "r265", "r387", "r571", "r573" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r229", "r231", "r232", "r233", "r288", "r422", "r453", "r488", "r489", "r550", "r553", "r554", "r555", "r557", "r564", "r565", "r577", "r585", "r589", "r595", "r642", "r680", "r681", "r682", "r683", "r684", "r685" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureOrganizationAndBusinessDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r229", "r231", "r232", "r233", "r288", "r422", "r453", "r488", "r489", "r550", "r553", "r554", "r555", "r557", "r564", "r565", "r577", "r585", "r589", "r595", "r642", "r680", "r681", "r682", "r683", "r684", "r685" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureOrganizationAndBusinessDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r229", "r231", "r232", "r233", "r280", "r288", "r319", "r320", "r321", "r398", "r422", "r453", "r488", "r489", "r550", "r553", "r554", "r555", "r557", "r564", "r565", "r577", "r585", "r589", "r595", "r598", "r639", "r642", "r681", "r682", "r683", "r684", "r685" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureOrganizationAndBusinessDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r229", "r231", "r232", "r233", "r280", "r288", "r319", "r320", "r321", "r398", "r422", "r453", "r488", "r489", "r550", "r553", "r554", "r555", "r557", "r564", "r565", "r577", "r585", "r589", "r595", "r598", "r639", "r642", "r681", "r682", "r683", "r684", "r685" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureOrganizationAndBusinessDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r139", "r140", "r248", "r265", "r387", "r572", "r573" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r10", "r594" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails", "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Payroll Taxes, Current", "terseLabel": "Payroll taxes" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r13", "r570" ], "calculation": { "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "terseLabel": "Payroll" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r22", "r23", "r80", "r122", "r445", "r458", "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated deficit" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r75", "r594", "r692" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r328", "r329", "r330", "r476", "r628", "r629", "r630", "r675", "r695" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r55", "r56", "r291" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r5", "r39", "r100" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Reclassification of warrant liability upon issuance of Exchange warrant" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r323", "r335" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r4", "r34", "r38" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangibles" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Antidilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r671" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologyPolytherapeuticsDetails", "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r591", "r672", "r673", "r674" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Purchase price agreement", "verboseLabel": "License Fee" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologyPolytherapeuticsDetails", "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionContingentConsiderationLiability": { "auth_ref": [ "r671" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized from contingent consideration in asset acquisition.", "label": "Asset Acquisition, Contingent Consideration, Liability", "terseLabel": "Amount of payment to be made" } } }, "localname": "AssetAcquisitionContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r671" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologyPolytherapeuticsDetails", "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionLineItems": { "auth_ref": [ "r671" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Asset Acquisition [Line Items]", "terseLabel": "IN-LICENSED TECHNOLOGY" } } }, "localname": "AssetAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologyPolytherapeuticsDetails", "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionTable": { "auth_ref": [ "r671" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset acquisition.", "label": "Asset Acquisition [Table]" } } }, "localname": "AssetAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologyPolytherapeuticsDetails", "http://www.quoinpharma.com/role/DisclosureInLicensedTechnologySkinvisibleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionTextBlock": { "auth_ref": [ "r671" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for asset acquisition.", "label": "Asset Acquisition [Text Block]", "terseLabel": "IN-LICENSED TECHNOLOGY" } } }, "localname": "AssetAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureInLicensedTechnology" ], "xbrltype": "textBlockItemType" }, "us-gaap_Assets": { "auth_ref": [ "r103", "r117", "r138", "r170", "r172", "r174", "r206", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r348", "r352", "r372", "r442", "r511", "r594", "r606", "r640", "r641", "r678" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r113", "r124", "r138", "r206", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r348", "r352", "r372", "r594", "r640", "r641", "r678" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r318", "r319", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation:" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IN-LICENSED TECHNOLOGY" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r26", "r115", "r566" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash balance" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and cash equivalents:" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r26", "r87", "r135" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents - end of period", "periodStartLabel": "Cash and cash equivalents - beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r2", "r87" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r110", "r119", "r120", "r121", "r138", "r158", "r159", "r162", "r164", "r168", "r169", "r206", "r236", "r238", "r239", "r240", "r243", "r244", "r263", "r264", "r267", "r270", "r277", "r372", "r467", "r468", "r469", "r470", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r498", "r520", "r542", "r558", "r559", "r560", "r561", "r562", "r614", "r625", "r631" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails", "http://www.quoinpharma.com/role/DisclosureSubsequentEventsDetails", "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails", "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [ "r119", "r120", "r121", "r168", "r263", "r264", "r265", "r267", "r270", "r275", "r277", "r467", "r468", "r469", "r470", "r585", "r614", "r625" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "verboseLabel": "SHAREHOLDERS' EQUITY" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants, exercise price of warrants (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "verboseLabel": "Warrants, number of securities called by warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Shares warrants may purchase" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r17", "r67", "r443", "r497" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Number of ordinary shares reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r596", "r597", "r598", "r600", "r601", "r602", "r603", "r628", "r629", "r675", "r690", "r695" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Ordinary shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Ordinary shares, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r74", "r498" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Ordinary shares, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Ordinary shares, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r5", "r74", "r498", "r517", "r695", "r696" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance at ending of year (in shares)", "periodStartLabel": "Balance at beginning of year (in shares)", "terseLabel": "Ordinary shares, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r74", "r444", "r594" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Ordinary shares, no par value per share, 500,000,000,000 ordinary shares authorized - 59,233,024,799 (987,217 ADS's) ordinary shares issued and outstanding at June 30, 2023 and 24,233,024,799 (403,884 ADS's) at December 31, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r96", "r245", "r246", "r251", "r252", "r253", "r256", "r257", "r258", "r259", "r260", "r580", "r581", "r582", "r583", "r584" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r15", "r45", "r48", "r59", "r60", "r61", "r69", "r98", "r99", "r141", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r380", "r580", "r581", "r582", "r583", "r584", "r626" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of prepaid expenses" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r289", "r293", "r324", "r325", "r327", "r590" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "STOCK BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Loss per ADS" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r131", "r147", "r148", "r149", "r150", "r151", "r155", "r158", "r162", "r163", "r164", "r166", "r363", "r364", "r438", "r451", "r574" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r131", "r147", "r148", "r149", "r150", "r151", "r158", "r162", "r163", "r164", "r166", "r363", "r364", "r438", "r451", "r574" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Fully-diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r28", "r29" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings (loss) per share:" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "STOCK BASED COMPENSATION" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized stock compensation expense expected to be recognized over the remaining weighted average service period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r669" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Employee stock option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SHAREHOLDERS' EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "SHAREHOLDERS' EQUITY" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r5", "r111", "r128", "r129", "r130", "r142", "r143", "r144", "r146", "r152", "r154", "r167", "r207", "r208", "r279", "r328", "r329", "r330", "r345", "r346", "r354", "r355", "r356", "r357", "r358", "r359", "r362", "r373", "r374", "r375", "r376", "r377", "r378", "r381", "r454", "r455", "r456", "r476", "r542" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r1", "r4" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "verboseLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r366", "r367", "r370" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r366", "r367", "r370" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r253", "r281", "r282", "r283", "r284", "r285", "r286", "r367", "r395", "r396", "r397", "r581", "r582", "r586", "r587", "r588" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r366", "r367", "r368", "r369", "r371" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FAIR VALUE OF FINANCIAL INSTRUMENTS" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r253", "r281", "r286", "r367", "r395", "r586", "r587", "r588" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair value of financial instruments:" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r253", "r281", "r282", "r283", "r284", "r285", "r286", "r395", "r396", "r397", "r581", "r582", "r586", "r587", "r588" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r365", "r371" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r261", "r275", "r360", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r450", "r578", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r633", "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Intangible assets, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsIncomeTaxesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r116", "r222" ], "calculation": { "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r93" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r93" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r93" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r93" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r220", "r221", "r222", "r223", "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Expected amortization expense" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r92", "r425" ], "calculation": { "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Total cost" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "INTANGIBLE ASSETS" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r35", "r37" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r92", "r424" ], "calculation": { "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net book value" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r4", "r40", "r41" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Forgiveness of trade payable", "negatedTerseLabel": "Forgiveness of accounts payable", "verboseLabel": "Gain on reduction in liability" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill and Intangible Asset Impairment", "terseLabel": "Impairment loss measurement" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r0", "r94" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Long-lived assets:" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r224", "r225", "r527" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r225", "r527" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r127", "r339", "r340", "r341", "r342", "r343", "r344", "r466" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income taxes:" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r3" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Decrease in prepaid expenses & other assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r33", "r36" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r85", "r259", "r583", "r584" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "negatedLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r65", "r689" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable", "terseLabel": "Accrued interest and financing expense" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r452", "r462", "r463", "r464", "r465", "r551", "r552" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments:" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Investments": { "auth_ref": [ "r441" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r12", "r138", "r206", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r349", "r352", "r353", "r372", "r496", "r575", "r606", "r640", "r678", "r679" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r79", "r104", "r447", "r594", "r627", "r637", "r676" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r14", "r114", "r138", "r206", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r349", "r352", "r353", "r372", "r594", "r640", "r678", "r679" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r57", "r338", "r670" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Technology license - Skinvisible" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS" } } }, "localname": "LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of items purchased under a long-term purchase commitment.", "label": "Category of Item Purchased [Axis]" } } }, "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]" } } }, "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-term Purchase Commitment [Line Items]", "terseLabel": "RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyDisclosures": { "auth_ref": [ "r226", "r227", "r228", "r230", "r232", "r233", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.", "label": "Contingencies Disclosure [Text Block]", "terseLabel": "CONTINGENCIES" } } }, "localname": "LossContingencyDisclosures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r134" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows provided by (used in) financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r134" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows used in investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r87", "r88", "r89" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows used in operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r81", "r89", "r105", "r112", "r125", "r126", "r130", "r138", "r145", "r147", "r148", "r149", "r150", "r153", "r154", "r160", "r170", "r171", "r173", "r175", "r206", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r364", "r372", "r449", "r519", "r540", "r541", "r576", "r604", "r640" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r132", "r147", "r148", "r149", "r150", "r155", "r156", "r161", "r164", "r170", "r171", "r173", "r175", "r576" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other income", "terseLabel": "Other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingCostAndExpenseRelatedPartyTypeExtensibleEnumeration": { "auth_ref": [ "r677" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of related party for operating cost and expense.", "label": "Operating Cost and Expense, Related Party, Type [Extensible Enumeration]" } } }, "localname": "OperatingCostAndExpenseRelatedPartyTypeExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "Operating Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND BUSINESS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r71", "r102", "r460", "r461" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "ORGANIZATION AND BUSINESS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureOrganizationAndBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other Expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r66", "r440", "r492", "r493", "r606", "r691" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "totalLabel": "Total" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r13", "r594" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "negatedLabel": "Less: Short-term portion", "terseLabel": "Due to officers - short term", "verboseLabel": "Outstanding indebtedness" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Long-term portion", "verboseLabel": "Due to officers - long term" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration": { "auth_ref": [ "r677" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of related party for liability classified as other and current.", "label": "Other Liability, Current, Related Party, Type [Extensible Enumeration]" } } }, "localname": "OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration": { "auth_ref": [ "r677" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of related party for liability classified as other and noncurrent.", "label": "Other Liability, Noncurrent, Related Party, Type [Extensible Enumeration]" } } }, "localname": "OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OtherLiabilityRelatedPartyTypeExtensibleEnumeration": { "auth_ref": [ "r677" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of related party for liability classified as other.", "label": "Other Liability, Related Party, Type [Extensible Enumeration]" } } }, "localname": "OtherLiabilityRelatedPartyTypeExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other (income) and expenses" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r623", "r638" ], "calculation": { "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Prepaid expense" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ACCRUED INTEREST AND FINANCING EXPENSE" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r86" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchase of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r123", "r217", "r218", "r568" ], "calculation": { "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseCurrentAndNoncurrent", "weight": 1.0 }, "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "negatedLabel": "Less: Short-term portion", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PREPAID EXPENSES" } } }, "localname": "PrepaidExpenseCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "auth_ref": [ "r64", "r123", "r510", "r688" ], "calculation": { "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.", "label": "Prepaid Expense", "totalLabel": "Total" } } }, "localname": "PrepaidExpenseCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseNoncurrent": { "auth_ref": [ "r622" ], "calculation": { "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseCurrentAndNoncurrent", "weight": 1.0 }, "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.", "label": "Prepaid Expense, Noncurrent", "terseLabel": "Prepaid expenses - long term", "totalLabel": "Long-term portion" } } }, "localname": "PrepaidExpenseNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r569", "r579", "r638" ], "calculation": { "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosurePrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r24" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Proceeds from maturity of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r604", "r693", "r694" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional Fees", "terseLabel": "Consulting fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r112", "r125", "r126", "r133", "r138", "r145", "r153", "r154", "r170", "r171", "r173", "r175", "r206", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r347", "r350", "r351", "r364", "r372", "r439", "r448", "r475", "r519", "r540", "r541", "r576", "r592", "r593", "r605", "r624", "r640" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r287", "r385", "r386", "r491", "r492", "r493", "r494", "r495", "r516", "r518", "r549" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r385", "r386", "r677" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r523", "r524", "r527" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r287", "r385", "r386", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r491", "r492", "r493", "r494", "r495", "r516", "r518", "r549", "r677" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r382", "r383", "r384", "r386", "r388", "r472", "r473", "r474", "r525", "r526", "r527", "r546", "r548" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r25" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedLabel": "Payment of amounts due to officers", "terseLabel": "Non-bearing interest indebtedness" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.", "label": "Research and Development Arrangement [Member]", "terseLabel": "Research and consulting agreement" } } }, "localname": "ResearchAndDevelopmentArrangementMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r70", "r337", "r686" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureResearchConsultingAgreementsAndCommitmentsDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development", "verboseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and development:" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r76", "r100", "r446", "r457", "r459", "r471", "r499", "r594" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r111", "r142", "r143", "r144", "r146", "r152", "r154", "r207", "r208", "r328", "r329", "r330", "r345", "r346", "r354", "r356", "r357", "r359", "r362", "r454", "r456", "r476", "r695" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RoyaltyIncomeNonoperating": { "auth_ref": [ "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.", "label": "Royalty Income, Nonoperating", "terseLabel": "Royalty revenues" } } }, "localname": "RoyaltyIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r35", "r37", "r424" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r35", "r37" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r62", "r63", "r523", "r524", "r527" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsAmountsDueToOfficersDetails", "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of amounts due to officers" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r290", "r292", "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r318", "r319", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r6", "r7", "r53" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of stock-based activities" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r42", "r43", "r44", "r45", "r46", "r47", "r48", "r98", "r99", "r100", "r119", "r120", "r121", "r168", "r263", "r264", "r265", "r267", "r270", "r275", "r277", "r467", "r468", "r469", "r470", "r585", "r614", "r625" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r83" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r3" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r290", "r292", "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r318", "r319", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "STOCK BASED COMPENSATION" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Contractual Terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable options (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Intrinsic value of outstanding options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding and exercisable at June 30, 2023", "periodStartLabel": "Outstanding at December 31, 2022" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "ADSs Underlying Warrants", "verboseLabel": "ADS Underlying Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding and exercisable at June 30, 2023", "periodStartLabel": "Outstanding at December 31, 2022" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price Per Share", "verboseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Percentage of ordinary shares reserved for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r318", "r319", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r289", "r297", "r316", "r317", "r318", "r319", "r322", "r331", "r332", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock based compensation:" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Purchase price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable options (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r90", "r136" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r110", "r119", "r120", "r121", "r138", "r158", "r159", "r162", "r164", "r168", "r169", "r206", "r236", "r238", "r239", "r240", "r243", "r244", "r263", "r264", "r267", "r270", "r277", "r372", "r467", "r468", "r469", "r470", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r498", "r520", "r542", "r558", "r559", "r560", "r561", "r562", "r614", "r625", "r631" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationDetails", "http://www.quoinpharma.com/role/DisclosureStockBasedCompensationOptionActivityDetails", "http://www.quoinpharma.com/role/DisclosureSubsequentEventsDetails", "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsLossPerShareDetails", "http://www.quoinpharma.com/role/DocumentDocumentAndEntityInformation", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r5", "r20", "r111", "r128", "r129", "r130", "r142", "r143", "r144", "r146", "r152", "r154", "r167", "r207", "r208", "r279", "r328", "r329", "r330", "r345", "r346", "r354", "r355", "r356", "r357", "r358", "r359", "r362", "r373", "r374", "r375", "r376", "r377", "r378", "r381", "r454", "r455", "r456", "r476", "r542" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r142", "r143", "r144", "r167", "r423", "r462", "r487", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r512", "r513", "r514", "r515", "r516", "r518", "r521", "r522", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r542", "r599" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Shareholders' Equity" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r142", "r143", "r144", "r167", "r423", "r462", "r487", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r512", "r513", "r514", "r515", "r516", "r518", "r521", "r522", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r542", "r599" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r5", "r19", "r45", "r100", "r255" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Shares issued upon conversion" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureAccruedInterestAndFinancingExpenseDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r5", "r73", "r74", "r100", "r467", "r542", "r559" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of ADS and Pre-Funded Warrants, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r5", "r73", "r74", "r100", "r303" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised Pre-Funded Warrants" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r5", "r73", "r74", "r100", "r476", "r542", "r559", "r605" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of ADS and Pre-Funded Warrants, net" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r74", "r77", "r78", "r91", "r500", "r517", "r543", "r544", "r594", "r606", "r627", "r637", "r676", "r695" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of year", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r97", "r137", "r262", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r279", "r361", "r545", "r547", "r563" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "SHAREHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [ "r379", "r390" ], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r379", "r390" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails", "http://www.quoinpharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r379", "r390" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r379", "r390" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails", "http://www.quoinpharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r379", "r390" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertaintiesDetails", "http://www.quoinpharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r389", "r391" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureOrganizationAndBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "ORGANIZATION AND BUSINESS" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureOrganizationAndBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "LIQUIDITY RISKS AND OTHER UNCERTAINTIES" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureLiquidityRisksAndOtherUncertainties" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental information - Non cash items:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Acquired technology - Polytherapeutics" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r68", "r118", "r567" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "terseLabel": "U.S. Treasury Bills" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r261", "r275", "r360", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r450", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r633", "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock Common [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r21", "r49", "r50" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "negatedLabel": "Treasury stock, 2,641,693, ordinary shares" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r5", "r74", "r100" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury Stock, ordinary shares" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_USTreasuryBillSecuritiesMember": { "auth_ref": [ "r687" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Bill Securities [Member]", "terseLabel": "US Treasury Bills" } } }, "localname": "USTreasuryBillSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r4", "r536", "r537", "r538", "r539", "r556" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives", "negatedLabel": "Unrealized loss" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r4" ], "calculation": { "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedLabel": "Unrealized loss and accrued interest on investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r30", "r31", "r32", "r106", "r107", "r108", "r109" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates:" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrant liability" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of warrants not settleable in cash classified as equity.", "label": "Warrants Not Settleable in Cash, Fair Value Disclosure", "terseLabel": "Incremental fair value" } } }, "localname": "WarrantsNotSettleableInCashFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r157", "r164" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Fully-diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average number of ADS's outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r155", "r164" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.quoinpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.B)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//350-30/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//450-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "450", "URI": "https://asc.fasb.org//450-30/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.C.Q3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(f)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(f)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(f)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(7)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13A(Column F))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r607": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r608": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r609": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r611": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r612": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r613": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r615": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r616": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r617": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r618": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r619": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r621": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org//205-40/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 72 0001410578-23-001531-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001410578-23-001531-xbrl.zip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̅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end